<DOCUMENT>
<TYPE>10SB12G/A
<SEQUENCE>1
<FILENAME>form10sba2final.txt
<TEXT>
                              United States
                    Securities and Exchange Commission
                          Washington, D.C. 20549

                               FORM 10-SB
                             Amendment No. 2

                 GENERAL FORM FOR REGISTRATION OF SECURITIES
                         OF SMALL BUSINESS ISSUERS

      Under Section 12(b) or (g) of The Securities Exchange Act of 1934

                       THIRD-ORDER NANOTECHNOLOGIES, INC.
                 ----------------------------------------------
                 (Name of Small Business Issuer in its charter)

          Nevada                                            82-049-7368
-------------------------------                         -------------------
(State or other jurisdiction of                          (I.R.S. Employer
incorporation or organization)                          Identification No.)


       2601 Annand Dr., Suite #16, Wilmington, Delaware        19808
       ------------------------------------------------      ----------
          (Address of principal executive offices)           (Zip Code)

Issuer's telephone number (302) 998-8824
                         -----------------

Securities to be registered under Section 12(b) of the Act:

       Title of each class                    Name of each exchange on which
       to be so registered                    each class is to be registered

       ______________________________         ______________________________

       ______________________________         ______________________________

Securities to be registered under Section 12(g) of the Act:

                     Common Stock, $0.001 Par Value
                     ------------------------------
                             (Title of class)

                     ------------------------------
                             (Title of class)

<PAGE>



            INFORMATION REQUIRED IN REGISTRATION STATEMENT

               Note Regarding Forward-Looking Statements

     This registration statement contains forward-looking statements.
These statements relate to future events or future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our company or its industry's actual
results, levels of activity, performance or achievements to be
materially different from any future results, levels of activity,
performance or achievements expressed or implied by the forward-
looking statements.

     In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "expects," "plans,"
"anticipates," "believes," "estimates," "predicts," "potential," or
the negative of these terms or other comparable terminology. These
statements are only predictions. Actual events or results may differ
materially. Although our Company believes that the expectations
reflected in the forward-looking statements are reasonable, our
Company cannot guarantee future results, levels of activity,
performance or achievements. The forward-looking statements are based
on our beliefs, assumptions and expectations of our future
performance, taking into account information currently available to
us. These beliefs, assumptions and expectations can change as a result
of many possible events or factors, including those events and factors
described by us in "Description of Business-Risk Factors," not all of
which are known to us. Our Company is under no duty to update any of
the forward-looking statements after the effective time of this date
of this registration statement to conform its prior statements to
actual results.

     Further, this registration statement contains forward looking
statements that involve substantial risks and uncertainties. Such
statements include, without limitation, all statements as to
expectation or belief and statements as to our future results of
operations, the progress of any research and product development, the
need for, and timing of, additional capital and capital expenditures,
partnering prospects, the protection of and the need for additional
intellectual property rights, effects of regulations, the need for
additional facilities and potential market opportunities. Our company'
actual results may vary materially from those contained in such
forward-looking statements because of risks to which our company is
subject, such as lack of available funding, competition from third
parties, intellectual property rights of third parties, regulatory
constraints, litigation and other risks to which our Company is
subject.

    You should not place undue reliance on these forward-looking
statements. Statements regarding the following subjects are forward-
looking by their nature:

    *    Our business strategy.
    *    Our future operating results.
    *    Our ability to obtain external financing.
    *    Our understanding of our competition.
    *    Industry and market trends.
    *    Future capital expenditures.
    *    The impact of technology on our products, operations and
         business.


                               2
<PAGE>

Item 1.   Description of Business.

                    Our Business Development

     PSI-TEC Corporation ("PSI-TEC") was founded in 1991 and
incorporated under the laws of the State of Delaware on September 12,
1995. PSI-TEC was founded in Upland, Pennsylvania by Dr. Frederick J.
Goetz where he established a laboratory with a small amount of private
funding.  PSI-TEC subsequently moved its operations to laboratory
space provided by the U.S. Army on the Aberdeen Proving Grounds in
cooperation with a division of the Department of Defense for the
advancement of ultra wide-bandwidth satellite telecommunications.
Thereafter, PSI-TEC commenced operations of its own organic synthesis
and thin-films laboratory in Wilmington, Delaware.

     In order to become a non-reporting publicly-traded corporation,
in July 2004 PSI-TEC reorganized with our Company pursuant to a
reorganization agreement between PSI-TEC and all of its shareholders, and
our Company's sole officer, director and majority shareholder. Pursuant
to the reorganization agreement, (i) our Company changed its name from
Eastern Idaho Internet Services, Inc. to PSI-TEC Holdings, Inc.; (ii)
our Company acquired all of the issued and outstanding shares of PSI-
TEC stock; (iii) PSI-TEC became the wholly-owned operating subsidiary
of our Company; and (iv) our Company's then sole officer and director
resigned, PSI-TEC's nominees were elected to our Company's board of
directors and new management was appointed. For accounting purposes,
this acquisition transaction was accounted for as a reverse-
acquisition, whereby PSI-TEC was deemed to have purchased our Company.
As a result, the historical financial statements of PSI-TEC became the
historical financial statements of our Company.

     Immediately prior to the time of the reorganization transaction,
our Company was a non-reporting development stage company whose stock was
traded on the OTC: Pink Sheets and that was seeking other business
opportunities; it had no substantive business operations. Our Company
was originally incorporated under the laws of the State of Nevada on
June 24, 1997 as Eastern Idaho Internet Services, Inc. to operate as
an Internet services marketing firm. It was unsuccessful in this
venture, and in June 1998 it ceased its operations and sold all of its
operating assets.

     On October 20, 2006, in order to consolidate the operations of
PSI-TEC Holdings, Inc. and PSI-TEC Corp. (PSI-TEC Holdings, Inc.'s
wholly owned subsidiary),PSI-TEC Holdings, Inc. and PSI-TEC Corp.
merged; and PSI-TEC Holdings, Inc., a Nevada corporation, survived
and changed its name to Third-Order Nanotechnologies, Inc. No change
of control or domicile occurred as a result of the merger.

     On April 13, 2007 our Company filed its initial Form 10-SB
registration statement with the United States Securities and Exchange
Commission to register its common stock under the provisions of Section
12(g) of the Securities Exchange Act of 1934. As a result, our Company
is now required to comply with periodic reporting, proxy solicitations
and certain other requirements of the Securities Exchange Act of 1934.

     Unless the context otherwise requires, all references to the
"Company," "we," "our" or "us" and other similar terms means
Third-Order Nanotechnologies, Inc., a Nevada corporation.

     Our principal executive office is located at 2601 Annand Dr.,
Suite #16, Wilmington, Delaware 19808, and our telephone number is
(302) 998-8824. Our website address is www.third-order.com. No
information found on our website is part of this registration
statement. Also, this registration statement includes the names of
various government agencies and the trade names of other companies.
Use or display by us of such other parties' names and trade names in
this registration statement is not intended to and does not imply a
relationship with, or endorsement or sponsorship of us by, any of
these other parties.

                               3
<PAGE>


                           Overview

     We are a development stage research and development company. We
have developed and are continuing to develop high-activity, high-
stability electro-optic polymers which we believe could have a broad
range of applications in the electro-optic device market.

     Electro-optic devices convert data from electric signals into
optical signals for use in communications systems and in optical
interconnects for high-speed data transfer. We expect our patented and
patent-pending technologies when completed and tested to be utilized
by electro-optic device manufacturers, such as telecommunications
component and systems manufacturers, networking and switching
suppliers, semiconductor companies, aerospace companies and government
agencies.

     Our electro-optic polymers (plastics) are property-engineered at
the molecular level (nanotechnology level) to meet the exacting
thermal, environment and performance specifications demanded by
electro-optic devices. We believe that our patented technologies will
enable us to design electro-optic polymers that are free from the
numerous diverse inherent flaws that plague competitive polymer
technologies employed by other companies and research groups. We
engineer our polymers with the intent to have temporal, thermal,
chemical and photochemical stability within our patented molecular
architectures.

     Our patented molecular architectures are based on a well-
understood chemical and quantum mechanical occurrence known as
aromaticity. Aromaticity provides a high degree of molecular
stability. Aromaticity is what will enable our core molecular
structures to maintain stability under a broad range of polymerization
conditions that otherwise appear to affect other current polymer
molecular designs.  Polymers, polymer-based devices and the processes
used to create them are often patentable, which can provide the
developers of such technology with a significant competitive
advantage. We consider our proprietary intellectual property to be
unique.

          Glossary of Select Technology Terms Used Herein

All-optical devices. All-optical devices convert data in the form of
-------------------
input light signals to a secondary light data stream. The future
market of all-optic devices is expected to include all-optical
transistors.

All-optical transistors. All-optical transistors are devices currently
-----------------------
underdevelopment that use an input light signal to switch a secondary
light signal. All-optical transistors are expected to enable the
fabrication of an entirely new high-speed generation of computers that
operate on light instead of electricity, which in turn should
significantly improve computation speeds.

Aromaticity. Aromaticity causes an extremely high degree of molecular
-----------
stability. It is a molecular arrangement wherein atoms combine into a
ring or rings and share their electrons among each other.  Aromatic
compounds are extremely stable because the electronic charge
distributes evenly over a great area preventing hostile moieties, such
as oxygen and free radicals, from finding an opening to attack.


                               4
<PAGE>


CLD-1:  An electro-optic material based upon unstable polyene molecular
-----
architectures.  Unlike Third-Order's molecular designs, CLD-1 is not a
CSC model molecule and exhibits thermal degradation at low temperatures
(~250 C) which makes it less suitable for commercial and military
applications.

CSC (Cyclical Surface Conduction) theory:   Most charge-transfer dyes
----------------------------------------
(e.g. Disperse Red 1, CLD, FTC) are based upon a polyene architecture
wherein the ground state and first excited state differ by the
alteration of single and double bonds.  CSC model molecules use
nitrogenous heterocyclical.


Electro-optic devices. Electro-optic devices convert data from
---------------------
electric signals into optical signals for use in communications
systems and in optical interconnects for high-speed data transfer.

Electro-optic materials. Electro-optic materials are materials that
-----------------------
are engineered at the molecular level. Molecular level engineering is
commonly referred to as Nanotechnology.

Electro-optic modulators. Electro-optic modulators are electro-optic
------------------------
devices that perform electric-to-optic conversions within the
infrastructure of the Internet.

Nanotechnology. Nanotechnology refers to the development of products
--------------
and production processes at the molecular level, which is a scale
smaller than 100 nanometers (a nanometer is one-billionth of a meter).

Nitrogenous heterocyclical structure: A multi-atom molecular ring or
------------------------------------
combination of rings that contain nitrogen.


Plastics/Polymers. Polymers, also known as plastics, are large carbon-
-----------------
based molecules that bond many small molecules together to form a long
chain. Polymer materials can be engineered and optimized using
nanotechnology to create a system in which unique surface, electrical,
chemical and electro-optic characteristics can be controlled.
Materials based on polymers are used in a multitude of industrial and
consumer products, from automotive parts to home appliances and
furniture, as well as scientific and medical equipment.

Polymerization. Polymerization is a molecular engineering process that
--------------
provides the environmental and thermal stability necessary for
functional electro-optical devices. Polymer materials can be
engineered and optimized using nanotechnology to create a system in
which unique surface, electrical, chemical and electro-optic
characteristics can be controlled.

Thermal Gravimetric Analysis (TGA):   The basic principle in TGA is to
---------------------------------
measure the mass of a sample as a function of temperature. This, in
principle, simple measurement is an important and powerful tool in
solid state chemistry and materials science. The method for example
can be used to determine water of crystallisation, follow degradation
of materials, determine reaction kinetics, study oxidation and
reduction, or to teach the principles of stoichiometry, formulae and
analysis.

Zwitterionic-aromatic push-pull: Most charge-transfer dyes (e.g.
-------------------------------
Disperse Red 1, CLD, FTC) have an excited state (such as during
photonic absorption) wherein a full charge is separated across the
molecule.  Such a molecule is said to be excited-state zwitterionic.
Within such a molecular system the zwitterionic state is unstable and
the molecule typically collapses rapidly into its lower dipole ground
state.  In our molecular designs, the excited state is further
stabilized by the aromatization of the molecular core.  In that
aromaticity stabilizes this excited state, it is said to "pull" the
molecule into this higher energy state; on the other hand, the
unstable zwitterionic state is said to "push" the molecule out of
the excited state.


                         Our Business

     Third-Order Nanotechnologies, Inc. is developing a new
generation of advanced electro-optic plastics that convert high-speed
electronic signals into optical (light) signals. Electro-optic
material is the core active ingredient in high-speed fiber-optic
telecommunication systems. Utilizing our proprietary technology, we
are in the process of engineering advanced electro-optic plastics
which we believe may lead to significant performance advancements,
component size and cost reduction, ease of processing, and thermal and
temporal stability.  We believe that polymer materials engineered at
the molecular level may have a significant role in the future
development of commercially significant electro-optic related
products.

     In order to transmit digital information over long or
intermediate distances at extremely high-speeds (wide bandwidth),
electrical signals, such as those produced by a computer or telephone,
must be converted into optical signals for transmission over long-
distance fiber-optic cable.  Within the infrastructure of the
Internet, a device known as an electro-optic modulator performs the
electric-to-optic conversion. Within the electro-optic modulator, an
electro-optic material performs the actual conversion of electricity
to an optical signal. These materials change their optical properties
in the presence of an electric field at extremely high frequencies
(wide bandwidths).


                               5
<PAGE>

     Currently, the core electro-optic material contained in most mod-
ulators is a crystalline material, such as lithium niobate or gallium
arsenide, which must be manufactured in strict dust-free conditions
since even slight contamination can render them inoperable. As a
result, these crystalline materials are expensive to produce. Current
electro-optic crystals are limited to telecommunication speeds that
are less than 40Gb/s (40 billion digital bits of data per second).
Lithium niobate devices require large power levels (modulation volt-
ages) to operate and are large in size -- typically measuring about
four inches long. Considering that most integrated circuits are
literally invisible to the naked eye, these devices are enormous.
Additionally, it is important to note that these crystalline-based
electro-optic modulators require expensive mechanical packaging
(housings) generally comprised of materials, such as gold-plated
Kovar, in order to assure operational integrity over required time and
operating temperature ranges.

     Unlike crystals, electro-optic plastics appear to be capable of
being tailored at the molecular level for optimal performance
characteristics. Additionally, electro-optic plastics are inexpensive
to manufacture and demand significantly lower power requirements
(modulation voltages).  The electro-optic plastics have demonstrated
the ability to perform many times faster (>100Gb/s) than existing
crystalline technology.

     We consider electro-optic plastics to be the most feasible tech-
nology for future high-speed (wide bandwidth) electronic-optical
conversion. Due to the ease of processing afforded by electro-optic
plastics, as well as their capacity to foster component size
reduction, we believe electro-optic plastics have the potential to
replace existing high-speed fiber-optics components that are used
today in many commercial and military applications.

     We also believe that the extreme miniaturization provided by
advanced electro-optic plastics may allow for the successful
fabrication of chip-to-chip (backplane) optical interconnect devices
for computers that create the high-speed data transmission necessary
for extremely high-speed computations. Additional potential
applications, in our opinion, for electro-optic plastics include
phased array radar, cable television (CATV), electronic counter
measure (ECM) systems, ultra-fast analog-to-digital conversion, land
mine detection, radio frequency photonics, spatial light modulation
and all-optical (light-switching-light) signal processing.

Our Electro-Optic Technology

     For the past two decades, diverse corporate interests, including,
to our knowledge, IBM, Lockheed Martin, DuPont, AT&T Bell Labs,
Corning, Honeywell and 3M, as well as numerous universities and U.S.
Government Agencies, have been attempting to produce high-performance,
high-stability electro-optic plastics for high-speed (wide bandwidth)
telecommunication applications. These efforts have largely been
unsuccessful due, in our opinion, to the industry's singular adherence
to an industry pervasive engineering model known as the Bond Length
Alternation ("BLA") theory model. The BLA model, like all other
current industry-standard molecular designs, consists of molecular
designs containing long strings of atoms called polyene chains. Longer
polyene chains provide higher electro-optic performance, but are also
more susceptible to environmental threats, which result in
unacceptably low-performing, thermally unstable electro-optic
plastics.


                               6
<PAGE>


     As a result, high frequency modulators engineered with electro-
optic plastics designed on the BLA model or any other polyene chain
design model are  unstable over typical operating temperature ranges,
and often exhibit performance degradation within days, hours or even
minutes. Similarly, lower frequency modulators exhibit comparable
failings, but to a lesser extent. These flaws have prevented commerc-
ial quality polymer-based modulators operating at 10-40 Gb/s from
entering the commercial marketplace. The thermal stability of these
devices does not generally meet the minimum Telcordia GR-468 operating
temperature range (-40 degrees Celsius to +85 degrees Celsius) much
less the more harsh MILSPEC 883D (military specification) range of
-55 degrees Celsius to 150 degrees Celsius.

      None of our molecular designs rely on the BLA polyene chain
design model. Our proposed solution lies in a far less mainstream, yet
firmly established scientific, phenomenon called aromaticity.
Aromaticity causes a high degree of molecular stability. It is a
molecular arrangement wherein atoms combine into multi-membered rings
and share their electrons among each other. Aromatic compounds are
stable because the electronic charge distributes evenly over a great
area preventing hostile moieties, such as oxygen and free radicals,
from finding an opening to attack. To our knowledge, no one has
previously been able to demonstrate molecular designs that could
effectively exploit aromaticity in the design of a high-performance
electro-optic plastic.

     Our research and findings in this area resulted in our Company
being the sole recipient of the 2006 Electro-Optic Materials Technology
Innovation of the Year Award by Frost & Sullivan. Frost & Sullivan's
Technology Innovation of the Year Award is bestowed upon candidates
whose original research has resulted in innovations that have, or are
expected to bring, significant contributions to multiple industries in
terms of adoption, change, and competitive posture. This award
recognizes the quality and depth of our Company's research and
development program as well as the vision and risk-taking that enabled
us to undertake such an endeavor. Our Company did not actively elicit
consideration or apply to receive this award.  Frost & Sullivan
independently contacted our Company and conducted several interviews
which included chemical and technical experts in the field of
electro-optics who were supplied with detailed public information
regarding our Company's technological innovations.


Our Patents

    We hold one patent and thirty pending patent applications (consisting of
five patent applications in each of Australia, Canada, China, European
Patent Convention, Japan and the U.S. based on the PCT applications below)
in the field of nonlinear optic chromophore design as follows:

6,041,157       -Environmentally sensitive compositions of matter based
               	 on 3H-fluoren-3-ylidenes and process for making same;
PCT/US05/39212 	-Tricyclic Spacer Systems for Nonlinear Optical Devices;
PCT/US05/39664	-Anti-Aromatic Chromophore Architectures;
PCT/US05/39213	-Heterocyclical Anti-Aromatic Chromophore Architectures;
PCT/US05/39010	-Heterocyclical Chromophore Architectures;
PCT/US06/11637	-Heterocyclical Chromophore Architectures with Novel
                 Electronic Acceptor Systems.

Heterocyclical Anti-Aromatic Systems. Two of our provisional patents
------------------------------------
cover heterocyclical anti-aromatic electronic conductive pathways,
which are the heart of our high-performance, high-stability molecular
designs. The completely heterocyclical nature of our molecular designs
"lock" conductive atomic orbitals into a planar (flat) configuration,
which provides improved electronic conduction and a significantly


                               7
<PAGE>

lower reaction to environmental threats (e.g. thermal, chemical,
photochemical, etc.) than the BLA design paradigm employed by other
competitive electro-optic polymers.

The anti-aromatic nature of these structures dramatically improves the
"zwitterionic-aromatic push-pull" of the systems, providing for low
energy charge transfer.  Low energy charge transfer is  important for
the production of extremely high electro-optic character.

Heterocyclical Steric Hindering System. This patent describes a
--------------------------------------
nitrogenous heterocyclical structure for the integration of steric
hindering groups that are necessary for the nanoscale material
integration.  Due to the [pi]-orbital configuration of the nitrogen
bridge, this structure has been demonstrated not to interfere with the
conductive nature of the electronic conductive pathway and thus is
non-disruptive to the electro-optic character of the core molecular
construction.  The quantum mechanical design of the system is designed
to establish complete molecular planarity (flatness) for optimal per-
formance.

Totally Integrated Material Engineering System. This patent covers
----------------------------------------------
material integration structures under a design strategy known as
Totally Integrated Material Engineering. These integration structures
provide for the "wrapping" of the core molecule in sterically hinder-
ing groups that maximally protect the molecule from environmental
threats and maximally protect it from microscopic aggregation (which
is a major cause of performance degradation and optical loss) within a
minimal molecular volume.  These structures also provide for the
integration of polymerizable groups for integration of materials into
a highly stable cross-linked material matrix.

Our Latest Tests and Results

      Prior to our recent experimental results, in 2004, quantum
mechanical calculations were independently performed on our novel
electro-optic plastic designs at government laboratories located at
the Naval Air Warfare Center Weapons Division in China Lake,
California. The results of these calculations suggest that our initial
aromatic molecules perform two and a half (2.5) to three and three-
tenths (3.3) times more efficiently than currently available telecom
grade electro-optic plastics. Logical extensions of this novel
molecular design paradigm further suggest even greater performance
improvements.  Subsequently, top scientists and engineers at Wright-
Patterson Air Force Base reviewed these calculations and concluded
that our molecular designs show promise of a five to ten times
improvement over existing commercial polymeric architectures. Our
conclusion is that performance improvements of this magnitude indicate
a significant breakthrough in the field of fiber-optic
telecommunication.

      In May and June of 2006, we initiated performance evaluations of
one of our first extremely high-performance electro-optic materials.
The initial tests were performed by electro-optic expert, Dr. C.C.
Teng, co-inventor of the renowned Teng-Man test, the industry-wide
standard method of evaluating the material performance of electro-
optic plastics, and subsequently confirmed by the University of
Arizona's College of Optical Sciences, one of the most respected and
fastest growing optical sciences departments in the world.  Under
identical laboratory conditions at low molecular loadings, one of our
recent molecular designs outperformed one of the industry's highest


                               8
<PAGE>

performance electro-optic systems by a factor as high as 650%.

      We believe recent results of the Teng-Man test have established
the validity of our novel, patented molecular design paradigm known as
CSC (Cyclical Surface Conduction) theory. We believe the success of
CSC theory has the potential to establish the fundamental blueprint of
electro-optic material design for decades to come, and to have broad
application in commercial and military telecommunication and advanced
computational systems.

      On September 25, 2006 we obtained independent laboratory results
that confirmed the thermal stability of our Perkinamine electro-optic
materials. Thermal stability as high as 350 degrees Celsius was
confirmed, significantly exceeding many other commercially available
high performance electro-optic materials, such as CLD-1 which exhibits
thermal degradation in the range of 250 degrees Celsius to 275 degrees
Celsius. This high temperature stability of our materials eliminates a
major obstacle to vertical integration of electro-optic polymers into
standard microelectronic manufacturing processes (e.g. wave/vapor-
phase soldering) where thermal stability of at least 300 degrees
Celsius is required. In independent laboratory tests, ten-percent
material degradation, a common evaluation of overall thermal
stability, did not occur until our Perkinamine material base was
exposed to temperatures as high as 350 degrees Celsius, as determined
by Thermo-Gravimetric Analysis (TGA).

      The test results supported our Company's progress to introduce
our materials into commercial applications such as optical
interconnections, high-speed telecom and datacom modulators, and
military/aerospace components.

      In July 2007, our Company developed an innovative process to
integrate our unique architecture into our anticipated commercial
devices, whereby dendridic spacer systems are attached to its core
chromophore. In the event we are successful in developing a
commercially viable product, we believe these dendrimers will reduce
the cost of manufacturing materials and reduce the cost and complexity
of tailoring the material to specific customer requirements.


                The Electro-Optic Device Market

General

     Electro-optic devices such as fiber-optic modulators translate
electric signals into optical signals. Such devices are used in
communication systems to transfer data over fiber-optic networks.
Optical data transfer is significantly faster and more efficient than
transfer technologies using only electric signals, permitting more
cost-effective use of bandwidth for broadband Internet and voice
services.

     Two distinct technologies currently exist for the fabrication of
fiber-optic devices, such as fiber-optic modulators. The first, which
is the more traditional technology, utilizes an electro-optically
active inorganic core crystalline material (e.g. lithium niobate). The
second, which is the up-and-coming technology, involves the
exploitation of electro-optic plastics.

      According to a market survey by Triple Play Communications
Corporation, a design and market consulting company we contracted
with, the 40Gb optical modulator market, alone, is expected to grow
to $2.6 Billion by 2014, with 40 Gb modulators accounting for just
over a $1 B in revenue. Higher speed modulators, including 100Gb
modulators, are predicted to be $140 million by 2014.



                               9
<PAGE>

Traditional Technology - Inorganic Crystals

     Traditional technology translates electric signals into optical
signals generally relying upon electro-optic materials, such as
lithium niobate or gallium arsenide. Six of the largest inorganic
fiber-optic component manufactures hold approximately 85% of the
electro-optic modulator component market. They are JDS Uniphase,
Sumitomo, Avanex, Covega, Fujitsu, and Bookham. These companies are
heavily invested in the production of crystalline-based electro-optic
modulator technologies, as well as the development of novel
manufacturing techniques and integrated laser/modulator designs. While
each company possesses their own modulator design and processing
patents, the underlying core constituents (lithium niobate, gallium
arsenide, indium phosphide) occur in nature and as such cannot be pat-
ented.

New Technology - Organic Plastics

     Our developing technology that translates electric signals into
optical signals relies upon organic electro-optic materials, such as
electro-optic plastics. Electro-optic plastics involve the material
integration of specifically engineered organic (carbon-based)
compounds. The molecular designs of these compounds are precise and do
not occur naturally; thus they may be protected under patent law.

     Plastic-based electro-optic modulators may provide considerable
advantages over traditional inorganic fiber-optic technology in terms
of:

     *    Costs.
     *    Size and versatility.
     *    Modulating/switching speed.
     *    Optical transmission properties.
     *    Lower operating voltages.

     Other than our own Company, we are aware of only one other group,
Lumera Corporation ("Lumera"), in collaboration with the University of
Washington, which has designed and patented potentially commercially
feasible electro-optic plastics. Prior to our own technological
developments, Lumera held an exclusive monopoly on this area of tech-
nology because Lumera holds an exclusive present and future license to
all electro-optic polymeric technology developed within the University
of Washington. Lumera has yet, to our knowledge, to publicly
demonstrate a robust, stable commercial modulator capable of low cost
volume production.

     As a result, no significant commercial market developments have
occurred with electro-optic plastic devices. This is because all
previously known electro-optic polymer design strategies incorporate
molecular structures that adversely react to the requisite
polymerization processes that thermally-stabilize the material matrix.
This inherent design flaw causes the polymer to melt at unreasonably
low temperatures, which corrupts the polymer's electro-optic
performance.


                               10
<PAGE>


     Our Company holds an extensive amount of internally developed
intellectual property in the field of electro-optic molecular design
that, as a whole, attempts to fundamentally solve these and other
problems associated with these molecular structures. We believe our
provisional patents describe broad, highly unique techniques for novel
paradigms in molecular design.

     Our innovative solution lies in a very well-known scientific
phenomenon called aromaticity, which causes a high degree of molecular
stability. Aromaticity is a molecular arrangement wherein atoms
combine into multi-membered rings and share their electrons among each
other.  Aromatic compounds are extremely stable because the electronic
charge distributes evenly over a great area preventing hostile
moieties, such as oxygen and free radicals, from finding an opening to
attack. Until now, to our knowledge, no one has been able to propose
molecular designs that could effectively exploit aromaticity in the
design of a high-performance electro-optic plastic.

     We believe now that we have fabricated electro-optic molecular
architectures that do in fact exhibit extremely high thermal sta-
bility, our technologies may soon replace inorganic electro-optic
materials in the marketplace due to their considerable advantages over
traditional inorganic fiber-optic materials.

                       Our Target Markets

     Our proprietary electro-optic plastics are designed at the
molecular level for potentially superior performance, stability and
cost-efficiency and we believe may have the potential to replace more
expensive, lower-performance materials used in fiber-optic ground,
wireless and satellite communication networks. Our electro-optic
plastics may have broad applications in civilian and military
telecommunications and advanced computational systems. Potential
future applications, in our opinion, include: (i) telecommunications;
(ii) backplane optical interconnects; (iii) entertainment; (iv)
medical applications; (iv) satellite reconnaissance; (vi) navigational
systems; (vii) radar applications; and (viii) all-optical transistors.

Telecommunications

     Telecommunications is the primary initial target application for
electro-optic plastics.  Electro-optic plastics could not only
simplify the device design of key components, such as modulators,
significantly reducing packaging costs, but could also provide for
higher speed devices with greater system miniaturization. Current
crystalline (e.g. lithium niobate) fiber-optic modulators are
difficult and expensive to manufacture due to the complexities of
producing single crystalline ingots of sufficient diameter (3 to 5
inches). Also, strict environmental controls must be enforced during
the growth of the core crystalline material. Plastics are not
inherently costly to produce nor do they require such strict
environmental conditions. Due to their material flexibility (e.g.
ability to more easily mold into specific topologies) they are
expected to enable smaller, cheaper, faster, less expensive, and more
integrated network components.  In many laboratory tests, electro-
optic polymers have demonstrated substantial (3-10x) transmission data
speed improvements over crystalline technologies (lithium niobate,
gallium arsenide, indium phosphide).


                               11
<PAGE>

Backplane Optical Interconnects

     It is reported that backplane optical interconnects are
envisioned by members within leading corporations (including IBM,
Intel and Agilent Technologies) as the future of high-speed
computation. These components could speed the transmission of informa-
tion within an integrated circuit, among integrated circuit chips in a
module, and across circuit boards at speeds unattainable with
traditional metallic interconnections and bus structures. In the
future, all-optical (light switching light) signal processing could
become possible using the third-order effect of our materials.

Entertainment

     Entertainment applications, including CATV and Internet, are a
highly important potential application subdivision of the
telecommunication market.  The ever-increasing number of entertainment
services such as VOD (video on demand) and digital cable, as well as
the future ability to download television and movies real-time from
the Internet, drives the demand for ever-increasing bandwidth.
Flexible displays utilizing organic light emitting diodes are
inherently compatible with our polymer waveguides.

Medical Applications

     Medical Applications for electro-optic plastics have been
proposed for many varied applications, including dentistry, oncology
and protein identification.  Although experimental, it is believed
that the successful fabrication of high-stability electro-optic
plastics could open up many future applications such as these.  Other
medical applications such as the higher-speed transmission of medical
records, X-ray and MRI scans over the Internet would be improved by
the broadening of Internet bandwidths.

Satellite Reconnaissance

     Satellite reconnaissance applications include a specific target
market within the Department of Defense, the 14-member Intelligence
Community and their contractors.  Electro-optic plastics have
historically been seen as attractive for potential application in this
market due to the constant need for the fastest bandwidth transmission
to meet the needs of national security.

Navigational Systems

     Navigational systems for both advanced aerial and missile
guidance require the use of electro-optic gyroscopes.  These devices
are currently fabricated out of lithium niobate or similar electro-
optic materials; the application of electro-optic plastics would
facilitate the development of more accurate and architecturally simple
device designs.

Radar Applications

     Radar Applications, specifically phased array radar, has been
traditionally understood as a potential application for successful
electro-optic material designs, along with electronic counter measure


                               12
<PAGE>


systems (ECM) systems, ultra-fast analog-to-digital conversion, land
mine detection, radio frequency photonics and spatial light
modulation.

All-Optical Transistors

     All-optical transistors are expected to be included in the future
market of all-optic devices. All-optical devices convert data in the
form of input light signals to a secondary light data stream. Some
experts anticipate that all-optical transistors will replace
traditional transistors used today in microprocessors. All-optical
transistors are expected to enable the fabrication of an entirely new
high-speed generation of "plastic" computers that operate on light
instead of electricity, which in turn should significantly improve
computation speeds.

                      Our Business Strategy

     Our economic model anticipates that our revenue stream will be
derived from one or some combination of the following: (i) technology
licensing for specific product application; (ii) joint venture
relationships with significant industry leaders; or (iii) the
production and direct sale of our own electro-optic device components.
Our objective is to be a leading provider of proprietary technology
and know-how in the electro-optic device market. In order to meet this
objective, we intend, subject to successful testing of our technology
and having available financial resources, to:

     *    Develop electro-optic product devices.
     *    Continue to develop proprietary intellectual property.
     *    Streamline our product development process.
     *    Develop a comprehensive marketing plan.
     *    Maintain/develop strategic relationships with government
          agencies, private firms, and academic institutions.
     *    Attract seasoned executives to join in senior management
          positions.
     *    Expand into a state-of-the-art development, testing and
          manufacturing facility.

Develop Electro-Optic Product Devices

     We intend to utilize our proprietary technology to create an
initial portfolio of commercially feasible electro-optic plastic
product devices and applications for various markets, including
telecommunications and government.  We expect our initial product
device line to include high speed 40Gb/s modulators and system
applications.

Continue to Develop Proprietary Intellectual Property

     We plan to advance our core competence in electro-optic plastic
technology by continuing to develop proprietary materials, processes,
designs and devices. We also plan to protect our technology by filing
patent applications where appropriate, obtaining exclusive technology
rights where available, and taking other appropriate steps to secure
and protect our intellectual property.


                               13
<PAGE>


Streamline Our Product Development Process

     We intend to streamline our development process and to design,
test and fabricate potential electro-optic plastic devices in order to
position our Company to take advantage of emerging market
opportunities.

Develop a Comprehensive Marketing Plan

     We intend to build a sales and marketing organization dedicated
to developing customers and multiple distribution channels for our
products. We plan to aggressively pursue sales of our potential
products through the use of industry-specific sales representation
organizations, such as electro-optic component distributors. In
addition, we plan to target market leaders as initial customers and to
leverage relationships with these market leaders to obtain future
contracts and sales references.

      In August 2006 we contracted with Triple Play Communications
Corporation, a design and market consulting company, to deliver a
comprehensive market opportunity assessment report for high speed
40Gb/s (commercial) & 100Gb/s + (military/aerospace) modulators and
system applications. The report was completed in November 2006, and
according to the report, the global high-speed optical equipment
market has performed better in the second quarter of 2006 than it has
in the past four years, rising to $3B.  More than $1B was spent in
North America alone as carriers expanded capacity of their metro and
backbone networks to make room for video traffic.

      The report focused on the emerging 40Gb/s telecommunications
market, one of our primary target markets for our polymer modulator
technology.  The report noted that this market segment alone is
projected to approach $1B in cumulative sales between now and 2011.

Maintain/Develop Strategic Relationships with Government Agencies,
Private Firms, and Academic Institutions

     Almost since our inception, we have had beneficial strategic
relationships with various government agencies that have provided us
with funding and access to important technology. We intend to re-
establish our relationship with DARPA, the Defense Advance Research
Project Agency (the agency in the Intelligence Community credited with
the origination of the Internet), by sharing the technical data and
test results on our aromatic molecular materials. DARPA previously
provided our Company with funding in order to advance of our
technologies and to bring them to the public market, but due to a
change in focus at DARPA our funding was not renewed.

     As we advanced towards the commercialization phase of our
strategic plan, we commenced discussions with several potential
strategic alliance partners ranging from micro-electronic component
firms to large-scale computer companies, as well as petrochemical
companies having very large volume production capabilities. We believe
strategic alliances and/or technology licensing will be a crucial step
in commercializing our novel technologies and achieving competitive
advantages. We recently entered into a memorandum of understanding


                               14
<PAGE>

with Photon-X, LLC, a technology solutions provider for polymer
waveguides that works in conjunction with various government agencies.

     We have also developed an excellent relationship with the
University of Delaware, an institution well known for excellence in
chemical engineering, which we intend to maintain and strengthen.

Attract Seasoned Executives to Join in Senior Management Positions

      Since we reached certain in-house technological milestones with
respect to our aromatic polyheterocyclical ring molecule, we are
recruiting seasoned executive managers to assist our Company with
product commercialization. From September 2005 to February 2007, we
engaged the services of Mr. Ronald Genova as our Interim Chief
Executive Officer. Mr. Genova is the former Vice-President of JDS
Uniphase's Telecom Optical Modules division and has nearly 30 years in
optoelectronics and semiconductor industries. In March 2007 we engaged
Mr. Harold R. Bennett, a corporate restructuring advisor, to join our
board of directors in anticipation of an internal restructuring of our
entire corporate management team that will be required to successfully
incorporate our technology into functional commercial products. We
subsequently named him as our chief executive officer.

Expand Into A State-Of-The-Art Development, Testing and Manufacturing
Facility

      We plan to expand into a state-of-the-art development, testing
and manufacturing facility in order to advance our technology
platforms, attract additional key industry talent, streamline our
product development processes and minimize our time to market. We have
already begun to integrate our operations with respect to streamlining
our product development process and minimizing the time to market for
our potential products through a multifaceted approach to material
development. We are able to accomplish this because our technology
provides us with the flexibility to create tailored material
properties for a multitude of specific applications, and also to allow
for the specific tailoring of materials for compatibility with
silicon, glass, metals or many plastics.

      In August 2006, we executed a co-location agreement with a New
Jersey-based micro-optics company, InPlane Photonics, that allowed our
scientists to advance our organic material development. The agreement
with InPlane was terminated in early 2007 in favor of a strategic
alliance formed in December, 2006 with Photon-X, LLC, a Pennsylvania-
based company that has significant experience in polymer waveguide
production. Photon-X is working as a strategic ally with our Company
to establish a pre-production line in order to test and integrate our
organic materials into waveguide devices and system prototypes as a
first step toward product commercialization.  The agreement affords
our Company access to a full suite of fabrication facilities capable
of producing commercial quantities of precision micro-optic devices
such as high-speed 40Gb/s telecom modulators, optical filters, and
optical interconnects important to military and civilian global
information movement and management markets. Photon-X is participating
as a strategic supplier to our Company in a proposal we've made to a
major US defense contracting company for a project involving analog
optical processing for national security and Homeland Defense.


                               15
<PAGE>


               Our Research and Development Process

     Our research and development process consists of the following
steps:

     *   We develop novel polymer materials utilizing our patented
         technology to meet certain performance specifications. We
         then develop methods to synthesize larger quantities of such
         material.

     *   We conduct a full battery of tests at the completion of the
         synthesis of each new polymer material to evaluate its
         characteristics. We also create development strategies to
         optimize materials to meet specifications for specific
         applications.

     *   We integrate data from the material characterization and
         test results to fabricate devices. We analyze device-testing
         results to refine and improve fabrication processes and
         methods. In addition, we investigate alternative material
         and design variations to possibly create more efficient
         fabrication processes.

     *   We create an initial device design using simulation
         software. Following device fabrication, we run a series of
         optical and electronic tests on the device.


                  Our Current Strategic Partners

Photon-X, LCC

     As mentioned above, we recently entered into a memorandum of
understanding with Photon-X, LLC, a technology solutions provider for
polymer waveguides that works in conjunction with various government
agencies. In connection therewith, we will provide Photon-X with our
unique polymeric material to be tested and used on certain niche
devices for anticipated military and commercial applications.  If the
tests are successful, our management believes that our alliance with
Photon-X will serve to simultaneously lead its commercialization as
well as publicly validate its scientific findings, creating a new
standard in electro-optic polymers.

Universal Capital Management, Inc.

    We have an advisory relationship with Universal Capital
Management, Inc. ("Universal"), a Delaware based Business Development
Company. Universal is a public venture capital company that invests
largely in start-up or mature stage companies that demonstrate
significant upside potential. Universal provides us with both capital
and managerial experience, and is assisting us in creating an
awareness of our developing technology in both the government and
commercial markets as we move closer to the commercialization phase of
our strategic plan. Universal's professionals participate in selected
Company's planning and operations by providing us with managerial,
strategic and financial expertise.

Others

     We also entered into a development agreement with Triple Play
Communications Corporation, a design and market consulting company,
and we are currently in discussions with other potential partners.


                               16
<PAGE>

            Our Past Government Program Participation

    Our Company has been a participant in several vital government
sponsored research and development programs with various government
agencies that protect the interests of our country. The following is a
list of some of the various divisions of government agencies that have
provided us with advisory, financial and/or materials support in the
pursuit of high-speed electro-optic materials. We are not partnered
with, strategically related to, or financially supported by any
governmental agency at this time.

National Reconnaissance Office (NRO)

    During 1998 and 1999, we worked with the NRO to advance the
development of extremely high performance electro-optic polymers
pursuant to an unclassified Director's Innovative Initiative. The NRO
is a member of the Department of Defense Agency and plays a primary
role in achieving information superiority for the U.S. Government and
Armed Forces. The NRO designs, builds, and operates reconnaissance
satellites, assists in military operation preparedness, and monitors
the environment. NRO products are paramount to national security and
are provided to an expanding list of users including the Central
Intelligence Agency and the Department of Defense.

Army Research Laboratory (ARL)

    During 1998 through 2000, we were provided strong support for our
electro-optic materials development by the Process and Properties
Branch of the Army Research Laboratory on the Aberdeen Proving Grounds
in Aberdeen, Maryland. This support was in cooperation with other
government agencies and included the advisory support of the Army
Missile Command at Redstone Arsenal. The Army Research Laboratory
provided us with access to its highly advanced organic chemical
development laboratories and state-of-the-art analytic equipment. PSI-
TEC operated out of more than five laboratories at the Army Research
Laboratory. During the nascent stages of our technological
development, this support provided us with the strong foundations we
needed to progress electro-optic technology into its second
generation. The technically skilled members at Army Missile Command
provided our engineers instruction on the latest advancements of the
military's research and development in the area of polymeric materials
and device fabrication. Much of our initial work at the Army Research
Laboratory was based upon revolutionary advancements of our Chief
Technical Officer's (Dr. Frederick J. Goetz) highly unique electro-
optic polymeric design as exhibited in our U.S. Patent #6,041,157:
"Environmentally sensitive compositions of matter based on 3H-fluoren-
3-ylidenes and process for making same."

Defense Advance Research Project Agency (DARPA)

    DARPA, the agency in the Intelligence Community credited with the
origination of the Internet, provided our Company with funding for the
advancement of our technologies and bridging these technologies to the
public market. Under the auspices of DARPA initiatives, the MORPH
(Molecular Photonics) and C2OI (Chip-to-Chip Optical Interconnects)
programs, our advanced technologies were reviewed by the Naval Air
Warfare Center Weapons Division (NAVAIR) and the Air Force Research


                               17
<PAGE>

Laboratory (AFRL). DARPA works to maintain the technological
superiority of the U.S. military and to prevent technological surprise
from harming our national security by sponsoring revolutionary, high-
payoff research that bridges the gap between fundamental discoveries
and their military use.

Naval Air Warfare Center Weapons Division (NAVAIR)

    Under the auspices of the Defense Advance Research Projects
Agency (DARPA), high-level scientists at the Naval Air Warfare Center
Weapons Division in China Lake, California reviewed our electro-optic
molecular design paradigms in 2004. Computer calculations regarding
the quantum mechanical performance of our electro-optic molecular
designs were repeated and verified by NAVAIR staff. These calculations
suggest an improvement in electro-optic performance over the current
state-of-the-art.

    Our unique, proprietary technology was demonstrated through
detailed computer calculations to improve existing approaches in the
production of ultra fast frequencies (wide bandwidths). Calculations
performed at NAVAIR regarding our preliminary, first-stage next-
generation molecular architectures indicate an improvement of
hyperpolarizability (electro-optic character) of several times
existing state-of-the-art molecular designs.

    These computer calculations have recently been validated by
independent tests performed on our recently developed electro-optic
materials at the University of Arizona.

Air Force Research laboratory (AFRL)

    In cooperation with the Defense Advance Research Projects Agency
(DARPA), our molecular design technologies were reviewed by top-level
and senior engineers and scientists at the Air Force Research
Laboratory at Wright-Patterson Air Force Base in Dayton, Ohio. An Air
Force Research Laboratory senior scientist and engineer, in connection
with a National Science Foundation proposal and as a result of reviews
conducted under the Defense Advance Research Projects Agency's C2OI
(Chip-to-Chip Optical Interconnects) and MORPH (Molecular Photonics),
concluded that, "[our] molecular designs show promise of a five to ten
times improvement over existing commercial polymeric architectures."
In review of detailed calculations performed on our future material
designs, Air Force Research Laboratory personnel further note,
"Computer simulations and modeling indicate that [our] approach to
materials synthesis has the potential for realizing high nonlinearity
(i.e., high electro-optic performance). This, in turn, could result in
five to ten times lower drive voltages for devices." "Synthesis of
[our] materials to verify the properties predicted by the computer
models is essential for new NLO (electro-optic) polymer material
development.... This is a very novel and promising approach that has
the potential for high payoff."

    These predictions have recently been validated by independent
tests performed on our recently developed electro-optic materials at
the University of Arizona, which performed approximately seven times
better than other competitive technologies.


                               18
<PAGE>


    In regards to applications of our materials, an Air Force
Research Laboratory senior scientist states, "Highly active NLO
(electro-optic) polymer materials are key for the realization of next
generation electro-optic devices and render high application potential
for high-speed fiber-optic telecommunication (i.e., Internet, HDTV),
satellite reconnaissance (i.e., homeland security), and navigation and
guidance systems."

                         Our Competition

    The markets we are targeting for our electro-optic polymer
technology are intensely competitive. Among the largest fiber-optic
component manufactures are JDS Uniphase, Avanex, Sumitomo, Fujitsu,
Mitsubishi, Corning, Bookham, OpNext and FiBest.  Additional
significant domestic component manufacturers include Covega, Apogee,
Multiplex, and CyOptics. All of these companies are heavily invested
in the production of crystalline-based electro-optic modulator
technologies as well as the development of novel manufacturing
techniques and modulator designs.

    Other than our own Company, we are aware of only one other group,
Lumera Corporation ("Lumera") in collaboration with the University of
Washington, that has designed and patented a commercially feasible
electro-optic plastic. Prior to our own technological developments,
Lumera held an exclusive monopoly on this area of technology. Lumera
holds an exclusive present and future license to all electro-optic
polymeric technology developed within the University of Washington.

    As one of only two companies known to us that are actively pursuing
the development of high-performance electro-optic materials for
application and development in the high-speed telecommunication
markets, we believe that upon the commercialization of our technology,
that we will be poised to obtain a significant portion of the
component manufacturing market.  Electro-optic plastics demonstrate
several advantages over other technologies, such as crystalline-based
technologies, due to their reduced manufacturing and processing costs,
higher performance and lower power requirements.  Our electro-optic
plastics are CSC model molecules that have demonstrated significant
stability advantages over our sole known competitor's (Lumera)
materials.  In the expectation of becoming the sole producer of
high-performance, high-stability electro-optic materials, we hope
to capture all or some of this potential electro-optic component market.


    We believe the principal competitive factors in our target
markets are:

    *    The ability to develop and commercialize highly stable
         polymer-based products, including obtaining appropriate
         patent and proprietary rights protection.

    *    Low cost, high production yield for these products.

    *    The ability to enable integration and implement advanced
         technologies.

    *    Strong sales and marketing channels for access to products.

    We believe that our current business planning will position our
Company to compete adequately with respect to these factors. Our
future success is difficult to predict because we are an early stage
company with all of our potential products still in development.

    Many of our existing and potential competitors have substantially
greater research and product development capabilities and financial,
scientific, marketing and human resources than we do. As a result,
these competitors may:

    *    Succeed in developing products that are equal to or
         superior to our potential products or that achieve greater
         market acceptance than our potential products.

    *    Devote greater resources to developing, marketing or
         selling their products.

    *    Respond more quickly to new or emerging technologies or
         scientific advances and changes in customer requirements,
         which could render our technologies or potential products
         obsolete.

    *    Introduce products that make the continued development of


                               19
<PAGE>


         our potential products uneconomical.

    *    Obtain patents that block or otherwise inhibit our ability
         to develop and commercialize our potential products.

    *    Withstand price competition more successfully than we can.

    *    Establish cooperative relationships among themselves or
         with third parties that enhance their ability to address
         the needs of our prospective customers.

    *    Take advantage of acquisition or other opportunities more
         readily than we can.

Our Laboratory Facilities

    Our Company operates an organic synthesis and thin-films
laboratory in Wilmington, Delaware. These facilities include state-of-
the-art equipment including NMR, IR, UV/VIS and HPLC analytical
systems, profilometry evaluation and electro-optic (r33) materials
characterization necessary to produce next generation fiber-optic
organic materials.  We also utilize an electro-optic test facility in
conjunction with local universities to perform critical evaluation
tests (eg. R33) on our polymer material films and future electro-optic
devices, such as our waveguides, modulators, and all-optical
transistors.

             Risk Factors Related To Our Business

     Investing in our common stock is risky. In addition to the other
information in this registration statement, you should consider
carefully the following risk factors in evaluating us and our
business. If any of the events described in the following risk factors
were to occur, our business, financial condition or results of
operations likely would suffer. In that event, the trading price of
our common stock could decline, and you could lose all or a part of
your investment.


We have incurred substantial operating losses since our inception and
will continue to incur substantial operating losses for the
foreseeable future.

    Since our inception, we have been engaged primarily in the
research and development of our polymer materials technologies and
potential products. As a result of these activities, we incurred
significant losses and experienced negative cash flow since our
inception. We incurred a net loss of $2,657,459 for the year ended
December 31, 2006 and $1,708,057 for the year ended December 31, 2005.
We anticipate that we will continue to incur operating losses through
at least 2007.

    We may not be able to generate significant revenue either through
development contracts from the U.S. government or government
subcontractors or through customer contracts for our potential
products or technologies. We expect to continue to make significant
operating and capital expenditures for research and development and to
improve and expand production, sales, marketing and administrative
systems and processes. As a result, we will need to generate
significant additional revenue to achieve profitability. We cannot
assure you that we will ever achieve profitability.


                               20
<PAGE>


    These conditions raise substantial doubt to our auditors about
our ability to continue as a going concern. Successful completion of
our research and development program and, ultimately, the attainment
of profitable operations is dependent upon future events, including
our ability to obtain adequate financing to fulfill our development
activities and achieving a level of sales adequate to support our
Company's cost structure.


Our independent auditors have expressed substantial doubt about our
ability to continue as a going concern

    Our independent auditors have included an explanatory paragraph in
their audit report issued in connection with our financial statements
which states that our significant losses and negative cash flow during
our development stage raise substantial doubt about our ability to
continue as a going concern. Our financial statements do not include
any adjustments that might result from the outcome of this uncertainty.
Our ability to continue as a going concern is dependent upon our
ability to successfully complete our development program and,
ultimately, attain profitable operations, which is dependent upon
future events, including obtaining adequate financing to fulfill
our development activities and achieving a level of revenue adequate
to support our cost structure. We cannot assure you that we will be
able to secure the necessary financing and/or equity investment or
achieve an adequate sales level.


We are subject to the risks frequently experienced by early stage
companies.

    The likelihood of our success must be considered in light of the
risks frequently encountered by early stage companies, especially
those formed to develop and market new technologies. These risks
include our potential inability to:

    *    establish product sales and marketing capabilities;

    *    establish and maintain markets for our potential products;

    *    identify, attract, retain and motivate qualified personnel;

    *    continue to develop and upgrade our technologies to keep
         pace with changes in technology and the growth of markets
         using polymer materials;

    *    develop expanded product production facilities and outside
         contractor relationships;

    *    maintain our reputation and build trust with customers;

    *    improve existing and implement new transaction-processing,
         operational and financial systems;

    *    scale up from small pilot or prototype quantities to large
         quantities of product on a consistent basis;

    *    contract for or develop the internal skills needed to master
         large volume production of our products; and

    *    fund the capital expenditures required to develop volume
         production due to the limits of our available financial
         resources.


We are entering new markets, and if we fail to accurately predict
growth in these new markets, we may suffer substantial losses.

     We are devoting significant resources to engineer next-generation
electro-optic plastics for future applications to be utilized by
electro-optic device manufacturers, such as telecommunications
component and systems manufacturers, networking and switching
suppliers, semiconductor companies, aerospace companies and government
agencies. We expect to continue to develop products for these markets
and to seek to identify new markets. These markets change rapidly and
we cannot assure you that they will grow or that we will be able to


                               21
<PAGE>

accurately forecast market demand, or lack thereof, in time to respond
appropriately. Our investment of resources to develop products for
these markets may either be insufficient to meet actual demand or
result in expenses that are excessive in light of actual sales
volumes. Failure to predict growth and demand accurately in new
markets may cause us to suffer substantial losses. In addition, as we
enter new markets, there is a significant risk that:

     *   the market may not accept the price and/or performance of our
         products;

     *   there may be issued patents we are not aware of that could
         block our entry into the market or could result in excessive
         litigation; and

     *   the time required for us to achieve market acceptance of our
         products may exceed our capital resources which would require
         additional investment.


The establishment and maintenance of collaborative relationships is
critical to the success of our business.

     We expect to sell many of our products directly to commercial
customers or through potential industry partners. For example, we
expect to sell our electro-optic plastic products to electro-optic
device manufacturers, such as telecommunications component and systems
manufacturers, networking and switching suppliers, semiconductor
companies, aerospace companies and government agencies. Our ability to
generate revenues depends significantly on the extent to which
potential customers and other potential industry partners develop,
promote and sell systems that incorporate our products. Any failure by
potential customers and other potential industry partners to
successfully develop and market systems that incorporate our products
could adversely affect our sales. The extent to which potential
customers and other industry partners develop, promote and sell
systems incorporating our products is based on a number of factors
that are largely beyond our ability to control.


Our future growth will suffer if we do not achieve sufficient market
acceptance of our electro-optic plastic products.

     We are developing our electro-optic polymer products to be
utilized by electro-optic device manufacturers, such as
telecommunications component and systems manufacturers, networking and
switching suppliers, semiconductor companies, aerospace companies and
government agencies. All of our potential products are still in the
development stage, and we do not know when a market for these products
will develop, if at all. Our success depends, in part, upon our
ability to gain market acceptance of our products. To be accepted, our
products must meet the technical and performance requirements of our
potential customers. OEMs, suppliers or government agencies may not
accept polymer-based products. In addition, even if we achieve some
degree of market acceptance for our potential products in one
industry, we may not achieve market acceptance in other industries for
which we are developing products. If the markets we are targeting fail
to accept polymer-based products or determine that other products are
superior, we may not be able to achieve market acceptance of our
products.


                               22
<PAGE>

    Achieving market acceptance for our products will require
marketing efforts and the expenditure of financial and other resources
to create product awareness and demand by customers. We may be unable
to offer products that compete effectively due to our limited
resources and operating history. Also, certain large corporations may
be predisposed against doing business with a company of our limited
size and operating history. Failure to achieve broad acceptance of our
products by customers and to compete effectively would harm our
operating results.


Successful commercialization of our current and future products will
require us to maintain a high level of technical expertise.

    Technology in our target markets is undergoing rapid change. To
succeed in our target markets, we will have to establish and maintain
a leadership position in the technology supporting those markets.
Accordingly, our success will depend on our ability to:

    *   accurately predict the needs of our target customers and
        develop, in a timely manner, the technology required to
        support those needs;

    *   provide products that are not only technologically
        sophisticated but are also available at a price acceptable to
        customers and competitive with comparable products;

    *   establish and effectively defend our intellectual property;
        and

    *   enter into relationships with other companies that have
        developed complementary technology into which our products
        may be integrated.

We cannot assure you that we will be able to achieve any of these
objectives.


Two of our significant target markets are the telecommunications and
networking markets, which continue to be subject to overcapacity and
slow growth or decline.

    Two of our significant target markets are the telecommunications
and networking markets, and developments that adversely affect the
telecommunications or networking markets, including delays in traffic
growth and changes in U.S. government regulation, could slow down, or
even halt our efforts to enter into these markets. Reduced spending
and technology investment by telecommunications companies may make it
more difficult for our products to gain market acceptance. Such
companies may be less willing to purchase new technology such as ours
or invest in new technology development when they have reduced capital
expenditure budgets.


Many of our products will have long sales cycles, which may cause us
to expend resources without an acceptable financial return and which
makes it difficult to plan our expenses and forecast our revenues.

    Many of our products will have long sales cycles that involve
numerous steps, including initial customer contacts, specification
writing, engineering design, prototype fabrication, pilot testing,
device certification, regulatory approvals (if needed), sales and
marketing and commercial manufacture. During this time, we may expend


                               23
<PAGE>


substantial financial resources and management time and effort without
any assurance that product sales will result. The anticipated long
sales cycle for some of our products makes it difficult to predict the
quarter in which sales may occur. Delays in sales may cause us to
expend resources without an acceptable financial return and make it
difficult to plan expenses and forecast revenues.


We will require additional capital to continue to fund our operations.
If we do not obtain additional capital, we may be required to
substantially limit our operations.

     Our business does not presently generate the cash needed to
finance our current and anticipated operations. Based on our current
operating plan and budgeted cash requirements, we believe that we will
be able to fund our operations through the latter part of 2007. We will
require additional capital to continue to fund our operations in
future periods. We expect that we will need to seek additional funding
through public or private financings, including equity financings, and
through other arrangements, including collaborative arrangements. Poor
financial results, unanticipated expenses or unanticipated
opportunities could require additional financing sooner than we
expect. We currently have no plans or arrangements with respect to the
possible acquisition of additional financing, and such financing may
be unavailable when we need it or may not be available on acceptable
terms. Additional financing may not be available to us, due to, among
other things, our Company not having a sufficient credit history,
income stream, profit level, asset base eligible to be collateralized,
or market for its securities. If we raise additional funds by issuing
equity or convertible debt securities, the percentage ownership of our
existing stockholders may be reduced, and these securities may have
rights superior to those of our common stock. If adequate funds are
not available to satisfy either short-term or long-term capital
requirements, or if planned revenues are not generated, we may be
required to limit our operations substantially. These limitations of
operations may include reductions in capital expenditures and
reductions in staff and discretionary costs.


We may incur debt in the future that might be secured with our
intellectual property as collateral, which could subject our Company
to the risk of loss of all of our intellectual property.

     If we incur debt in the future, we may be required to secure the
debt with our intellectual property, including all of our patents and
patent pendings. In the event we default on the debt, we could incur
the loss of all of our intellectual property, which would materially
and adversely affect our Company and cause you to lose your entire
investment in our Company.


Our quarter-to-quarter performance may vary substantially, and this
variance, as well as general market conditions, may cause our stock
price to fluctuate greatly and potentially expose us to litigation.

     We have generated no sales to date and we cannot accurately
estimate future quarterly revenue and operating expenses based on
historical performance. Our quarterly operating results may vary
significantly based on many factors, including:

     *    fluctuating demand for our potential products and
          technologies;


                               24
<PAGE>


     *    announcements or implementation by our competitors of
          technological innovations or new products;

     *    amount and timing of our costs related to our marketing
          efforts or other initiatives;

     *    the status of particular development programs and the timing
          of performance under specific development agreements;

     *    timing and amounts relating to the expansion of our
          operations;

     *    product shortages requiring suppliers to allocate minimum
          quantities;

     *    announcements or implementation by our competitors of
          technological innovations or new products;

     *    the status of particular development programs and the timing
          of performance under specific development agreements;

     *    our ability to enter into, renegotiate or renew key agreements;

     *    timing and amounts relating to the expansion of our operations;

     *    costs related to possible future acquisitions of technologies
          or businesses; or

     *    economic conditions specific to our industry, as well as
          general economic conditions.

     Our current and future expense estimates are based, in large
part, on estimates of future revenue, which is difficult to predict.
We expect to continue to make significant operating and capital
expenditures in the area of research and development and to invest in
and expand production, sales, marketing and administrative systems and
processes. We may be unable to, or may elect not to, adjust spending
quickly enough to offset any unexpected revenue shortfall. If our
increased expenses are not accompanied by increased revenue in the
same quarter, our quarterly operating results would be harmed.

      In one or more future quarters, our results of operations may
fall below the expectations of investors and the trading price of our
common stock may decline as a consequence. We believe that quarter-to-
quarter comparisons of our operating results will not be a good
indication of our future performance and should not be relied upon to
predict the future performance of our stock price. In the past,
companies that have experienced volatility in the market price of
their stock have often been subject to securities class action
litigation. We may be the target of this type of litigation in the
future. Securities litigation against us could result in substantial
costs and divert our management's attention from other business
concerns, which could seriously harm our business.


                               25
<PAGE>


We cannot predict the pace of marketable products we may generate, and
any inability to generate a sufficient number of marketable products
would reduce our revenues and harm our business.

      Our future revenues and profitability are dependent upon our
ability to create marketable products, whether through our own
research and development efforts or through collaborations with
customers or industry partners. Because of the inherently uncertain
nature of research and development activities, we cannot predict the
pace of new product introductions. We must undertake additional
research and development before we are able to develop additional
products for commercial sale. Product development delays by us or
potential product development partners, or the inability to enter into
relationships with these potential partners, may delay or prevent us
from introducing products for commercial sale. In addition, our
product candidates may not result in products having the commercial
potential we anticipate. Any of these factors could reduce our
potential commercial sales and lead to inability to generate revenue
and attain profitability.


Our failure to compete successfully could harm our business.

     The markets that we are targeting for our electro-optic polymer
technology are intensely competitive. Most of our present and
potential competitors have or may have substantially greater research
and product development capabilities, financial, scientific,
marketing, manufacturing and human resources, name recognition and
experience than we have. As a result, these competitors may:

     *    succeed in developing products that are equal to or superior
          to our potential products or that will achieve greater market
          acceptance than our potential products;

     *    devote greater resources to developing, marketing or selling
          their products;

     *    respond more quickly to new or emerging technologies or
          scientific advances and changes in customer requirements,
          which could render our technologies or potential products
          obsolete;

     *    introduce products that make the continued development of our
          potential products uneconomical;

     *    obtain patents that block or otherwise inhibit our ability to
          develop and commercialize our potential products;

     *    withstand price competition more successfully than we can;

     *    establish cooperative relationships among themselves or with
          third parties that enhance their ability to address the needs
          of our prospective customers; and

     *    take advantage of acquisitions or other opportunities more
          readily than we can.


                               26
<PAGE>

The failure to compete successfully against these existing or future
competitors could harm our business.


We may be unable to establish sales and marketing capabilities
necessary to successfully commercialize our potential products.

     We currently have limited sales and marketing capabilities. To
date, we have relied upon our strategic partners to assist us in
creating an awareness of our developing technology in both the
government and commercial markets. We will need to either hire sales
personnel with expertise in the markets we intend to address or
contract with others to provide for sales support. Although our
potential products are all based on our polymer materials technology,
the potential products themselves address different markets and can be
offered through multiple sales channels. Addressing each market
effectively will require sales and marketing resources tailored to the
particular market and to the sales channels that we choose to employ.
In addition, the markets in which we operate are highly complex and
technical; we may not have the adequate expertise to adequately market
our products. We may be unable to establish marketing and sales
capabilities necessary to commercialize and gain market acceptance for
our potential products. Co-promotion or other marketing arrangements
with others to commercialize products could significantly limit the
revenues we derive from these products, and these parties may fail to
commercialize such products successfully.


We may be unable to obtain effective intellectual property protection
for our potential products and technology.

     Our intellectual property, or any intellectual property that we
have or may acquire, license or develop in the future, may not provide
meaningful competitive advantages. Our patents and patent
applications, including those we license, may be challenged by
competitors, and the rights granted under such patents or patent
applications may not provide meaningful proprietary protection. For
example, numerous patents held by third parties relate to polymer
materials and electro-optic devices. These patents could be used as a
basis to challenge the validity or limit the scope of our patents or
patent applications. A successful challenge to the validity or
limitation of the scope of our patents or patent applications could
limit our ability to commercialize our polymer materials technology
and, consequently, reduce our revenues.

     Moreover, competitors may infringe our patents or those that we
license, or successfully avoid these patents through design
innovation. To combat infringement or unauthorized use, we may need to
resort to litigation, which can be expensive and time-consuming and
may not succeed in protecting our proprietary rights. In addition, in
an infringement proceeding a court may decide that our patents or
other intellectual property rights are not valid or are unenforceable,
or may refuse to stop the other party from using the intellectual
property at issue on the ground that it is non-infringing. Policing
unauthorized use of our intellectual property is difficult and
expensive, and we may not be able to, or have the resources to,
prevent misappropriation of our proprietary rights, particularly in
countries where the laws may not protect these rights as fully as the
laws of the United States.


                               27
<PAGE>


     We also rely on the law of trade secrets to protect unpatented
technology and know-how. We try to protect this technology and know-
how by limiting access to those employees, contractors and strategic
partners with a need to know this information and by entering into
confidentiality agreements with these parties. Any of these parties
could breach the agreements and disclose our trade secrets or
confidential information to our competitors, or these competitors
might learn of the information in other ways. Disclosure of any trade
secret not protected by a patent could materially harm our business.


We may be subject to patent infringement claims, which could result in
substantial costs and liability and prevent us from commercializing
our potential products.

     Third parties may claim that our potential products or related
technologies infringe their patents. Any patent infringement claims
brought against us may cause us to incur significant expenses, divert
the attention of our management and key personnel from other business
concerns and, if successfully asserted against us, require us to pay
substantial damages. In addition, as a result of a patent infringement
suit, we may be forced to stop or delay developing, manufacturing or
selling potential products that are claimed to infringe a patent
covering a third party's intellectual property unless that party
grants us rights to use its intellectual property. We may be unable to
obtain these rights on terms acceptable to us, if at all. Even if we
are able to obtain rights to a third party's patented intellectual
property, these rights may be non-exclusive, and therefore our
competitors may obtain access to the same intellectual property.
Ultimately, we may be unable to commercialize our potential products
or may have to cease some of our business operations as a result of
patent infringement claims, which could severely harm our business.

     If our potential products infringe the intellectual property
rights of others, we may be required to indemnify customers for any
damages they suffer. Third parties may assert infringement claims
against our current or potential customers. These claims may require
us to initiate or defend protracted and costly litigation on behalf of
customers, regardless of the merits of these claims. If any of these
claims succeed, we may be forced to pay damages on behalf of these
customers or may be required to obtain licenses for the products they
use. If we cannot obtain all necessary licenses on commercially
reasonable terms, we may be unable to continue selling such products.


Our technology may be subject to government rights and retained
research institution rights.

     We may have obligations to government agencies or universities in
connection with the technology that we have developed, including the
right to require that a compulsory license be granted to one or more
third parties selected by certain government agencies. In addition,
academic research partners often retain certain rights, including the
right to use the technology for noncommercial academic and research
use, to publish general scientific findings from research related to
the technology, and to make customary scientific and scholarly
disclosures of information relating to the technology. It is difficult
to monitor whether our partners will limit their use of the technology
to these uses, and we could incur substantial expenses to enforce our
rights to our licensed technology in the event of misuse.


                               28
<PAGE>


The loss of certain of our key personnel, or any inability to attract
and retain additional personnel, could impair our ability to attain
our business objectives.

     Our future success depends to a significant extent on the
continued service of our key management personnel, particularly
Frederick J. Goetz, Jr. our president, Dr. Frederick J. Goetz, our
Chief Technical Officer and Andrew J. Ashton, our senior vice
president. We currently do not have written employment agreements with
any of our key management personnel, and we currently do not maintain
key person life insurance on any executive officer. Accordingly, the
loss of the services of any of these persons would adversely affect
our business and our ability to timely commercialize our products, and
impede the attainment of our business objectives.

     Our future success will also depend on our ability to attract,
retain and motivate highly skilled personnel. In particular, we will
need to hire seasoned executive managers to assist us with product
commercialization, in addition to a significant number of technical
personnel. Competition for highly educated qualified personnel in the
polymer industry is intense. If we fail to hire and retain a
sufficient number of qualified management, engineering, sales and
technical personnel, we will not be able to attain our business
objectives.


If we fail to develop and maintain the quality of our manufacturing
processes, our operating results would be harmed.

     The manufacture of our potential products is a multi-stage
process that requires the use of high-quality materials and advanced
manufacturing technologies. Also, polymer-related device development
and manufacturing must occur in a highly controlled, clean environment
to minimize particles and other yield and quality-limiting
contaminants. In spite of stringent quality controls, weaknesses in
process control or minute impurities in materials may cause a
substantial percentage of a product in a lot to be defective. If we
are not able to develop and continue to improve on our manufacturing
processes or to maintain stringent quality controls, or if
contamination problems arise, our operating results would be harmed.


We may utilize third parties to manufacture our current products and
our revenues could decline if these third parties do not timely
complete our orders and our reputation could suffer if we do not
maintain high quality standards.

     We may enter into manufacturing arrangements with third party
manufacturers and we intend to enter into agreements with additional
corporate partners, OEMs and other third parties. We expect to
contract with manufacturing companies to perform various portions of
our product manufacturing, testing, assembly and shipping and purchase
components to be used in our potential products from third-party
vendors. If these third parties do not timely complete our orders, or
do not properly manufacture our products, our reputation could be
harmed, and our revenues could decline. We cannot assure you that we
will be able to negotiate arrangements with these third parties on
acceptable terms, if at all, or that these arrangements will be
successful in yielding commercially viable products. If we cannot
maintain our current relationships or establish new arrangements, we
will require additional capital to undertake those activities on our


                               29
<PAGE>

own and will require manufacturing expertise that we do not currently
possess and that may be difficult to obtain.


If we decide to make commercial quantities of products at our
facilities, we will be required to make significant capital
expenditures to increase capacity.

     We lack the internal ability to manufacture products at a level
beyond the stage of early commercial introduction. To the extent we do
not have an outside vendor to manufacture our products, we will have
to increase our internal production capacity and we will be required
to expand our existing facilities or to lease or construct new
facilities or to acquire entities with additional production
capacities. These activities would require us to make significant
capital investments and may require us to seek additional equity or
debt financing. We cannot assure you that such financing would be
available to us when needed on acceptable terms, or at all. If we are
unable to expand internal production capacity on a timely basis to
meet increases in demand, we could lose market opportunities for
sales. Further, we cannot assure you that any increased demand for our
potential products would continue for a sufficient period of time to
recoup our capital investments associated with increasing our internal
production capacity.

     In addition, we do not have experience manufacturing our
potential products in large quantities. In the event of significant
demand for our potential products, large-scale production might prove
more difficult or costly than we anticipate and lead to quality
control issues and production delays.


We may not be able to manufacture products at competitive prices.

     To date, we have produced limited quantities of products for
research, development and demonstration purposes. The cost per unit
for these products currently exceeds the price at which we could
expect to profitably sell them. If we cannot substantially lower our
cost of production as we move into sales of products in commercial
quantities, our financial results will be harmed.


We conduct significantly all of our research and development
activities at a single facility, and circumstances beyond our control
may result in considerable interruptions.

     We conduct significantly all of our research and development
activities at a single facility in Wilmington, Delaware. A disaster
such as a fire, flood or severe storm at or near this facility could
prevent us from further developing our technologies or manufacturing
our potential products, which would harm our business.


We could be exposed to significant product liability claims that could
be time-consuming and costly and impair our ability to obtain and
maintain insurance coverage.

     We may be subject to product liability claims if any of our
potential products are alleged to be defective or harmful. Product
liability claims or other claims related to our potential products,
regardless of their outcome, could require us to spend significant
time and money in litigation, divert our management's time and
attention from other business concerns, require us to pay significant


                               30
<PAGE>


damages, harm our reputation or hinder acceptance of our potential
products. Any successful product liability claim may prevent us from
obtaining adequate product liability insurance in the future on
commercially reasonable terms. Any inability to obtain sufficient
insurance coverage at an acceptable cost or otherwise to protect
against potential product liability claims could impair our ability to
commercialize our potential products.


We may be unable to effectively implement new transaction accounting,
operational and financial systems.

     To manage the expected growth of our operations and personnel, we
will be required to implement complex transaction accounting,
operational and financial systems, procedures and controls and to
retain personnel experienced in the use of these systems. Deficiencies
in the design and operation of our systems, procedures and controls,
including internal controls, could adversely affect our ability to
record, process, summarize and report material financial information.
We cannot assure you that our current and planned systems, procedures
and controls will be adequate to support our future operations.

Our failure to effectively manage and support our growth could
adversely affect our business.

     Failure to effectively manage and support our growth could
adversely affect our business. To date, substantially all of our
activities and resources have been directed at the research and
development of our technology and development of potential products.
The transition from research and development to a product vendor or
licensor will create significant additional demands on our
infrastructure and will require effective planning and management. We
cannot assure you that our resources will be adequate to support our
future growth. In addition, future expansion will be expensive and
will likely strain our management and other resources. In order to
effectively manage growth, we must:

     *   manage in-house our operating and financial control systems;

     *   continue to develop an effective planning and management
         process to implement our business strategy;

     *   hire, train and integrate new personnel in all areas of our
         business; and

     *   expand our facilities and increase our capital investments.

     We cannot assure you that we will be able to accomplish these
tasks effectively or otherwise effectively manage our growth.


We are subject to regulatory compliance related to our operations.

     We are subject to various U.S. governmental regulations related
to occupational safety and health, labor and business practices.
Failure to comply with current or future regulations could result in


                               31
<PAGE>


the imposition of substantial fines, suspension of production,
alterations of our production processes, cessation of operations, or
other actions, which could harm our business.


We may be unable to export our potential products or technology to
other countries, convey information about our technology to citizens
of other countries or sell certain products commercially, if the
products or technology are subject to United States export or other
regulations.

     We are developing certain polymer-based products that we believe
the United States government and other governments may be interested
in using for military and information gathering or antiterrorism
activities. United States government export regulations may restrict
us from selling or exporting these potential products into other
countries, exporting our technology to those countries, conveying
information about our technology to citizens of other countries or
selling these potential products to commercial customers. We may be
unable to obtain export licenses for products or technology if
necessary. We currently cannot assess whether national security
concerns would affect our potential products and, if so, what
procedures and policies we would have to adopt to comply with
applicable existing or future regulations.


We may incur liability arising from the use of hazardous materials.

     Our business and our facilities are subject to a number of
federal, state and local laws and regulations relating to the
generation, handling, treatment, storage and disposal of certain toxic
or hazardous materials and waste products that we use or generate in
our operations. Many of these environmental laws and regulations
subject current or previous owners or occupiers of land to liability
for the costs of investigation, removal or remediation of hazardous
materials. In addition, these laws and regulations typically impose
liability regardless of whether the owner or occupier knew of, or was
responsible for, the presence of any hazardous materials and
regardless of whether the actions that led to the presence were taken
in compliance with the law. In our business, we use hazardous
materials that are stored on site. We use various chemicals in our
manufacturing process that may be toxic and covered by various
environmental controls. The waste created by use of these materials is
transported off-site by an unaffiliated waste hauler. Many
environmental laws and regulations require generators of waste to take
remedial actions at an off-site disposal location even if the disposal
was conducted lawfully. The requirements of these laws and regulations
are complex, change frequently and could become more stringent in the
future. Failure to comply with current or future environmental laws
and regulations could result in the imposition of substantial fines,
suspension of production, alteration of our production processes,
cessation of operations or other actions, which could severely harm
our business.


Our plan to develop relationships with strategic partners may not be
successful.

     Part of our business strategy is to maintain and develop
strategic relationships with government agencies, private firms, and
academic institutions to conduct research and development of
technologies and products. For these efforts to be successful, we must
identify partners whose competencies complement ours. We must also
successfully enter into agreements with them on terms attractive to
us, and integrate and coordinate their resources and capabilities with
our own. We may be unsuccessful in entering into agreements with
acceptable partners or negotiating favorable terms in these
agreements. Also, we may be unsuccessful in integrating the resources
or capabilities of these partners. In addition, our strategic partners


                               32
<PAGE>


may prove difficult to work with or less skilled than we originally
expected. If we are unsuccessful in our collaborative efforts, our
ability to develop and market products could be severely limited.


As our business grows, if we need to establish global operations, we
will be subject to various risks.

     Many of the markets that we propose to address are global and may
require us to conduct foreign operations, including the establishment
of sales, manufacturing and possible research and development
facilities in other countries. While the specific risks that will
apply to these activities would depend on the circumstances, we could
become subject to risks relating to foreign currency fluctuations,
political and social unrest, local regulatory systems and varying
standards for the protection of intellectual property. The existence
of any of these risks will complicate our business and may lead to
unexpected and adverse effects on our business. If we are required to
conduct significant foreign operations, we will also need expertise in
such operations, which we do not presently have.


Our limited operating history makes financial forecasting difficult
for us and for others that may publish estimates of our future
financial results.

     As a result of our limited operating history, it is difficult to
accurately forecast our revenue and results, including product sales,
cost of revenue, research and development expenses, marketing, general
and administrative expenses and other financial and operating data. We
have a limited amount of meaningful historical financial data upon
which to base projected revenue or expenses. We base our current
expense levels and estimates of future expense levels on our operating
plans and estimates of future revenue, and our future expenses will be
dependent in large part upon our future levels of product sales. Sales
and results are difficult to forecast because we do not currently have
any commercial customers or government contracts, we are uncertain of
the extent of orders for our products and the mix, volume and timing
of any such orders. As a result, we may be unable to make accurate
financial forecasts of revenue or expenses. Financial analysts and
others that may seek to project our future performance face similar
difficulties. This inability to accurately forecast our revenue and
expenses could cause our financial results to differ materially from
any projected financial results and could cause a decline in the
trading price of our common stock.


          Risks Factors Related to Owning Our Common Stock

The market price of our shares may experience extreme price and volume
fluctuations for reasons over which we have little control.

     The trading price of our common stock has been, and is likely to
continue to be, extremely volatile. Over the past 12 months, the
closing price of our common stock as reported on the OTC has ranged
from a high of $2.22 to a low of $0.39. Our stock price could be


                               33
<PAGE>

subject to wide fluctuations in response to a variety of factors,
including, but not limited to, the risks relating to an investment in
our stock described above and the following:

     *    new products or services offered by us or our competitors;

     *    failure to meet any publicly announced revenue projections;

     *    actual or anticipated variations in quarterly operating
          results;

     *    changes in financial estimates by securities analysts;

     *    announcements of significant acquisitions, strategic
          partnerships, joint ventures or capital commitments by us
          or our competitors;

     *    issuances of debt or equity securities; and

     *    other events or factors, many of which are beyond our
          control.

     In addition, companies that trade their securities in the over-
the-counter markets experience extreme price and volume fluctuations
that are often unrelated or disproportionate to the operating
performance of these companies. A multitude of factors could
negatively affect the market price of our common stock, regardless of
our actual operating performance.

The Staff of the Securities and Exchange Commission's Fort Worth
District Office is conducting an informal inquiry concerning our Company.

    During the spring of 2005 we raised $1,000,000 through the sale of
4,000,000 shares of our common stock in a limited offering to persons
considered to be accredited investors. In December 2005, we were
informed by the Securities and Exchange Commission (the "Commission")
that it is investigating the circumstances surrounding that offering
including the subsequent public resale of certain shares originally
sold in the offering, along with related matters. Our Company has
further been informed that the original issuance of the stock
and subsequent resale thereof may have been done, in the opinion
of the Commission, in violation of the registration provisions of
the Securities Act of 1933, as amended. These matters could lead to
enforcement action by the Commission. At this time, we are unable to
determine whether this informal investigation may lead to potentially
adverse action.

Our Company's securities are subject to the United States Securities
and Exchange Commission's penny stock regulations, which may cause our
stockholders to experience difficulties in reselling their securities.

    Our securities are subject to the United States Securities and
Exchange Commission's (the "SEC" or "Commission") rules that regulate
broker-dealer practices in connection with transactions in "penny
stocks." Generally, penny stocks are equity securities traded over-
the-counter with a price of less than $5.00 (other than securities
registered on certain national securities exchanges or quoted on the
NASDAQ system, provided that current price and volume information with
respect to transactions in such securities is provided by the exchange
or system). The penny stock rules require a broker-dealer, prior to a
transaction in a penny stock not otherwise exempt from the rules, to
deliver a standardized risk disclosure document prepared by the
Commission that provides information about penny stocks and the nature
and level of risks in the penny stock market. The broker-dealer also
must provide the customer with bid and offer quotations for the penny
stock, the compensation of the broker-dealer and its salesperson in
the transaction, and monthly account statements showing the market
value of each penny stock held in the customer's account. In addition,
the penny stock rules require that prior to a transaction in a penny
stock not otherwise exempt from such rules the broker-dealer must make
a special written determination that the penny stock is a suitable
investment for the purchaser and receive the purchaser's written
agreement to the transaction. These disclosure requirements may have
the effect of reducing the level of trading activity in the secondary
market for a stock that is subject to the penny stock rules. Since our
securities are subject to the penny stock rules, stockholders in our
Company may encounter some difficulties while selling their shares of
common stock.


                               34
<PAGE>


Shares eligible for sale in the future could depress the market price
of our common stock and impair our ability to raise additional capital
through the sale of our equity securities.

     All but approximately 5,082,785 shares out of our 31,622,535
presently issued and outstanding shares of common stock are either
(i) freely tradable; or (ii) eligible for sale under Rule 144 of the
Securities Act of 1933, as amended ("Rule 144"), so long as all of
the conditions of Rule 144 are met. Sales of a substantial number of
shares of common stock into the public market, or the perception that
such sales may occur, could depress the market price of our common
stock and impair our ability to raise additional capital through
the sale of our equity securities.


If we authorize the issuance of additional securities, existing
stockholders may experience future ownership dilution.

     Our Articles of Incorporation provide that we may issue up to
50,000,000 shares of common stock, $0.001 par value and 1,000,000
shares of preferred stock, $0.001 par value. In the event we issue
additional shares of common stock in connection with our contemplated
growth plans or otherwise, our stockholders will experience future
ownership dilution that could adversely affect prevailing market
prices for our common stock.


Our board of directors has the discretion to assign rights and
preferences to our blank check preferred stock.

     Pursuant to our Company's Articles of Incorporation, we are
authorized to issue 1,000,000 shares of preferred stock, and our board
of directors has the discretion to assign rights and preferences to
our preferred stock without the approval of our common stockholders.
The rights and preferences of this preferred stock may be superior to
the rights and preferences of our common stock; and the issuance of
this preferred stock could serve to deter or prevent a takeover from a
third party. This type of preferred stock is commonly referred to as
"Blank Check Preferred Stock."


Item 2.   Management's Discussion and Analysis or Plan of Operation.

                      Plan of Operation

     The following plan of operation provides information that
management believes is relevant to an assessment and understanding of
our plans and financial condition. The following selected financial
information is derived from our historical financial statements and
should be read in conjunction with such financial statements and notes
thereto set forth elsewhere herein and the "Forward-Looking
Statements" explanation included herein.

Overview

      Third-Order Nanotechnologies, Inc., formerly, PSI-TEC Holdings,
Inc., formerly Eastern Idaho Internet Service, Inc. was organized
under the laws of the State of Nevada in 1997, where we engaged in the
business of marketing Internet services until June 30, 1998 when our


                               35
<PAGE>


operations were discontinued.  We were then inactive until we acquired
PSI-TEC Corporation as our wholly owned subsidiary on July 14, 2004,
at which time our name was changed to PSI-TEC Holdings, Inc.  On
October 20, 2006, we completed a parent-subsidiary merger with PSI-TEC
Corporation whereby we were the surviving corporation of the merger,
and our name was changed to Third-Order Nanotechnologies, Inc.

     We are a developmental stage company that has developed and
continues to develop high-activity, high-stability electro-optic
polymers (plastics) that we believe could have a broad range of
applications in the electro-optic device market. We engineer our
proprietary electro-optic plastics at the molecular level for superior
performance, stability, cost-efficiency and ease of processability.
We expect our electro-optic plastics to broadly replace more
expensive, lower-performance materials that are currently used in
fiber-optic ground, wireless and satellite communication networks.

     In order to transmit digital information at extremely high-speeds
(wide bandwidth) over the Internet, it is necessary to convert the
electrical signals produced by a computer into optical signals for
transmission over long-distance fiber-optic cable.  The actual
conversion of electricity to an optical signal may be performed by a
molecularly-engineered material known as an electro-optic plastic.

     We are currently developing electro-optic plastics that promise
performance many times faster than any technology currently available
and that have unprecedented thermal stability. High-performance
electro-optic materials produced by our Company have demonstrated
stability as high as 350 degrees Celcius.  Stability above 300
degrees Celcius is necessary for vertical integration into many
semi-conductor production lines. Recent results, independently
confirmed by the University of Arizona, have demonstrated that the
molecular performance of some of our Company's molecular designs
perform 650% better than competitive electro-optic compounds.

     Our revenue model relies substantially on the assumption that we
will be able to successfully develop electro-optic products for
applications within the industries described below. When appropriate,
we intend to create specific materials for each of these applications
and use our proprietary knowledge base to continue to enhance its
discoveries.

     *    Satellite Reconnaissance
     *    Navigational Systems
     *    Radar Applications
     *    Telecommunications
     *    Backplane Optical Interconnects
     *    Entertainment
     *    Medical Applications

To be successful, we must, among other things:

     *    Develop and maintain collaborative relationships with
          strategic partners;

     *    Continue to expand our research and development efforts for
          our products;

     *    Develop and continue to improve on our manufacturing
          processes and maintain stringent quality controls;


                               36
<PAGE>


     *    Produce commercial quantities of our products at
          commercially acceptable prices;

     *    Rapidly respond to technological advancements;

     *    Attract, retain and motivate qualified personnel; and

     *    Obtain and retain effective intellectual property protection
          for our products and technology.

     We believe that Moore's Law (a principle which states the number
of transistors on a silicon chip doubles approximately every eighteen
months) will create markets for our high-performance electro-optic
material products.

Plan of Operation

     Since our inception, we have been engaged primarily in the
research and development of our polymer materials technologies and
potential products. We are devoting significant resources to engineer
next-generation electro-optic plastics for future applications to be
utilized by electro-optic device manufacturers, such as
telecommunications component and systems manufacturers, networking and
switching suppliers, semiconductor companies, aerospace companies and
government agencies. We expect to continue to develop products that we
intend to introduce to these rapidly changing markets and to seek to
identify new markets. We expect to continue to make significant
operating and capital expenditures for research and development
activities.

     As we move from a development stage company to a product vendor,
we expect that our financial condition and results of operations will
undergo substantial change. In particular, we expect to record both
revenue and expense from product sales, to incur increased costs for
sales and marketing and to increase general and administrative
expense. Accordingly, the financial condition and results of
operations reflected in our historical financial statements are not
expected to be indicative of our future financial condition and
results of operations.

     We expect to have a proof of concept of an electro-optic modulator
in the first quarter of 2008, and we intend to utilize the services of
Dr. Robert Norwood at the University of Arizona Photonics Department
to perform these tests, as we have in the past.  We may incur delays
in this process due to slower than expected material production within
our laboratories and/or delays caused by the testing procedures at the
University of Arizona.  Should these tests produce a functional 10 Gb/s
or greater modulator we expect to go forward with product marketing and
development in the telecommunication market with partners in the
telecommunication field. We cannot anticipate the details of the
customer adoption cycle until we have produced a function prototype
to create a credible technology offering.

     On August 8, 2006, we contracted with Triple Play Communications
Corporation, a design and market consulting company, to deliver a
comprehensive market opportunity assessment report for high speed 40G
(commercial) & 100G+ (military/aerospace) modulators and system
applications.

     In August, 2006 we entered into a co-location agreement with
InPlane Photonics, a New Jersey-based micro-optics company that
allowed our scientists to establish a pre-production line in order to
test and integrate our organic materials into waveguide devices and
system prototypes as a first step toward product commercialization.
This agreement was terminated at the end of January 2007 so that we
could focus on  pursuing a strategic relationship with Photon-X LLC,
a Pennsylvania-based firm with extensive experience in polymer
waveguide processing. We entered into a non-binding memorandum of
understanding with Photon-X, LLC in December 2006 to work towards
creating a "fee for services" agreement with Photon-X, LLC to design,
develop, produce and market electro-optic components based upon our
polymer technology. Such an agreement with Photon-X would afford our
Company access to a full suite of fabrication facilities capable of
producing commercial quantities of precision micro-optic devices
such as high-speed (40GHz) telecom modulators, optical filters, and
optical interconnects important to military and civilian global
information movement and management markets.

                               37
<PAGE>


     On September 25, 2006 we obtained independent laboratory results
that confirmed the thermal stability of our Perkinamine electro-optic
materials. Thermal stability as high as 350 degrees Celsius was
confirmed, significantly exceeding many other commercially available
high performance electro-optic materials, such as CLD-1 which exhibits
thermal degradation in the range of 250 degrees Celsius to 275 degrees
Celsius. This high temperature stability of our materials eliminates a
major obstacle to vertical integration of electro-optic polymers into
standard microelectronic manufacturing processes (e.g. wave/vapor-
phase soldering) where thermal stability of at least 300 degrees
Celsius is required. In independent laboratory tests, ten-percent
material degradation, a common evaluation of overall thermal
stability, did not occur until our Perkinamine material base was
exposed to temperatures as high as 350 degrees Celsius, as determined
by Thermo-Gravimetric Analysis (TGA). The test results supported our
Company's progress to introduce our materials into commercial
applications such as optical interconnections, high-speed telecom and
datacom modulators, and military/aerospace components.

     We ultimately intend to use our next-generation electro-optic
plastics for future applications vital to the following industries. We
expect to create specific materials for each of these applications as
appropriate:

     *   Satellite Reconnaissance
     *   Navigational Systems
     *   Radar Applications
     *   Telecommunications
     *   Backplane Optical Interconnects
     *   Entertainment
     *   Medical Applications

     In an effort to maximize our future revenue stream from our
electro-optic polymer products, we are currently evaluating each of or
some combination of the following approaches:

     *   Licensing our technology for individual specific applications;
     *   Entering into collaborative or joint venture agreements with
         one or a number of partners; or
     *   Selling our products directly to commercial customers.

     Additionally, we must create an infrastructure, including
operational and financial systems, and related internal controls, and
recruit qualified personnel. Failure to do so could adversely affect
our ability to support our operations.


                               38
<PAGE>

     We have incurred substantial net losses since inception. We have
satisfied our capital requirements since inception primarily through
the issuance and sale of common stock. During 2004 we raised approximately
$529,000 from the issuance of convertible promissory notes, of which
$30,000 was converted into common stock of the company during 2004 and
the remaining $499,000 converted in 2005. Also, during 2005, we
raised an aggregate of $1,000,000 from the private sale of our common
stock. During 2006, we raised approximately $425,000 from the private
sale of our common stock, and from January 1, 2007 to date, we raised
$1,241,000 from the private sale of our common stock.

Recent Developments

     Award

     On September 26, 2006, we were awarded the 2006 Electro-Optic
Materials Technology Innovation of the Year Award by Frost & Sullivan.
Frost & Sullivan's Technology Innovation of the Year Award is bestowed
upon candidates whose original research has resulted in innovations
that have, or are expected to bring, significant contributions to
multiple industries in terms of adoption, change, and competitive
posture. This award recognizes the quality and depth of our Company's
research and development program as well as the vision and risk-taking
that enabled us to undertake such an endeavor.

     Stock Issuances

     On April 25, 2007, our Company's board of directors authorized our
Company to raise up to $1,000,000 of capital by selling its equity
securities and warrants to purchase its equity securities pursuant to
a private offering. To date, this private offering has raised an
aggregate of $667,000. Pursuant to the terms of this private offering,
up to 20 units were offered at the offering price of $50,000 per unit,
with each unit comprised of 100,000 shares of common stock, and a
warrant to purchase 50,000 shares of common stock at $0.50 per share.
The warrants are exercisable at any time for a period of two years
commencing on the date our Company accepted the purchaser's subscription
pursuant to this offering.


     On June 15, 2006, our Company's board of directors authorized our
Company to raise up to $1,500,000 of capital by selling its equity
securities and warrants to purchase its equity securities pursuant to
a private offering. On December 11, 2006, our Company's board of
directors authorized our Company to amend its this private offering to
authorize our Company to raise up to $1,000,000 of capital by selling
its equity securities and warrants to purchase its equity securities
pursuant to an amended private offering. The amended private offering
raised an aggregate of $999,000, $425,000 during 2006 and $574,000
during the first quarter of 2007, and was closed in March 2007.

     Pursuant to the terms of the amended offering, up to 20 units
were offered at the offering price of $50,000 per unit, with each unit
comprised of 100,000 shares of common stock, and a warrant to purchase
50,000 shares of common stock at $0.50 per share. The warrants are
exercisable at any time for a period of two years commencing on the
date our Company accepted the purchaser's subscription pursuant to the
amended offering.

     In connection with both of the above-described offerings,, we and
our investors entered into a registration rights agreement pursuant to
which we agreed that if within 12 months after the closing of the
respective offering our Company files a Form SB-2 registration
statement (or such other form that it is eligible to use) with the
Securities and Exchange Commission to register some or all of our
outstanding shares of common stock for resale and distribution, that


                               39
<PAGE>

subject to certain limitations, upon their request, we would include
all of the shares of common stock offered and sold to our investors
pursuant to the above-described offerings. Our Company is not subject
to any cash or other penalty in the event we do not file a Form SB-2
registration statement (or such other form that we are eligible to use)
with the Securities and Exchange Commission to register the shares of
common stock offered and sold to our investors pursuant to the
above-described offerings.

     On February 8, 2007, our Company authorized the issuance of 151,785
shares of our Company's common stock, $0.001 par value, to a stock
analyst firm for stock analyst services.

     On February 28, 2007, our Company authorized the issuance of 1,000,000
shares of our Company's common stock, $0.001 par value, to our management
firm for management services.

     On April 17, 2007, our Company authorized the issuance of 100,000
shares of our Company's common stock, $0.001 par value, to our legal
counsel in exchange for legal services.


Results of Operations

Comparison of Six Months Ended June 30, 2007 to Six Months Ended June
30, 2006

	Revenues

	We had no revenues during the six months ended June 30, 2007 or
2006 since we are a development stage company that has yet to commence
revenue creating operations.

	Operating Expenses

	Our operating expenses were $1,917,012 and $1,464,161 for the six
months ended June 30, 2007 and 2006, respectively, for an increase of
$452,851. This increase in operating expenses was due primarily to our
hiring additional personnel, significantly increasing our research and
development activities and legal, accounting and other costs
associated with preparing to become a public company.

	Included in our operating expenses for the six months ended June
30, 2007 was $845,206 for research and development expenses compared
to $613,040 for that same period in 2006; and $1,071,806 for general
and administrative expenses for the six months ended June 30, 2007
compared to $851,121 for that same period in 2006.

	Research and development expenses currently consist primarily of
compensation for employees and contractors engaged in internal
research and product development activities; laboratory operations,
outsourced development and processing work; fees and expenses related
to patent applications and intellectual property protection; costs
incurred in acquiring and maintaining licenses; and related operating
expenses.

	We expect to continue to incur substantial research and
development expense to develop commercial products that utilize our
electro-optic plastics. These expenses could increase as a result of
continued development and commercialization of our electro-optic
materials technology; subcontracting work to potential development
partners; expanding and equipping in-house laboratories; hiring
additional technical and support personnel; pursuing other potential
business opportunities; and incurring related operating expenses.

	General and administrative expense consists primarily of
compensation and support costs for management and administrative
staff, and for other general and administrative costs, including
executive, investor relations, accounting and finance, legal,
consulting and other operating expenses, including laboratory space
rental costs.

	We expect general and administrative expense to increase in
future periods as we increase the level of corporate and
administrative activity, including increases associated with our
operation as a public company; and significantly increase expenditures
related to the future production and sales of our products.

	Other Income (Expense)

	Other expense was $1,765 for the six months ended June 30, 2007,
consisting of $1,584 of interest income on cash deposits and short
term investments and $3,349 of interest expense compared to other
expense of $1,767 for the six months ended June 30, 2006, consisting
of $241 of interest income on cash deposits and short term
investments, $126 of dividend income on short term investments and
$2,134 of interest expense.

     Net Loss

     Net loss was $1,918,777 and $1,465,298 for the six months ended
June 30, 2007 and 2006, respectively, for an increase of $453,479,
primarily resulting from research and development and general and
administrative expenses incurred as described above.

Comparison of Fiscal 2006 to Fiscal 2005

     Revenues

     We had no revenues in fiscal 2006 or 2005 since we are a
development stage company that has yet to commence revenue creating
operations.

     Operating Expenses

     Our operating expenses were $2,994,749 and $1,708,057 for the
years ended December 31, 2006 and 2005, respectively, for an increase
of $1,286,692. This increase in operating expenses was due primarily to
our hiring additional personnel, significantly increasing our research
and development activities and legal, accounting and other costs
associated with preparing to become a public company.

     Included in our operating expenses for 2006 was $1,179,997 for
research and development expenses compared to $813,725 for 2005.
Research and development expenses currently consist primarily of
compensation for employees and contractors engaged in internal
research and product development activities; laboratory operations,
outsourced development and processing work; fees and expenses related
to patent applications and intellectual property protection; costs
incurred in acquiring and maintaining licenses; and related operating
expenses.

     We expect to continue to incur substantial research and
development expense to develop commercial products that utilize our
electro-optic plastics. These expenses could increase as a result of
continued development and commercialization of our electro-optic
materials technology; subcontracting work to potential development
partners; expanding and equipping in-house laboratories; hiring
additional technical and support personnel; pursuing other potential
business opportunities; and incurring related operating expenses.

     General and administrative expense consists primarily of
compensation and support costs for management and administrative
staff, and for other general and administrative costs, including
executive, investor relations, accounting and finance, legal,
consulting and other operating expenses, including laboratory space
rental costs.


                               40
<PAGE>


     General and administrative expenses increased $920,420 to
$1,814,752 for 2006 compared to $894,332 for 2005. The increase of
$920,420 is due primarily to our increases in accounting and auditing
fee, legal fee, wages and salaries, rent, insurance, state income tax,
and travel and entertainment expenses, which were offset by a decrease
in management fees, Internet/website costs and other costs.

     Accounting and auditing fees were $-0- and $83,933 in 2005 and 2006.
The increase of $83,933 was primarily due to our Company requiring SEC
audits on a yearly basis, transfer agent fees and accounting fees as a
result of becoming a publicly traded entity. Legal fees increased $68,412
to $142,711 in 2006 compared to $74,299 in 2005 due to fees associated
with the preparation of the Form 10-SB and other legal services provided
to our Company.

     Payroll expense increased $52,849 from $372,653 in 2005 to $425,502
in 2006 due to the amortization of employee options and an increase in
pay for some of the officers. Consultant expense was $-0- and $649,648
in 2005 and 2006.  An increase of $559,648 was due to the Company hiring
a CEO who had received warrants/options that were amortized and expensed
in 2006.    The additional increase of $90,000 was due to the Company
entering into two consulting contracts during 2006.

     Rent increased $10,075 from $10,200 in 2005 to $20,275 in 2006 due
to our Company signing an additional lease of $3,000 per month for a
laboratory in New Jersey.  This lease was canceled in December 2006.
Insurance expenses increased $38,384 from $22,340 in 2005 to $60,721
in 2006 due to our Company obtaining a director and officer insurance
policy that began in 2006.

     State income tax was paid during 2006 for taxes due on payroll in
prior years.  This amount of $20,169 was an increase from the prior year,
where there was no additional payroll taxes paid for prior years.

     Travel expenses increased $23,561 to $37,700 in 2006 compared to
$14,139 in 2005 due to a conference trip, travel to accept our Frost &
Sullivan award, travel expenses for consultants and travel and
entertainment expenses for potential investors.

     Management fees decreased $21,831 from $340,376 in 2005 to $318,545
in 2006 as a result of not renewing a particular consultant during 2006.
Internet/website expense decreased $18,325 from $21,455 in 2005 to $3,130
in 2006 due to the Company incurring significant one time costs to create
their Internet website in 2005.

     We expect general and administrative expense to increase in future
periods as we increase the level of corporate and administrative activity,
including increases associated with our operation as a public company;
and significantly increase expenditures related to the future production
and sales of our products.

     Other Income (Expense)

     Other income was $60,940 in the year ended December 31, 2006,
consisting of $243 of interest income on cash deposits and short term
investments, $1,527 of dividend income, $63,187 of realized gain on
investment and $4,017 of interest expense compared to other income
(expense) of $(13,708) in the year ended December 31, 2005, consisting
of $6,994 of interest income on cash deposits and short term
investments and $20,702 of interest expense.

     Net Loss

     Net loss was $2,933,809 and $1,721,765 for the years ended
December 31, 2006 and 2005, respectively, for an increase of $1,212,044,
primarily resulting from research and development and general and
administrative expenses incurred as described above.

Comparison of Fiscal 2005 to Fiscal 2004

     Revenues

     We had no revenues in fiscal 2005 or 2004 since we are a
development stage company that has yet to commence revenue creating
operations.

     Operating Expenses

     Our operating expenses were $1,708,057 and $722,386 for the years
ended December 31, 2005 and 2004, respectively, for an increase of
$985,671. This increase in operating expenses was due primarily to our
hiring additional personnel, significantly increasing our research and
development activities and costs associated with being a public
company.

     Included in our operating expenses for 2005 was $813,725 for
research and development expenses compared to $263,702 for 2004 and
$894,332 for general and administrative expenses compared to $458,684
for 2004.

     Research and development expenses currently consist primarily of
compensation for employees and contractors engaged in internal
research and product development activities; laboratory operations,
outsourced development and processing work; fees and expenses related
to patent applications and intellectual property protection; costs
incurred in acquiring and maintaining licenses; and related operating
expenses.




                               41
<PAGE>

     General and administrative expense consists primarily of
compensation and support costs for management and administrative
staff, and for other general and administrative costs, including
executive, investor relations, accounting and finance, legal,
consulting and other operating expenses, including laboratory space
rental costs.

     General and administrative expenses increased $435,649 to
$894,332 for 2005 compared to $458,684 for 2004. The increase of
$435,648 is due primarily to our increases in professional management
fees, payroll expenses and Internet/website costs, which were offset
by a decrease in legal fees and other costs.

     Professional management fees increased $133,687 to $340,376 in 2005
compared to $206,689 in 2004 due to a management agreement our Company
signed with Universal Capital Management, Inc. during 2005.

     Legal fees increased $30,823 to $74,300 in 2005 compared to $43,477
in 2004.

     Payroll expense increased $163,916 from $208,738 in 2004 to $372,654
in 2005 because payroll was paid for 8 months in 2004 and for 12 months
in 2005. Additionally, employee health insurance expense increased from
$-0- in 2004 to $22,340 in 2005 since we did not offer health insurance
in 2004.

     Interest expense decreased $3,933 from $24,635 in 2004 to $20,702 in
2005. This decrease is due to interest on convertible notes issued in 2004
being accrued during 2004 and 2005.  The amount accrued in 2004 and 2005
was $19,098 and $16,526.  These notes were converted in 2005.  In 2004,
interest expense was included in the cost of goods sold and in 2005 it
was recorded as a separate line item on the financial statements.

     Internet/website expense increased $21,050 from $405 in 2004 to
$21,455 in 2005 due to the Company incurring significant one time costs
to create their Internet website in 2005.


     Other Income (Expense)

     Other income (expense) was $(13,708) in the year ended December
31, 2005, consisting of $6,994 of interest income on cash deposits and
short term investments and $20,702 of interest expense compared to
other income of $240 of interest income on cash deposits and short
term investments in the year ended December 31, 2004.

     Net Loss

     Net loss was $1,721,765 and $722,146 for the years ended December
31, 2005 and 2004, respectively, for an increase of $999,619,
primarily resulting from research and development and general and
administrative expenses incurred as described above.

Critical Accounting Policies

     The Company's accounting policies are more fully described in
Note 1 of Notes to Financial Statements. As disclosed in Note 1 of
Notes to Financial Statements, the preparation of financial statements
in conformity with accounting principles generally accepted in the
United States requires management to make estimates and assumptions
about future events that affect the amounts reported in the financial
statements and accompanying notes. Future events and their effects
cannot be determined with absolute certainty. Therefore, the
determination of estimates requires the exercise of judgment. Actual
results inevitably will differ from those estimates, and such
differences may be material to the financial statements. The Company
believes that, of its significant accounting policies, the following
may involve a higher degree of judgment, estimation, or complexity
than other accounting policies.

     Merger

     On July 14, 2004, the Company acquired PSI-TEC.  Under the terms
of the merger agreement, the stockholders of PSI-TEC received
15,600,000 shares of common stock in exchange for its 2,206,280
shares.  Following the merger, the Company changed its name to PSI-TEC
Holdings, Inc.  Under accounting principles generally accepted in the
United States, the share exchange is considered to be a capital


                               42
<PAGE>

transaction in substance rather than a business combination.  That is,
the share exchange is equivalent to the issuance of stock by PSI-TEC
Holdings, Inc. for the net monetary assets of PSI-TEC, accompanied by
a recapitalization, and is accounted for as a change of capital
structure.  Accordingly, the accounting for the share exchange will be
identical to that resulting from a reverse acquisition, except no
goodwill will be recorded.  Under reverse takeover accounting, the
post-reverse acquisition comparative historical financial statements
of the legal acquirer, PSI-TEC Holdings, Inc., are those of the legal
acquiree, PSI-TEC, which is considered to be the accounting acquirer.
On October 20, 2006, PSI-TEC Holdings, Inc. and PSI-TEC merged and
changed its name to Third-Order Nanotechnologies, Inc.

     Stock Based Compensation

     In December 2004, the Financial Accounting Standards Board
("FASB") issued SFAS 123 (revised 2004), Share-Based Payment ("SFAS
123R").  SFAS 123(R) supersedes APB Opinion No. 25, Accounting for
Stock Issued to Employees, and amends SFAS No. 95, Statement of Cash
Flows.  Generally, the approach in SFAS 123(R) is similar to the
approach described in SFAS 123.  However, SFAS 123(R) requires share-
based payments to employees, including grants of employee stock
options, to be recognized in the income statement based on their fair
values at the date of grant.  Pro forma disclosure is no longer an
alternative.

     On January 1, 2006, the Company adopted SFAS 123(R) using the
modified prospective method as permitted under SFAS 123(R).  Under
this transition method, compensation cost recognized in the first
quarter of 2006 includes compensation cost for all share-based
payments granted prior to but not yet vested as of December 31, 2005,
based on the grant-date fair value estimated in accordance with the
provisions of SFAS 123.  In accordance with the modified prospective
method of adoption, the Company's results of operations and financial
position for prior periods have not been restated.

     The Company uses the Black-Scholes option pricing model to
calculate the grant-date fair value of an award.

Liquidity and Capital Resources

	During the six months ended June 30, 2007, net cash used in
operating activities was $659,517 and net cash used in investing
activities was $143,016, which was due primarily to the Company
applying for patents and the purchase of equipment. Net cash provided
by financing activities for the six months ended June 30, 2007 was
$1,238,676.  At June 30, 2007, our cash and cash equivalents totaled
$436,671, our assets totaled $783,202, our liabilities totaled
$229,671, and we had stockholders' equity of $553,531.

     During the six months ended June 30, 2006, net cash used in
operating activities was $355,062, net cash used by investing
activities was $680 and net cash provided by financing activities was
$248,068. At June 30, 2006, our cash and cash equivalents totaled
$42,353, our assets totaled $1,630,975, our liabilities totaled $123,772
and we had stockholders' equity of $1,507,203.

     During 2006, net cash used in operating activities was $742,675
and net cash provided by investing activities was $166,873, which was
derived primarily by proceeds from the sale of available securities.
Net cash provided by financing activities during 2006 was $426,303.
At December 31, 2006, our cash and cash equivalents totaled $528, our
assets totaled $839,746, our liabilities totaled $264,974, and we had
stockholders' equity of $574,772.

     During 2005, net cash used in operating activities was $775,298
and net cash used in investing activities was $238,687, which were
financed primarily by proceeds from the sale of common stock. Net cash
provided by financing activities during 2005 was $995,620.  At
December 31, 2005, our cash and cash equivalents totaled $150,027, our
assets totaled $959,110, our liabilities totaled $127,232 and we had
stockholders' equity of $831,878.


                               43
<PAGE>

     Sources and Uses of Cash

     Our future expenditures and capital requirements will depend on
numerous factors, including: the progress of our research and
development efforts; the rate at which we can, directly or through
arrangements with original equipment manufacturers, introduce and sell
products incorporating our plastic materials technology; the costs of
filing, prosecuting, defending and enforcing any patent claims and
other intellectual property rights; market acceptance of our products
and competing technological developments; and our ability to establish
cooperative development, joint venture and licensing arrangements. We
expect that we will incur in excess of $1 million of expenditures over
the next 12 months. Our cash requirements are expected to increase at
a rate consistent with revenue growth as we expand our activities and
operations with the objective of commercializing our electro-optic
plastic technology during 2008.

     Our business does not presently generate the cash needed to
finance our current and anticipated operations. We believe we have
raised sufficient capital to finance our operations for the next three
(3) months, however, we will need to obtain additional future
financing during the latter part of 2007 to finance our operations
until such time that we can conduct profitable revenue-generating
activities. Such future sources of financing may include cash from
equity offerings, exercise of warrants and stock options and proceeds
from debt instruments; but we cannot assure you that such equity or
borrowings will be available or, if available, will be at rates or
prices acceptable to us.  If adequate funds are not available to
satisfy either short-term or long-term capital requirements, or if
planned revenues are not generated, we may be required to
substantially limit our operations. This limitation of operations may
include reductions in capital expenditures and reductions in staff and
discretionary costs.

     We expect that our cash used in operations will increase during
2007 and beyond as a result of the following planned activities:

     *   The addition of management, sales, marketing, technical and
         other staff to our workforce;

     *   Increased spending for the expansion of our research and
         development efforts, including purchases of additional
         laboratory and production equipment;

     *   Increased spending in marketing as our products are introduced
         into the marketplace;

     *   Developing and maintaining collaborative relationships with
         strategic partners;

     *   Developing and improving our manufacturing processes and
         quality controls; and

     *   Increases in our general and administrative activities
         related to our operations as a reporting public company and
         related corporate compliance requirements.


                               44
<PAGE>


     Analysis of Cash Flows

	For the six moths ended June 30, 2007

	Net cash used in operating activities was $659,517 for the six
months ended June 30, 2007, consisting of payments for management,
legal, professional and consulting expenses, rent and other
expenditures necessary to develop our business infrastructure, offset
by $1,002,834 in deferred charges, $180,892 in warrants issued for
services, $61,346 in options issued for services, $3,947 in prepaid
expenses, $5,292 in stock issued for services and $3,499 in accrued
expenses.

	Net cash used by investing activities was $143,016 for the six
months ended June 30, 2007, consisting of $100,480 for intangibles, as
well as the purchase of equipment for $42,536.

	Net cash provided by financing activities was $1,238,676 for the
six months ended June 30, 2007 and consisted of $1,241,000 of proceeds
from the sale of our common stock, offset by the repayment of $2,324
of notes payable.

     For the year ended December 31, 2006

     Net cash used in operating activities was $742,675 for the year
ended December 31, 2006, consisting of payments for management, legal,
professional and consulting expenses, rent and other expenditures
necessary to develop our business infrastructure, offset by $1,502,562
in deferred charges, $66,500 in warrants issued for services, $428,888
in options issued for services, $75,000 in receivables, $153,763 in
accounts payable and $24,800 in accrued expenses.


     Net cash provided by investing activities was $166,873 for the
year ended December 31, 2006, consisting of proceeds from the sale of
available for sale securities of $175,387, offset by $8,514 for
intangibles.

     Net cash provided by financing activities was $426,303 for the
year ended December 31, 2006 and consisted of $425,000 of proceeds
from the sale of our common stock, and $6,500 from a subscription
receivable, offset by the repayment of $5,197 of notes payable.

     For the year ended December 31, 2005

     Net cash used in operating activities was $775,298 for the year
ended December 31, 2005, consisting of payments for management, legal,
professional and consulting expenses, rent and other expenditures
necessary to develop our business infrastructure, offset by $840,390 in
deferred charges, $77,100 in warrants issued for services, $11,000 in
receivables, $1,605 in prepaid expenses and $32,484 in accrued expenses.


     Net cash used in investing activities was $238,687 for the year
ended December 31, 2005, consisting of $24,825 for laboratory
equipment, $13,862 for intangibles, as well as the purchase of
$200,000 of investment securities.

     Net cash provided by financing activities was $995,620 for the
year ended December 31, 2005 and consisted of $1,000,000 of proceeds
from the sale of our common stock, offset by the payment of $4,380
related to a loan payable.

Inflation and Seasonality

     We do not believe that our operations are significantly impacted
by inflation. Our business is not seasonal in nature.


Item 3.   Description Of Property.

     We share approximately 1,200 square feet of office space with
Universal Capital Management, Inc. for our executive and business
office headquarters that are located at 2601 Annand Dr. #16,
Wilmington, Delaware 19808. We coordinate our operations and market
our services from this space. Universal Capital Management, Inc.
allows us to utilize this office space free of charge on a month-to-
month basis.

                               45
<PAGE>


     We also lease approximately 1,400 square feet of laboratory space
at 41A Germay Drive, Wilmington, Delaware 19804-1100. We operate an
organic synthesis and thin-films laboratory from this facility, which
has state-of-the-art equipment including NMR, IR, UV/VIS and HPLC
analytical systems, profilometry evaluation and electro-optic (r33)
materials characterization necessary to produce next generation fiber-
optic organic materials. We lease this space at fair market value
rates from a third party. The lease expires on December 31, 2008 and
annual rent for the space is $8,400.

    We believe our executive and business office headquarters are
adequate for our reasonably foreseeable needs.

Item 4.  Security Ownership Of Certain Beneficial Owners And
         Management.

         Security Ownership of Certain Beneficial Owners

    The following table sets forth the names, addresses, amount and
nature of beneficial ownership and percent of such ownership of each
person or group known to our Company to be the beneficial owner of
more than five percent (5%) of our common stock:

<TABLE>
<CAPTION>
  Name and Address                Amount and Nature
of Beneficial Owner (1)        of Beneficial Ownership(3)   % of Class Owned (5)
-----------------------        --------------------------   --------------------
<S>                            <C>                          <C>
Frederick J. Goetz, Jr.  (2)            3,372,000                   10.66%

Frederick J. Goetz (2)                  6,597,000 (4)               20.86%

Mary Goetz (2)                          6,597,000 (4)               20.86%

Andrew J. Ashton                        3,132,000                    9.90%

</TABLE>
---------------------------

1.   In care of our Company at 2601 Annand Dr. #16, Wilmington,
     Delaware 19808.
2.   Frederick J. Goetz and Mary Goetz are Husband and wife, and
     Frederick J. Goetz, Jr. is their son.
3.   To our best knowledge, as of the date hereof, such holders had
     the sole voting and investment power with respect to the voting
     securities beneficially owned by them, unless otherwise indicated
     herein. Includes the person's right to obtain additional shares
     of common stock within 60 days from the date hereof.
4.   Consists of (i) 3,465,000 shares of common stock owned by
     Frederick J. Goetz; and (ii) 3,132,000 shares of common stock
     owned by Mary Goetz. Each of Frederick J. Goetz and Mary Goetz
     disclaim any beneficial ownership of their spouse's shares of
     common stock.
5.   Based on 31,622,535 shares of common stock outstanding. Does not
     include shares underlying: (i) options to purchase shares of our
     common stock under our 2005 Stock Option Plan, or (ii)
     outstanding warrants to purchase shares of our common stock.


                               46
<PAGE>


                Security Ownership of Management


     The following table sets forth the names, addresses, amount and
nature of beneficial ownership and percent of such ownership of our
common stock of each of our officers and directors, and officers and
directors as a group:

<TABLE>
<CAPTION>
  Name and Address                Amount and Nature
of Beneficial Owner (1)        of Beneficial Ownership(2)   % of Class Owned
(3)(4)
-----------------------        --------------------------   -----------------------
<S>                            <C>                          <C>
Ronald R. Genova
Interim Chief Executive
Officer (5)                                 -- (6)                  --%

Harold R. Bennett
Director
Chief Executive Officer (7)            175,000 (8)                   *

Frederick J. Goetz, Jr. (9)
Director, President                  3,372,000                     10.66%

Frederick J. Goetz (9)
Chief Science Officer                6,597,000 (10)                20.86%

David F. Eaton
Chief Technology Officer                87,500 (11)                  *

Andrew J. Ashton
Director, Executive
Vice President, Treasurer
Secretary                            3,132,000                      9.90%

Directors and Officers as
a Group (5 Persons)                 13,363,500                     42.26%

----------------------------
</TABLE>

*    Less than 1%

1.   In care of our Company at 2601 Annand Dr. #16, Wilmington,
     Delaware 19808.
2.   To our best knowledge, as of the date hereof, such holders had
     the sole voting and investment power with respect to the voting
     securities beneficially owned by them, unless otherwise indicated
     herein. Includes the person's right to obtain additional shares
     of common stock within 60 days from the date hereof.
3.   Based on 31,622,535 shares of common stock outstanding. Does not
     include shares underlying: (i) options to purchase shares of our
     common stock under our 2005 Stock Option Plan, or (ii)
     outstanding warrants to purchase shares of our common stock.
4.   If a person listed on this table has the right to obtain
     additional shares of common stock within 60 days from the date
     hereof, the additional shares are deemed to be outstanding for
     the purpose of computing the percentage of class owned by such
     person, but are not deemed to be outstanding for the purpose of
     computing the percentage of any other person.
5.   From September 2005 to February 2007, Mr. Genova served as our
     Interim Chief Executive Officer.


                               47
<PAGE>

6.   Mr. Genova's  option to purchase up to 444,000 shares of
     Common stock expired on May 30, 2007.
7.   Mr. Bennett was appointed to serve as our Chief Executive Officer
     in March 2007.
8.   On April 17, 2007 Mr. Bennett received a warrant to purchase up to
     300,000 shares of common stock that vest pursuant to the following
     schedule: (i) 25,000 shares vested on April 17, 2007; and (ii)
     275,000 shares vest in 11 equal monthly installments of 25,000
     shares per month commencing on the 15th day of each month
     following April 17, 2007.
9.   Frederick J. Goetz and Mary Goetz are Husband and wife, and
     Frederick J. Goetz, Jr. is their son.
10.  Consists of (i) 3,465,000 shares of common stock owned by
     Frederick J. Goetz; and (ii) 3,132,000 shares of common stock
     owned by Mary Goetz. Frederick J. Goetz disclaims any beneficial
     ownership of the 3,132,000 shares of common stock owned by Mary
     Goetz, his wife.
11.  On April 17, 2007 Mr. Eaton received a warrant to purchase up to
     150,000 shares of common stock that vest pursuant to the following
     schedule: (i) 12,500 shares vested on April 17, 2007; and (ii)
     137,500 shares shall vest in 11 equal monthly installments of
     12,500 shares per month commencing on the 15th day of each month
     following April 17, 2007.

Item 5.  Directors And Executive Officers, Promoters And Control
         Persons.

Our current directors and executive officers are as follows:

<TABLE>
<CAPTION>
     Name                  Age     Position                   Term/Period Served
     ----                  ---     --------                   ------------------
<S>                        <C>     <C>                        <C>
Harold R. Bennett          50      Director, Chief Executive   1 yr./Since 2007
                                   Officer
Frederick J. Goetz, Jr.    32      Director, President         1 yr./Since 2004

Frederick J. Goetz (1)     64      Chief Science Officer        ----/Since
Inception (1)

David F. Eaton             60      Chief Technology Officer     ----

Andrew J. Ashton           31      Director, Senior Vice       1 yr./Since 2004
                                   President, Treasurer,
                                   Secretary
</TABLE>
------------------------

1.   Dr. Goetz was the founder of PSI-TEC Corporation and has served
     as an officer and until 2005, a director, of our Company since
     its inception.

     Mr. Harold R. Bennett.  Mr. Bennett has served as an officer and
     ---------------------
director of our Company since March 2007. Since 1994 to the present,
Mr. Bennett has acted as an independent management consultant
serving as a corporate restructuring advisor for large high-tech
corporations, including DuPont, Silicon Graphics, 3M and Sun
Microsystems. Most recently, Mr. Bennett successfully implemented a
program for DuPont to outsource innovation by creating a new business
model for DuPont Ventures. Prior to 1994, Mr. Bennett gained extensive
experience in starting and growing companies in Silicon Valley,
including Aprex, West End Partners Imaging and Digital Research.
Mr. Bennett has a degree in Mathematical Physics from Stanford
University and is named on several U.S. Patents.

     Mr. Frederick J. Goetz, Jr. Mr. Goetz has served as an officer
     ---------------------------
and director of our Company since July 2004. Mr. Goetz is in charge of
the day-to-day operations of our Company and its movement to a fully
functioning commercial corporation. He is a leader in the corporate
coding and operation of electrostatic simulation software for
nonlinear optic materials development and aids in the development of
novel molecular designs and quantum mechanical interpretation at our
Company.


                               48
<PAGE>

Prior to joining our Company, Mr. Goetz began his career at Lawrence
Berkeley Laboratory and the Army Research Laboratory on Aberdeen
Proving Grounds after graduating first in his class in physics from
the University of Delaware in 1997. He holds a degree in physics and
currently serves as technical advisor on the board of Universal Capital
Management. Frederick J. Goetz, Jr. is Dr. Goetz's son.

      Dr. Frederick J. Goetz. Dr. Goetz founded our Company in 1991 and
      -----------------------
has served as an officer and until 2005, a director, of our Company
since its inception. Dr. Goetz has dedicated his life to the
advancement of electro-optics. A recognized industrial expert in
polyheterocyclic organic chemistry, his distinguished career began at
American Aniline Products, where he served as a research project team
leader. He went on to lead groups at American Color and Chemical
Corporation, Hooker Chemical and Plastics, Occidental Petroleum
(Senior Scientist), Occidental Chemical, DuPont Experimental Station
(Research Associate), Pennwalt, and Atochem North America. Dr. Goetz
established an electro-optics program at Atochem, before founding PSI-
TEC Corporation in 1991. Dr. Goetz is Frederick J. Goetz, Jr.'s
father.

     Dr. David F. Eaton.  Mr. Eaton has served as an officer of our Company
     --------------------
since May 2007. For over 30 years, Mr. Eaton was employed in DuPont's
chemical division, with his most recent appointment being its technology
director. Most recently, from September 2003 to present, Mr. Eaton founded
and is the principal of Light Insights, LLC, a consulting firm, and from
March 2005 to present, Mr. Eaton has served as vice president of
technology for software company Precision Cure, LLC.  Mr. Eaton has a
bachelor's degree in chemistry from Wesleyan University and a Ph.D. in
chemistry from the California Institute of Technology.

     Mr. Andrew J. Ashton.  Mr. Ashton has served as an officer and
     --------------------
director of our Company since July 2004. Since that time his assistance
in the creation of the synthetic chemistry of our novel molecular
architecture has been fundamental to our Company's success.  His
current duties include the development of chemical synthesis, providing
extensive analytical support and assisting with our Company's management
goals. Mr. Ashton is a skilled computer scientist and organic chemist
who began his career in 1998 at the Army Research Laboratory on the
Aberdeen Proving Grounds where he helped to design and implement
computer interfaces for fiberglass composite analysis.  At that time
he joined PSI-TEC Corporation as a financial manager and was responsible
for day to day administrative duties.  He was instrumental in securing
government funding, PSI-TEC's sole financial source, until 2003.

Item 6.  Executive Compensation.

      The table below summarizes all compensation awarded to, earned
by, or paid to our current executive officers for the fiscal years
ended December 31, 2006 and 2005.

<TABLE>
<CAPTION>
                    Summary Compensation Table
                    --------------------------
                                                                              Nonqualified
Name                                                           Non-Equity       Deferred
and                                       Stock     Option   Incentive Plan   Compensation     All Other
principal                Salary   Bonus   Awards    Awards    Compensation      Earnings     Compensation     Total
position           Year   ($)      ($)     ($)       ($)          ($)             ($)            ($)           ($)
--------           ----  ------   -----   ------   --------  --------------   ------------   ------------   --------
<S>                <C>   <C>      <C>     <C>      <C>       <C>              <C>            <C>           <C>

Ronald R. Genova,  2006  96,000     0       0      $473,737       0               0               0         $569,737
Interim CEO(1)     2005  51,000     0       0         0           0               0               0         $ 51,000

Frederick J.       2006  96,000     0       0         0           0               0               6,000(5)  $102,000
 Goetz, Jr.,       2005  96,000     0       0         0           0               0               6,000(5)  $102,000
President,
Director(2)

Frederick J.       2006  72,000     0       0         0           0               0               0         $ 72,000
 Goetz, Sr.,       2005  72,000     0       0         0           0               0               4,000     $ 76,000
Chief Tech.
Officer, Former
Director(3)

Andrew J. Ashton,  2006  96,000     0       0         0           0               0               0         $ 96,000
Vice Pres.,        2005  96,000     0       0         0           0               0               0         $ 96,000
Treasurer,
Director(4)

</TABLE>

                               49
<PAGE>


(1)  From September 2005 to February 2007, Mr. Genova served as our
     Interim Chief Executive Officer. Mr. Genova received $8,000 per month
     for serving as our interim chief executive officer. During 2005,
     $24,000 of Mr. Genova's salary was for serving as our interim chief
     executive officer and $27,000 was for consulting services Mr. Genova
     provided our Company prior to September 2005. Mr. Genova deferred
     payment of $24,000 owed to him during 2006 due to our limited
     operating capital.  Previously, on May 6, 2005, we entered into an
     Advisory Board Agreement with Mr. Genova whereby we named Mr. Genova
     to our Advisory Board to provide advisory services to our Company, and
     pursuant to that agreement we issued to Mr. Genova a warrant to
     purchase 100,000 shares of our common stock at an exercise price of
     $2.10 per share. On February 14, 2006, we canceled that warrant and
     granted Mr. Genova stock options to purchase up to 500,000 shares of
     our common stock at the exercise price of $1.00 per share pursuant to
     our 2005 Stock Option Plan.
(2)  We have no written employment agreement with Fred Goetz, Jr. Mr.
     Goetz receives an annual salary of $96,000. Due to our limited
     operating capital, Mr. Goetz deferred payment of $16,000 and $8,000
     owed to him during 2006 and 2005, respectively.
(3)  Mr. Fred Goetz, Sr. ceased being a director on December 20, 2005.
     We have no written employment agreement with Fred Goetz, Sr. Mr. Goetz
     receives an annual salary of $72,000. Due to our limited operating
     capital, Mr. Goetz deferred payment of $18,000 owed to him during
     2006.
(4)  We have no written employment agreement with Andrew J. Ashton.
     Mr. Ashton receives an annual salary of $96,000. Due to our limited
     operating capital, Mr. Ashton deferred payment of $16,000 and $8,000
     owed to him during 2006 and 2005, respectively.
(5)  We provide an automobile that Mr. Fred Goetz, Jr. utilizes at a
     cost to us of approximately $6,000 per year.

Summary of Options Grants

     Set forth below is a summary of our option awards to executive
officers outstanding as of December 31, 2006, our latest fiscal year end.

<TABLE>
<CAPTION>

                                                Number of Securities
                  Number of Securities          Underlying              Option      Option
                  Underlying Unexercised        Unexercised Options     Exercise    Expiration
Name              Options (#) Exercisable (1)   (#) Unexercisable       Price ($)   Date
----              ---------------------------   --------------------    ---------   ----------
<S>               <C>                           <C>                     <C>         <C>

Ronald R. Genova         444,000                        ---              1.00        5/30/07
</TABLE>

(1)  We grant stock options to our executive officers based on their
     level of experience and contributions to our Company. The aggregate
     fair value of these options are computed in accordance with FAS 123R
     and are reported in the Summary Compensation Table above in the column


                               50
<PAGE>

     titled "Option Awards." On February 14, 2006, we granted Mr. Genova
     options to purchase up to 500,000 shares of our common stock at the
     exercise price of $1.00 per share with an expiration date of February
     14, 2009, pursuant to our 2005 Stock Option Plan, and we canceled a
     previously issued 100,000 share warrant to purchase our common stock
     at an exercise price of $2.10 per share. On November 10, 2006, we
     extended the option expiration date to February 13, 2016 and modified
     the vesting schedule of unvested options from 300,000 options vesting
     from 2/14/06 to 2/14/09 and 200,000 options vesting from 1/1/07 to
     2/14/09 to 420,000 options vesting on November 10, 2006 and 80,000
     options vesting at the rate of 8,000 options per month from 12/1/06 to
     9/1/07. Pursuant to our 2005 Stock Option Plan, since Mr. Genova's
     employment with the Company ceased effective February 28, 2007, the
     expiration date of his options accelerated to 5/30/07. At no time
     during the last fiscal year was any outstanding option otherwise
     modified or re-priced, and there was no tandem feature, reload
     feature, or tax-reimbursement feature associated with any of the stock
     options we granted to our executive officers or otherwise.

     There were no other options granted or exercised by the named
executive officers in the last two fiscal years.

                    Compensation of Directors

     During fiscal years 2005 and 2006, no officer or director
received any type of compensation from our Company for serving as
such. Presently, our directors, including those who serve as officers
of our Company, are not compensated for serving as such, other than
reimbursement for out of pocket expenses incurred in attending
director meetings.

    We adopted our 2005 Stock Option Plan for the benefit of our
directors, officers, employees and consultants, and we have reserved
1,000,000 shares of common stock for such persons pursuant to this
Plan.

    Our board of directors currently has no formal committees, such
as a compensation committee or an audit committee.


Item 7.   Certain Relationships and Related Transactions.

    None.

Item 8.   Description of Securities.

                            General

    As of the date of this registration statement, we have the
authority to issue 51,000,000 shares of stock, consisting of
50,000,000 shares of common stock, par value $0.001 per share; and
1,000,000 shares of preferred stock, par value $0.001 per share. As of
the date of this registration statement, we have a total of 31,622,535
shares of common stock outstanding, held of record by approximately
103 stockholders. We do not have any shares of preferred stock
outstanding.


                               51
<PAGE>

                         Common Stock

    Each outstanding share of common stock is entitled to one vote on
all matters to be submitted to a vote of the stockholders. Holders do
not have preemptive rights, so we may issue additional shares that may
reduce each holder's voting and financial interest in our Company.
Cumulative voting does not apply to the election of directors, so
holders of more than 50% of the shares voted for the election of
directors can elect all of the directors. All elections for directors
shall be decided by a plurality vote; all other questions shall be
decided by majority vote except as otherwise provided by Nevada
Statutes. Our bylaws permit the holders of the same percentage of all
shareholders entitled to vote at a meeting to take action by written
consent without a meeting.

    Holders of common stock are entitled to receive dividends when,
as and if declared by the board of directors out of funds legally
available therefor. In the event of liquidation, dissolution or
winding up of our Company, holders are entitled to share ratably in
all assets remaining available for distribution to them after payment
of liabilities and after provision has been made for each class of
stock, if any, having preference over the common stock. Holders do not
have any conversion, redemption provisions or other subscription
rights. All of the outstanding shares of common stock are fully paid
and non-assessable.

                       Preferred Stock

    Pursuant to our Company's Articles of Incorporation, our board of
directors is empowered, without stockholder approval, to issue series
of preferred stock with any designations, rights and preferences as
they may from time to time determine. The rights and preferences of
this preferred stock may be superior to the rights and preferences of
our common stock; consequently, preferred stock, if issued, could have
dividend, liquidation, conversion, voting or other rights that could
adversely affect the voting power or other rights of the common stock.
Additionally, Preferred stock, if issued, could be utilized, under
special circumstances, as a method of discouraging, delaying or
preventing a change in control of our business or a takeover from a
third party.

                           PART II

Item 1.   Market Price of and Dividends on the Registrant's Common
          Equity and Related Stockholder Matters.

                      Market Information

     Our common stock is currently traded under the symbol TDON on the
Pink Sheets' Electronic Quotation Service (the "Pink Sheets").

     The following table set forth below lists the range of high and
low bids for our common stock for each fiscal quarter for the last two
fiscal years as reported by the Pink Sheets. The prices in the table
reflect inter-dealer prices, without retail markup, markdown or
commission and may not represent actual transactions.


                               52
<PAGE>

<TABLE>
<CAPTION>
                         High             Low
                         ----             ---
     2005             Bid    Asked    Bid    Asked
     ----             ---    -----    ---    -----
     <S>             <C>     <C>     <C>     <C>
     1st Quarter     $4.40   $4.85   $0.56   $0.65
     2nd Quarter     $4.60   $4.80   $1.85   $1.865
     3rd Quarter     $3.05   $3.13   $2.00   $2.09
     4th Quarter     $2.06   $2.10   $1.30   $1.45

     2006
     ----

     1st Quarter     $2.10   $2.15   $2.15   $0.90
     2nd Quarter     $1.87   $2.00   $2.00   $1.10
     3rd Quarter     $1.14   $1.25   $1.25   $0.53
     4th Quarter     $0.83   $0.86   $0.38   $0.42


     2007
     ----

     1st Quarter     $0.72   $0.74    $0.42   $0.48
</TABLE>

                            Holders

    As of the date of this registration statement, we have a total of
31,622,535 shares of common stock outstanding, held of record by
approximately 109 shareholders. We do not have any shares of preferred
stock outstanding.


                           Dividends

    No cash dividends have been declared or paid on our common stock
to date. No restrictions limit our ability to pay dividends on our
common stock. The payment of cash dividends in the future, if any,
will be contingent upon our Company's revenues and earnings, if any,
capital requirements and general financial condition. The payment of
any dividends is within the discretion of our board of directors. Our
board of director's present intention is to retain all earnings, if
any, for use in our business operations and, accordingly, the board of
directors does not anticipate paying any cash dividends in the
foreseeable future.

  Securities Authorized for Issuance Under Equity Compensation Plans

The following table provides information about our compensation plans
under which shares of common stock may be issued upon the exercise of
options as of December 31, 2006.


                               53
<PAGE>


<TABLE>
<CAPTION>
         Equity Compensation Plans as of December 31, 2006

---------------------------------------------------------------------------------------------------
                    A                               B                       C
---------------------------------------------------------------------------------------------------
                                                                            Number of securities
                                                                            remaining available for
                                                    Weighted-               future issuance under
                    Number of securities            average exercise        equity compensation
                    to be issued upon               price of                plans (excluding
                    exercise of outstanding         outstanding options,    securities reflected
Plan category       options, warrants and rights    warrants and rights      in column (A))
---------------------------------------------------------------------------------------------------
<S>                 <C>                             <C>                     <C>

Equity compensation
plans approved by
security holders(1)        700,000                         1.00                 300,000

---------------------------------------------------------------------------------------------------

Equity compensation
plans not approved
by security holders          ---                            ---                  ---

---------------------------------------------------------------------------------------------------

Total                      700,000                        $1.00                 300,000
---------------------------------------------------------------------------------------------------
</TABLE>

     On December 20, 2005, we adopted our 2005 Stock Option Plan for
the benefit of our directors, officers, employees and consultants, and
we have reserved 1,000,000 shares of common stock for such persons
pursuant to this Plan.

           Over-the-counter Bulletin Board Listing Matters

    By virtue of filing this registration statement, we are making an
application with the Securities and Exchange Commission (the "SEC" or
"Commission") to register our common stock under the provisions of
Section 12(g) of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"). This registration will require our Company to comply
with periodic reporting, proxy solicitations and certain other
requirements of the Exchange Act.

     We intend to seek the listing of our common stock on the over-
the-counter bulletin board ("OTCBB") upon the completion of this
registration statement. In order to become listed on the OTCBB, a NASD
market maker must apply on our behalf to make a market of our common
stock on the OTCBB. We cannot assure you that a market maker will make
an application on our behalf, or that if an application is made on our
behalf, that the NASD will list our Company on the OTCBB.


                               54
<PAGE>

       Penny Stock Regulations and Restrictions on Marketability

     The SEC has adopted rules that regulate broker-dealer practices
in connection with transactions in penny stocks. Penny stocks are
generally equity securities with a market price of less than $5.00,
other than securities registered on certain national securities
exchanges or quoted on the NASDAQ system, provided that current price
and volume information with respect to transactions in such securities
is provided by the exchange or system. The penny stock rules require a
broker-dealer, prior to a transaction in a penny stock, to deliver a
standardized risk disclosure document prepared by the SEC, that: (a)
contains a description of the nature and level of risk in the market
for penny stocks in both public offerings and secondary trading; (b)
contains a description of the broker's or dealer's duties to the
customer and of the rights and remedies available to the customer with
respect to a violation of such duties or other requirements of the
securities laws; (c) contains a brief, clear, narrative description of
a dealer market, including bid and ask prices for penny stocks and the
significance of the spread between the bid and ask price; (d) contains
a toll-free telephone number for inquiries on disciplinary actions;
(e) defines significant terms in the disclosure document or in the
conduct of trading in penny stocks; and (f) contains such other
information and is in such form, including language, type size and
format, as the SEC shall require by rule or regulation.

     The broker-dealer also must provide, prior to effecting any
transaction in a penny stock, the customer with (a) bid and offer
quotations for the penny stock; (b) the compensation of the broker-
dealer and its salesperson in the transaction; (c) the number of
shares to which such bid and ask prices apply, or other comparable
information relating to the depth and liquidity of the market for such
stock; and (d) a monthly account statement showing the market value of
each penny stock held in the customer's account.

     In addition, the penny stock rules require that prior to a
transaction in a penny stock not otherwise exempt from those rules,
the broker-dealer must make a special written determination that the
penny stock is a suitable investment for the purchaser and receive the
purchaser's written acknowledgment of the receipt of a risk disclosure
statement, a written agreement as to transactions involving penny
stocks, and a signed and dated copy of a written suitability
statement.

     These disclosure requirements may have the effect of reducing the
trading activity for our common stock. Therefore, stockholders may
have difficulty selling our securities.

                       Our Transfer Agent

     StockTrans, Inc. is the transfer agent for our common stock. They
are located at 44 West Lancaster Ave., Ardmore, Pennsylvania 19003.


Item 2.  Legal Proceedings.

     During the spring of 2005, we raised $1,000,000 through the sale
of 4,000,000 shares of our common stock in a limited offering to
persons considered to be accredited investors. Our Company received a
legal opinion from outside counsel as to the availability of an
exemption from registration with the Securities and Exchange


                               55
<PAGE>

Commission (the "SEC" or "Commission") with respect to the limited
offering.

     In December 2005, we were informed by the Commission that it is
investigating the circumstances surrounding the $1,000,000 offering
described above including the subsequent public resale of certain
shares originally sold in the offering, along with related matters.
Our Company has further been informed that the original issuance of
the stock and subsequent resale thereof may have been done, in the
opinion of the Commission, in violation of the registration provisions
of the Securities Act of 1933, as amended. These matters could lead to
enforcement action by the Commission. Our Company has committed to
cooperate fully with the Commission with the intention that all issues
will be resolved as quickly as possible.

	Ronald R. Genova v. Third-Order Nanotechnologies, Inc., PSI-TEC
Holdings, Inc. and Universal Capital Management

	This case was filed in Philadelphia County, Court of Common
Pleas, on July 23, 2007. Ronald R. Genova is the Plaintiff. Third-
Order Nanotechnologies, Inc., PSI-TEC Holdings, Inc. and Universal
Capital Management are each a Defendant. The case is in the early stages.

	Ronald R. Genova ("Genova") served as a consultant and then as
the interim chief executive officer of our Company, Third-Order
Nanotechnologies, Inc. The Company terminated Genova effective
February 28, 2007. On March 26, 2007 the Company paid Genova $9,806,
which the Company determined was the full amount the Company owed
Genova. Genova sued, claiming he was owed an additional $84,650.38
plus interest for unpaid consulting fees in the amount of $32,515.68,
a performance bonus in the amount of $50,000, and an expense
reimbursement in the amount of $2,134.70. Pursuant to the complaint,
Genova is alleging breach of contract, fraud and promissory estoppel
in an amount in excess of $180,000, in addition to the right to
exercise his options, that expired on May 30, 2007, until February 13,
2016 or a judgment in an additional amount equal to the monetary value
of such options plus punitive damages, interest and costs. Our Position
is that Genova has been fully paid all amounts due to him, that Genova's
options expired and that he is not entitled to exercise such options at
any time now or in the future.

	On September 4, 2007 our Company has answered the complaint seeking
dismissal of all allegations contained in the complaint and denying that
Genova is entitled to any of the relief he is seeking. Additionally, our
Company counter-claimed Genova seeking an undetermined amount of damages
from Genova for fraud, breach of contract, breach of duty of loyalty, and
breach of duty of disclosure.  No discovery has commenced in this proceeding
to date.  We intend to vigorously contest the matter. Although the facts
ascertained to date indicate a favorable outcome is a likely result, it is
too early in the process to provide a detailed evaluation of the likelihood
of success. It is also too early to provide an estimate of the amount or
range of potential loss, although according to the complaint, Genova is
seeking in excess of $180,000, in addition to the right to exercise his
options, that expired on May 30, 2007, until February 13, 2016 or a
judgment in an additional amount equal to the monetary value of such
options plus punitive damages, interest and costs, so the assumption can
be made that this would be at the high end of that range.

        Other than described herein, we are not aware of any litigation
or threatened litigation of a material nature.

Item 3.   Changes In and Disagreements with Accountants.

     Not Applicable.

Item 4.   Recent Sales of Unregistered Securities.

     Our Company has sold the following securities within the past
three years without registering the securities under the Securities
Act:

     Common Stock/Convertible Notes

     During 2004, our Company and subsidiary issued $499,000 in
convertible promissory notes and 187,500 shares of our common stock to
forty-one accredited investors. Our Company and subsidiary relied on
Rule 506 of Regulation D for these transactions. The 187,500 shares of
our common stock were issued at the price of 0.16 per share. As of
June of 2005, all of the convertible promissory notes were converted
into 3,118,750 shares of our common stock at the conversion price of
approximately $0.16 per share.

     In July 2004, pursuant to our plan of reorganization, PSI-TEC
shareholders were issued 15,600,000 shares of our common stock. These
persons were the only offerees in connection with this transaction. We
relied on Section 4(2) of the Securities Act.

     Also in July 2004, our Company issued 637,500 shares of common
stock to five other persons, including 100,000 shares to our
president, in exchange for the services such persons provided to our
Company and subsidiary prior to August 1, 2004. The shares were valued
at $0.16 per share for an aggregate amount of $75,000. These persons
were the only offerees in connection with this transaction. We relied
on Section 4(2) of the Securities Act since the transaction did not
involve any public offering.


                               56
<PAGE>

     During April 2005 we issued 4,000,000 shares of common stock to
seven persons our Company considered to be accredited investors at
$0.25 per share for an aggregate amount of $1,000,000. We relied on
Rule 504 of Regulation D for this transaction.

     During August 2005 we issued 200,000 shares of common stock to
one accredited investor, in exchange for management advisory services
it provided to our Company and its subsidiary. The shares were valued
at $2.92 per share for an aggregate amount of $584,000. This person
was the only offeree in connection with this transaction. We relied on
Section 4(2) of the Securities Act since the transaction did not
involve any public offering.

     Also, during August 2005 we issued 210,000 shares of common stock
to two accredited investors in exchange for consulting services
provided to our Company and its subsidiary. The shares were valued at
an average price of approximately $2.79 per share for an aggregate
amount of $585,500. These persons were the only offerees in connection
with these transactions. We relied on Section 4(2) of the Securities
Act since the transactions did not involve any public offering.

     During December 2005, our Company adopted its 2005 Stock Option
Plan and reserved up to 1,000,000 shares of our Company's common stock
for issuance pursuant to the Stock Option Plan. Since then, we have
granted options to purchase up to 700,000 shares of our common stock
at an exercise price of $1.00 per share.

     During December 2005, we issued 300,000 shares of common stock to
one accredited investor for $75,000 pursuant to a warrant to purchase
300,000 shares of our common stock at an exercise price of $0.25 per
share issued during that same time. We relied on Section 4(2) of the
Securities Act since the transaction did not involve any public
offering.

     During February 2006 we issued an aggregate of 300,000 shares of
common stock to two accredited investors for professional and
consulting services. The shares were valued at $0.90 per share for an
aggregate amount of approximately $270,000.  We relied on Section 4(2)
and/or Rule 701 of the Securities Act since the transaction did not
involve any public offering.

     During May and June of 2006 we issued an aggregate of 425,000
shares of common stock to three accredited investors for professional
and consulting services. The shares were valued at approximately $1.45
to 1.60 per share for an aggregate amount of approximately $656,250.
We relied on Section 4(2) and/or Rule 701 of the Securities Act since
the transaction did not involve any public offering.

      During June 2006, we authorized the private offering of our
common stock, which offering was amended in August and again in
December 2006. Ultimately, the private offering terms were to raise up
to an aggregate of $1,000,000, with up to 20 units to be offered at
the offering price of $50,000 per unit, with each unit comprised of
100,000 shares of common stock, and a warrant to purchase 50,000
shares of common stock at $0.50 per share. The private offering raised
a total of $999,000, $425,000 during 2006 and $574,000 during the
first quarter of 2007, and was closed in March 2007. We relied on
Section 4(2) and Rule 506 of Regulation D of the Securities Act since
the transaction does not involve any public offering.


                               57
<PAGE>

     During November 2006, we issued 60,000 shares of our common stock
to one accredited investor for consulting services. The shares were
valued at approximately $0.49 per share for an aggregate amount of
$29,400. We relied on Section 4(2) of the Securities Act since the
transaction did not involve any public offering.

     During February 2007, we issued: (i) 151,785 shares of our common
stock to one accredited investor for stock analyst services. The
shares were valued at approximately $0.70 per share for an aggregate
amount of approximately $106,250; and (ii) 1,000,000 shares of our
common stock to one accredited investor for management advisory
services. The shares were valued at approximately $0.58 per share for
an aggregate amount of approximately $580,000. These persons were the
only offerees in connection with these transactions. Our Company
relied on Section 4(2) of the Securities Act since the transaction did
not involve any public offering.

     During April 2007, we issued 100,000 shares of our common stock to
one accredited investor for professional services. The shares were valued
at approximately $0.35 per share for an aggregate amount of approximately
$35,000. This person was the only offeree in connection with these
transactions. We relied on Section 4(2) and/or Rule 701 of the Securities
Act since the transaction did not involve any public offering.

     Also during April 2007, we authorized a $1,000,0000 private offering of
our common stock and warrants to purchase our common stock. Pursuant to the
terms of this private offering, up to 20 units were offered at the offering
price of $50,000 per unit, with each unit comprised of 100,000 shares of
common stock, and a warrant to purchase 50,000 shares of common stock at
$0.50 per share. To date, this private offering has raised an aggregate
of $667,000. We relied on Section 4(2) and Rule 506 of Regulation D of
the Securities Act since the transaction does not involve any public
offering.

      Warrants to Purchase Common Stock

     Our Company has outstanding the following warrants to purchase
shares of our Company's common stock as described below:

<TABLE>
<CAPTION>
                           Shares Underlying
   Date Issued          Warrants/ Exercise Price    Exercise/Expiration Schedule
   -----------          ------------------------    ----------------------------
<S>                    <C>                          <C>

September 1, 2005             50,000/$2.00          25,000 shares from 9/1/06 - 9/1//07(1)(2)
                                                    25,000 shares from 9/1/07 - 9/1//08(1)(2)

June 1, 2006                  300,000/$0.25         300,000 shares from 6/1/06 - 5/31/08(2)

  ----(3)                     999,000/$.50                    ----(4)(5)

April 17, 2007                100,000/$0.25         100,000 shares from 4/17/07 - 4/17/10(2)
                              300,000/$0.25         300,000 shares from 4/17/07 - 4/17/10(2)
                              150,000/$0.25         150,000 shares from 4/17/07 - 4/17/10(2)
                              100,000/$0.25         100,000 shares from 4/17/07 - 4/17/10(2)
                              500,000/$0.25         500,000 shares from 4/17/07 - 4/17/10(2)
                              500,000/$0.25         500,000 shares from 4/17/07 - 4/17/12(2)

  ----(6)                     667,000/$.50                    ----(4)(5)
--------------------
</TABLE>

1.   The warrant holder must remain an employee of, or an active
     advisor or consultant to our Company during such exercise
     period.
2.   The warrants were issued in connection with advisory or consulting
     services provided to our Company and vest at various times pursuant
     to the specific terms of the advisor's or consultant's warrant
     agreement. These persons were the only offerees in connection with
     this transaction. Our Company relied on Section 4(2) of the Securities
     Act since the transaction did not involve any public offering.
3.   Issued at various times in connection with our June 16,
     2006 amended private offering.
4.   The warrants are immediately exercisable for a period of
     two (2) years from the date of purchase.
5.   We relied upon Section 4(2) and Rule 506 of Regulation D of
     the Securities Act since the transaction did not involve
     any public offering.
6.   Issued at various times in connection with our April
     2007 private offering.

     No underwriters were utilized and no commissions or fees were
paid with respect to any of the above transactions.


                               58
<PAGE>

Item 5.   Indemnification of Directors and Officers.

    Nevada Revised Statutes provide for indemnification of the
corporation's directors, officers, employees and agents for
liabilities and expenses that they may incur as a result of his or her
acting in such capacities. In general, directors, officers, employees
and agents are indemnified with respect to actions taken in good
faith, in a manner reasonably believed to be in, or not opposed to,
the best interests of the corporation, and with respect to any
criminal action or proceeding, actions that the indemnitee had no
reasonable cause to believe were unlawful. Our Articles of
Incorporation provide that a director or officer shall be liable to
the extent provided by applicable law, (i) for acts or omission which
involves intentional misconduct, fraud or a knowing violation of the
law, or (ii) for the payment of dividends in violation of the Nevada
Revised Statutes.

     Insofar as indemnification arising under the Securities Act may
be permitted to our directors, officers and controlling persons
pursuant to the foregoing provisions or otherwise, we have been
advised that in the opinion of the Commission such indemnification is
against public policy as expressed in the Securities Act and is,
therefore, unenforceable.














                               59
<PAGE>













                            PART F/S










<PAGE>








             THIRD-ORDER NANOTECHNOLOGIES, INC.
                (A Development Stage Company)

                    FINANCIAL STATEMENTS

                        JUNE 30, 2007

                         (UNAUDITED)

















<PAGE>










                  THIRD-ORDER NANOTECHNOLOGIES, INC.
                    (A Development Stage Company)






                               CONTENTS

                                                         PAGE

BALANCE SHEETS                                            F-1

STATEMENTS OF OPERATIONS                                  F-2

STATEMENTS OF COMPREHENSIVE LOSS                          F-3

STATEMENTS OF STOCKHOLDERS' EQUITY                        F-4

STATEMENTS OF CASH FLOWS                               F-5 - F-6

NOTES TO FINANCIAL STATEMENTS                          F-7 - F-11







<PAGE>

                    THIRD-ORDER NANOTECHNOLOGIES, INC.
                      (A Development Stage Company)
                             BALANCE SHEETS
<TABLE>
<CAPTION>

                                                         June 30, 2007   December 31, 2006
                                                           (Unaudited)       (Audited)
                                                         -------------   -----------------
                                                                            (Restated)
<S>                                                        <C>            <C>
                    ASSETS

 CURRENT ASSETS
  Cash and cash equivalents                                $   436,671    $       528
  Deferred charges                                              76,146        586,171
  Prepaid expenses                                               5,406          9,353
  Receivables                                                      100            100
                                                           -----------    -----------
                                                               518,323        596,152

 AVAILABLE FOR SALE SECURITIES
  Related party                                                 43,900         59,265
  Other                                                          1,472          2,535
                                                           -----------    -----------
                                                                45,372         61,800

 PROPERTY AND EQUIPMENT - NET                                   76,651         42,335

 OTHER ASSETS
  Deferred charges                                                   -         97,083
  Intangible assets                                            142,856         42,376
                                                           -----------    -----------
 TOTAL ASSETS                                              $   783,202    $   839,746
                                                           ===========    ===========


            LIABILITIES AND STOCKHOLDERS' EQUITY

 CURRENT LIABILITIES
  Loan payable - current portion                           $     5,154    $     4,977
  Accounts payable                                             129,575        100,714
  Accounts payable - related party                                   -         65,339
  Accrued expenses                                              87,211         83,712
  Officer loans                                                  1,468          1,468
                                                           -----------    -----------
                                                               223,408        256,210

 CONTINGENCY                                                         -              -

 LOAN PAYABLE - NET OF CURRENT PORTION                           6,263          8,764
                                                           -----------    -----------

 TOTAL LIABILITIES                                             229,671        264,974
                                                           -----------    -----------
 STOCKHOLDERS' EQUITY
  Preferred stock, $0.001 par value,
     1,000,000 authorized
  No shares issued or outstanding                                    -              -
  Common stock $0.001 par value, 50,000,000
    authorized 31,622,535 and 27,888,750
    issued and outstanding at June 30, 2007
    and December 31, 2006                                       31,623         27,889
  Additional paid-in-capital                                 8,455,612      5,966,430
  Deferred charges                                            (578,952)             -
  Unrealized loss on Available for Sale Securities             (42,428)       (26,000)
  Accumulated deficit                                          (15,827)       (15,827)
  Deficit accumulated during development stage              (7,296,497)    (5,377,720)
                                                           -----------    -----------

 TOTAL STOCKHOLDERS' EQUITY                                    553,531        574,772
                                                           -----------    -----------

 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                $   783,202    $   839,746
                                                           ===========    ===========
</TABLE>


The accompanying notes are an integral part of these financial statements.

                                   F-1
<PAGE>



                     THIRD-ORDER NANOTECHNOLOGIES, INC.
                        (A Development Stage Company)
                           STATEMENTS OF OPERATIONS
                      FOR THE THREE AND SIX MONTHS ENDING
                   JUNE 30, 2007 AND 2006 AND FOR THE PERIOD
                JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT STAGE)
                               TO JUNE 30, 2007
                                  (UNAUDITED)
<TABLE>
<CAPTION>
                                        Cumulative   For the Three  For the Three  For the Six    For the Six
                                          Since      Months Ending  Months Ending  Months Ending  Months Ending
                                        Inception    June 30, 2007  June 30, 2006  June 30, 2007  June 30, 2006
                                       -----------   ------------   -------------  -------------  -------------
<S>                                    <C>            <C>            <C>            <C>            <C>
NET SALES                              $         -    $         -    $         -    $         -    $         -

COST AND EXPENSE
Research and development                 3,102,630        459,318        363,105        845,206        613,040
General and administrative               4,239,574        717,515        462,963      1,071,806        851,121
                                       -----------    -----------    -----------    -----------    -----------
                                         7,342,204      1,176,833        826,068      1,917,012      1,464,161

LOSS FROM OPERATIONS                    (7,342,204)    (1,176,833)      (826,068)    (1,917,012)    (1,464,161)

OTHER INCOME (EXPENSE)
Interest income                              9,061          1,581              7          1,584            241
Dividend income                              1,527              -            126              -            126
Realized gain on investment                 63,187              -              -              -              -
Interest expense                           (28,068)        (1,341)        (1,408)        (3,349)        (2,134)
                                       -----------    -----------    -----------    -----------    -----------

NET LOSS                               $(7,296,497)   $(1,176,593)   $  (827,343)   $(1,918,777)   $(1,465,928)
                                       ===========    ===========    ===========    ===========    ===========
Basic and Diluted Loss per Share                      $     (0.04)   $     (0.03)   $     (0.06)   $     (0.06)
                                                      ===========    ===========    ===========    ===========
Basic and Diluted Weighted Average Number of Shares    31,149,313     26,841,028     29,988,039     26,623,667
                                                      ===========    ===========    ===========    ===========
</TABLE>


The accompanying notes are an integral part of these financial statements.

                                  F-2
<PAGE>

                    THIRD-ORDER NANOTECHNOLOGIES, INC.
                      (A Development Stage Company)
                      STATEMENTS OF COMPREHENSIVE LOSS
       FOR THE THREE AND SIX MONTHS ENDING JUNE 30, 2007 AND 2006
      AND FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT
                          STAGE) TO JUNE 30, 2007
                                (UNAUDITED)

<TABLE>
<CAPTION>
                                       Cumulative    For the Three  For the Three  For the Six    For the Six
                                          Since      Months Ending  Months Ending  Months Ending  Months Ending
                                        Inception    June 30, 2007  June 30, 2006  June 30, 2007  June 30, 2006
                                       -----------   ------------   -------------  -------------  -------------
<S>                                    <C>            <C>            <C>            <C>            <C>
NET LOSS                               $(7,296,497)   $(1,176,593)   $  (827,343)   $(1,918,777)   $(1,465,928)

OTHER COMPREHENSIVE INCOME/(LOSS)
Unrealized gain/(loss) on Available
  for Sale Securities                      (42,428)       (22,457)         4,624        (16,428)         4,624
                                       -----------    -----------    -----------    -----------    -----------

COMPREHENSIVE LOSS                     $(7,338,925)   $(1,199,050)   $ (822,719)   $ (1,935,205)   $(1,461,304)
                                       ===========    ===========    ==========    ============    ===========
</TABLE>


The accompanying notes are an integral part of these financial statements.

                                    F-3
<PAGE>


                    THIRD-ORDER NANOTECHNOLOGIES, INC.
                      (A Development Stage Company)
                    STATEMENT OF STOCKHOLDERS' EQUITY
        FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT
                          STAGE) TO JUNE 30, 2007
                                (UNAUDITED)
<TABLE>
<CAPTION>
                                                                                                 Deficit
                                                                                                Accumulated
                                                                                                  During    Unrealized
                        Number of   Common     Paid-in   Subscription  Deferred    Accumulated  Development   Loss on
                         Shares     Stock      Capital    Receivable   Charges      Deficit        Stage    Securities    Total
                       ----------  --------  ----------  ------------ -----------  -----------  ----------- ---------- -----------
<S>                    <C>         <C>       <C>         <C>          <C>          <C>          <C>         <C>        <C>
ENDING BALANCE AT
  DECEMBER 31, 2003           100   $     1  $        -  $          - $         -  $  (15,827)  $         - $        - $   (15,826)

Retroactive
recapitalization
upon reverse
acquisition               706,973       706        (706)            -           -           -             -          -           -
                       ----------  --------  ----------  ------------ -----------  -----------  ----------- ---------- -----------
BALANCE AT
 JANUARY 1, 2004          707,073       707        (706)            -           -     (15,827)            -          -     (15,826)

Common stock
 issued to
 founders              13,292,927    13,293     (13,293)            -           -           -             -          -           -
Common stock issued
  for future services
  in July 2004 at
  $0.16/share            1,600,000    1,600     254,400             -           -            -            -          -     256,000
Common stock issued
  at merger              2,000,000    2,000      (2,000)            -           -            -            -          -           -
Common stock issued
  for future services
  in August 2004 at
  $0.12/share              637,500      638      74,362             -           -            -            -          -      75,000
Conversion of note
  payable in December
  2004 at $0.16/share      187,500      187      29,813             -           -            -            -          -      30,000
Net loss for the year
 ended December 31, 2004         -        -           -             -           -            -     (722,146)         -    (722,146)
                       ----------  --------  ----------  ------------ -----------  -----------  ----------- ---------- -----------
BALANCE AT
  DECEMBER 31, 2004    18,425,000    18,425     342,576             -           -     (15,827)     (722,146)         -    (376,972)

Common stock issued in
 private placement in
 April 2005 at
 $0.25/share            4,000,000     4,000     996,000             -           -            -            -          -   1,000,000
Conversion of notes
 payable in May 2005
 at $0.16/share         3,118,750     3,119     495,881             -           -            -            -          -     499,000
Subscription receivable         -         -           -        (6,500)          -            -            -          -      (6,500)
Common stock issued for
 future services in
 August 2005, valued
 at $2.79/share           210,000       210     585,290             -           -            -            -          -     585,500
Common stock issued
 for future services
 in August 2005,
 valued at $2.92/share    200,000       200     583,800             -           -            -            -          -     584,000
Warrants issued for
 services in May 2005,
 vested during 2005,
 valued at $1.13/share          -         -      37,000             -           -            -            -          -      37,000
Warrants issued for
 services in September
 2005, vested during
 2005, valued at
 $1.45/share                    -         -      24,200             -           -            -            -          -      24,200
Warrants issued for
 services in October
 2005, vested during
 2005, valued at
 $0.53/share                    -         -      15,900             -           -            -            -          -      15,900
Warrants issued for
 future services in
 December 2005, vested
 during 2005, valued
 at $1.45/share                 -         -     435,060             -           -            -            -          -     435,060
Deferred charges for
 common stock issued
 for future services
 in August 2005, valued
 at $2.92/share                 -         -           -             -    (584,000)           -            -          -    (584,000)
Amortization of
 deferred charges                                                         265,455                                          265,455
Exercise of warrants
 in December 2005 at
 $0.25/share              300,000       300      74,700             -           -            -            -          -      75,000
Net loss for the year
 ended December 31, 2005        -         -           -             -           -           -    (1,721,765)         -  (1,721,765)
                       ----------  --------  ----------  ------------ -----------  -----------  ----------- ---------- -----------
BALANCE AT
 DECEMBER 31, 2005     26,253,750    26,254   3,590,407        (6,500)   (318,545)    (15,827)   (2,443,911)         -     831,878

Common stock issued
 in private placement
 during 2006 at
 $0.50/share              850,000       850     424,150             -           -            -            -          -     425,000
Common stock issued
 for future services
 in February 2006,
 valued at $0.90/share    300,000       300     269,700             -           -            -            -          -     270,000
Common stock issued for
 future services in
 May 2006, valued at
 $1.55/share              400,000       400     619,600             -           -            -            -          -     620,000
Common stock issued for
 future services in
 June 2006, valued at
 $1.45/share               25,000        25      36,225             -           -            -            -          -      36,250
Common stock issued
 for future services
 in November 2006,
 valued at $0.49/share     60,000        60      29,340             -           -            -            -          -      29,400
Warrants issued for
 services in September
 2005, vested during
 2006, valued at
 $1.45/share                    -         -      66,500             -           -            -            -          -      66,500
Warrants issued for
 future services in
 June 2006, vested
 during 2006, valued
 at $1.55/share                 -         -     465,996             -           -            -            -          -     465,996
Options issued for
 services in February
 2006, vested during
 2006, valued at
 $1.01/share                    -         -     428,888             -           -            -            -          -     428,888
Contributed capital
 related to accrued
 interest                       -         -      35,624             -           -            -            -          -      35,624
Subscription receivable         -         -           -         6,500           -            -            -          -       6,500
Amortization of
 deferred charges               -         -           -             -     318,545            -            -          -     318,545
Unrealzed gain (loss)
 on securities                  -         -           -             -           -            -            -    (26,000)    (26,000)
Net loss for the year
 ended December 31, 2006        -         -           -             -           -           -    (2,933,809)         -  (2,933,809)
                       ----------  --------  ----------  ------------ -----------  -----------  ----------- ---------- -----------
BALANCE AT
 DECEMBER 31, 2006
 (AUDITED)(Restated)   27,888,750    27,889   5,966,430             -           -      (15,827)  (5,377,720)   (26,000)    574,772

Common stock issued
 in private placement
 during 2007 at
 $0.50/share            2,482,000     2,482   1,238,518             -           -            -            -          -   1,241,000
Common stock issued
 for future services
 in February 2007,
 valued at $0.70/share    151,785       152     106,098             -           -            -            -          -     106,250
Common stock issued for
 future services in
 March 2007, valued
 at $0.58/share         1,000,000     1,000     579,000             -           -            -            -          -     580,000
Common stock issued
 for services and
 settlement for
 accounts payable in
 April 2007, valued
 at $0.04/share           100,000       100      34,900             -           -            -            -          -      35,000
Warrants issued for
 services in September
 2005, vested through
 June 2007, valued at
 $1.45/share                    -         -      18,086             -           -            -            -          -      18,086
Warrants issued for
 services in March
 2007, vested through
 June 2007, valued
 at $0.69/share                 -         -      20,388             -           -            -            -          -      20,388
Warrants issued for
 services in April
 2007, vested through
 June 2007, valued
 at $0.69/share                 -         -      84,175             -           -            -            -          -      84,175
Warrants issued for
 services in April
 2007, vested through
 June 2007, valued
 at $0.63/share                 -         -      47,839             -           -            -            -          -      47,839
Warrants issued for
 services in May
 2007, vested through
 June 2007, valued
 at $0.56/share                 -         -      10,404             -           -            -            -          -      10,404
Options issued for
 services in February
 2006, vested through
 June 2007, valued at
 $1.01/share                    -         -      17,589             -           -            -            -          -      17,589
Options issued for
 services in February
 2006, vested through
 June 2007, valued at
 $1.09/share                    -         -      43,757             -           -            -            -          -      43,757
Warrants issued for
 future services in
 March 2007, vested
 during 2007, valued
 at $0.58/share                 -         -     288,428             -           -            -            -          -     288,428
Deferred charges for
 common stock issued
 for future services
 in March 2007, valued
 at $0.58/share                 -         -           -             -    (868,428)           -            -          -    (868,428)
Amortization of
 deferred charges               -         -           -             -     289,476            -            -          -     289,476
Unrealzed gain (loss)
 on securities                  -         -           -             -           -            -            -    (16,428)    (16,428)
Net loss for the six
 months ending
 June 30, 2007                  -         -           -             -           -            -   (1,918,777)         -  (1,918,777)
                       ----------  --------  ----------  ------------ -----------  -----------  ----------- ---------- -----------
BALANCE AT
 JUNE 30, 2007
 (UNAUDITED)           31,622,535  $ 31,623  $8,455,612  $          - $  (578,952) $  (15,827)  $(7,296,497)$  (42,428)$   553,531
                       ==========  ========  ==========  ============ ===========  ==========   =========== ========== ===========
</TABLE>


The accompanying notes are an integral part of these financial statements.

                                   F-4
<PAGE>


                      THIRD-ORDER NANOTECHNOLOGIES, INC.
                        (A Development Stage Company)
                            STATEMENTS OF CASH FLOW
               FOR THE SIX MONTHS ENDED JUNE 30, 2007 AND 2006 AND
             FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT
                           STAGE) TO JUNE 30, 2007
                         (UNAUDITED)
<TABLE>
<CAPTION>

                                                            Cumulative        For the Six       For the Six
                                                              Since          Months Ending      Months Ending
                                                            Inception        June 30, 2007       June 30, 2006
                                                           -------------      -------------     -------------
<S>                                                        <C>                <C>               <C>
CASH FLOWS FROM OPERATING ACTIVITIES
 Net loss                                                  $  (7,296,497)     $  (1,918,777)    $  (1,465,928)
 Adjustment to reconcile net loss to net cash
   used in operating activities
 Amortization of deferred charges                              3,345,786          1,002,834           400,936
 Warrants issued for services                                    324,492            180,892           507,150
 Stock options issued for services                               823,734             61,346           169,683
 Common stock issued for services                                  5,292              5,292                 -
 Depreciation                                                     36,996              8,220             6,081
 Realized gain on investments                                    (63,187)                 -              (126)
 (Increase) decrease in assets
  Receivables                                                     69,439                  -            75,000
  Prepaid expenses                                                (5,406)             3,947           (11,330)
 Increase (decrease) in liabilities
 Accounts payable                                                217,490             58,569            (7,491)
 Accounts payable - related party                                      -            (65,339)                -
 Accrued expenses                                                 21,697              3,499           (29,037)
                                                           -------------      -------------     -------------

  Net cash used in operating activities                       (2,520,164)          (659,517)         (355,062)
                                                           -------------      -------------     -------------
CASH FLOWS FROM INVESTING ACTIVITIES
  Cost of intangibles                                           (142,856)          (100,480)             (680)
  Proceeds from sale of available for sale securities            175,387                  -                 -
  Purchase of available for sale securities                     (200,000)                 -                 -
  Purchase of equipment                                          (67,361)           (42,536)                -
                                                           -------------      -------------     -------------

  Net cash used in investing activities                         (234,830)          (143,016)             (680)
                                                           -------------      -------------     -------------
CASH FLOWS FROM FINANCING ACTIVITIES
  Issuance of common stock, private placement                  2,666,000          1,241,000           215,000
  Proceeds (Repayment) of notes payable                          (13,226)            (2,324)           33,068
  Proceeds from subscription receivable                            6,500                  -                 -
  Advances to stockholders                                        (3,435)                 -                 -
  Proceeds from convertible notes                                529,000                  -                 -
  Advances from officers                                           1,468                  -                 -
                                                           -------------      -------------     -------------

  Net cash provided by financing activities                    3,186,307          1,238,676           248,068
                                                           -------------      -------------     -------------

NET INCREASE IN CASH AND CASH EQUIVALENTS                        431,313            436,143          (107,674)

CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD                    5,358                528           150,027
                                                           -------------      -------------     -------------

CASH AND CASH EQUIVALENTS - END OF PERIOD                  $     436,671      $     436,671     $      42,353
                                                           =============      =============     =============
</TABLE>


The accompanying notes are an integral part of these financial statements.

                                  F-5
<PAGE>

                     THIRD-ORDER NANOTECHNOLOGIES, INC.
                       (A Development Stage Company)
                         STATEMENTS OF CASH FLOW
              FOR THE SIX MONTHS ENDED JUNE 30, 2007 AND 2006 AND
            FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT
                         STAGE) TO JUNE 30, 2007
                                (UNAUDITED)
<TABLE>
<CAPTION>
                                                            Cumulative         For the Six       For the Six
                                                              Since           Months Ending     Months Ending
                                                            Inception         June 30, 2007     June 30, 2006
                                                           -------------      -------------     -------------
<S>                                                        <C>                <C>               <C>
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

CASH PAID DURING THE PERIOD FOR:
   Interest                                                $      15,459      $       3,349    $        2,134
                                                           =============      =============    ==============
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING
AND FINANCING ACTIVITIES

Common stock issued in exchange for deferred charges       $   3,142,400      $     686,250    $      926,250
  `
Warrants issued in exchange for deferred charges           $   1,189,484      $     288,428    $            -

Common stock issued as settlement for accounts payable     $      29,708      $      29,708    $            -

Increase/(Decrease) in fair value of investment securities $     (42,428)     $     (16,428)   $            -

Accrued interest contributed as capital                    $      35,624      $           -    $            -

Common stock issued in the conversion of notes payable     $     529,000      $           -    $            -

Acquisition of automobile through loan payable             $      24,643      $           -    $            -

Common stock issued upon exercise of a warrant
    in exchange for receivable                             $      75,000     $            -    $            -
</TABLE>


The accompanying notes are an integral part of these financial statements.

                              F-6
<PAGE>


             THIRD-ORDER NANOTECHNOLOGIES, INC.
                (A Development Stage Company)
                NOTES TO FINANCIAL STATEMENTS
                   JUNE 30, 2007 AND 2006
                         (UNAUDITED)

NOTE 1- FINANCIAL STATEMENTS

The accompanying unaudited financials statements have been
prepared by Third-Order Nanotechnologies, Inc. (the
Company).  These statements include all adjustments
(consisting only of its normal recurring adjustments) which
management believes necessary for a fair presentation of the
statements and have been prepared on a consistent basis
using the accounting polices described in the Summary of
Accounting Policies included in the 2006 Annual Report.
Certain financial information and footnote disclosures
normally indicated in financial statements prepared in
accordance with accounting principals generally accepted in
the United States have been condensed or omitted pursuant to
those rules and regulations, although the Company firmly
believes that the accompanying disclosures are adequate to
make the information presented not misleading.  The Notes to
Financial Statements included in the 2006 Annual Report
should be read in conjunction with the accompanying interim
financial statements.  The interim operating results for the
three and six months ended June 30, 2007 may not be
indicative of operating results expected for the full year.

Loss per Share
The company follows SFAS 128, "Earnings per Share",
resulting in the presentation of basic and diluted loss per
share.  The basic loss per share calculations includes the
change in capital structure for all periods presented.
Since the Company does not have any outstanding stock
equivalents, the amounts reported for basic and dilutive
loss per share were the same.

Recently Issued Accounting Pronouncements
In June 2006, the Financial Accounting Standards Board
("FASB") issued Interpretation No. 48 ("FIN 48"), Accounting
for Uncertainty in Income Taxes.  FIN 48 prescribes detailed
guidance for the financial statement recognition,
measurement and disclosure of uncertain tax positions
recognized in an enterprise's financial statements in
accordance with FASB Statement No. 109, Accounting for
Income Taxes.  Tax positions must meet a more-likely-than-
not recognition threshold at the effective date to be
recognized upon the adoption of FIN 48 and in subsequent
periods.  FIN 48 will be effective for fiscal years
beginning after December 31, 20006 and will become effective
for us beginning with the first quarter of 2007, and the
provisions of FIN 48 will be applied to all tax positions
under Statement No. 109 upon initial adoption.  The
cumulative effect of applying the provisions of this
interpretation will be reported as an adjustment to the
opening balance of retained earnings for that fiscal year.
The Company adopted FIN 48 effective January 1, 2007.  The
adoption of FIN 48 did not require an adjustment to the
opening balance of retained earnings as of January 1, 2007.

In  September 2006, the FASB issued SFAS No. 157, Fair Value
Measurements  ("SFAS No. 157"). SFAS No. 157  establishes  a
framework  for measuring fair value and expands  disclosures
about  fair  value  measurements.  The  changes  to  current
practice  resulting from the application  of  SFAS  No.  157
relate to the definition of fair value, the methods used  to
measure  fair value and the expanded disclosures about  fair
value  measurement.  SFAS No. 157 is  effective  for  fiscal
years  after  November 15, 2007 and interim  periods  within
those  fiscal years. The Company does not believe  that  the
adoption  of the provisions of SFAS No. 157 will  materially
impact its financial position or results of operations.


                              F-7
<PAGE>


             THIRD-ORDER NANOTECHNOLOGIES, INC.
                (A Development Stage Company)
                NOTES TO FINANCIAL STATEMENTS
                   JUNE 30, 2007 AND 2006
                         (UNAUDITED)


NOTE 1- FINANCIAL STATEMENTS (CONTINUED)

Recently Issued Accounting Pronouncements (Continued)
In February 2007, the FASB issued SFAS No. 159, The Fair
Value Option for Financial Assets and Financial Liabilities
("SFAS No. 159"). SFAS No. 159 permits entities to choose to
measure many financial instruments and certain other items
at fair value that are not currently required to be measured
at fair value. The objective is to improve financial
reporting by providing entities with the opportunity to
mitigate volatility in reported earnings caused by measuring
related assets and liabilities differently without having to
apply complex hedge accounting provisions. SFAS No. 159 also
establishes presentation and disclosure requirements
designed to facilitate comparisons between entities that
choose different measurement attributes for similar types of
assets and liabilities. SFAS No. 159 is effective for
financial statements issued for fiscal years beginning after
November 15, 2007 and will become effective for the Company
beginning with the first quarter of 2008. The Company has
not yet determined the impact of the adoption of SFAS
No. 159 on its financial statements and footnote
disclosures.


NOTE 2 - GOING CONCERN

The  accompanying  financial statements have been prepared
assuming the Company will continue as a going concern. The
Company has incurred  significant losses and experienced
negative  cash flow  during the development stage.  These
conditions raise  substantial  doubt  about the Company's
ability to  continue  as  a going concern.  The financial
statements do not include any adjustments that might result
from the outcome of this uncertainty.

The  Company is in the development stage at June  30, 2007.
Currently, management is raising $600,000 to  maintain  the
Company's  operations  through March  2008.  The Company's
development  is proceeding on schedule and management hopes
to  demonstrate  a  prototype by December 2007.  Successful
completion of the Company's prototype will lead to adequate
financing to fulfill its development activities and  achieve
a  level  of revenue adequate to support the Company's cost
structure for the following three years.  Management is in
the  process of developing a business plan that it  believes
will  be  attractive  enough  to  investors to raise the
necessary capital.  However, there can be no assurances that
the  Company will be able to secure the necessary  financing
and/or equity investment or achieve an adequate sales level.

NOTE 3 - INTANGIBLE ASSETS

This represents legal fees associated with the registration
of patents.  The Company has not recorded any amortization
expenses since the patents have yet to be declared
effective.  Once issued, the cost of the patents will be
amortized over their legal lives, which is generally 20
years.


                             F-8
<PAGE>


             THIRD-ORDER NANOTECHNOLOGIES, INC.
                (A Development Stage Company)
                NOTES TO FINANCIAL STATEMENTS
                   JUNE 30, 2007 AND 2006
                         (UNAUDITED)

NOTE 4 - STOCKHOLDERS' EQUITY

Common Stock and Warrants
Through  June 30, 2007, the Company issued 2,482,000 shares
of common stock for proceeds of $1,241,000.

During  February 2007, the Company issued 151,785 shares of
common  stock  for  investor relations  services valued at
$106,250,  fair  value,  which was recorded  as a deferred
charge and amortized over one year, the term of the services
contract.

During February 2007, the Company terminated its CEO.  The
48,000 options that were recorded as deferred charges of
$42,730  were not vested and were forfeited and the  452,000
vested options expired.

During March 2007, the Company issued 1,000,000 shares of
common  stock for management consulting services  valued at
$580,000, fair value.  During April 2007, the Company issued
500,000 warrants as an addendum to the original contract for
management  consulting services valued  at  $288,428,  fair
value.  This  contract was recorded as a contra-equity
deferred charges account and is amortized over one year, the
term  of the  contract.  The balance at June 30,  2007 was
$578,952.  During the six months ended June 30,  2007, the
Company  amortized  $303,486  of   deferred charges   in
conjunction with the management contract.

During  April  2007, the Company issued  100,000 shares of
common stock for  legal services valued at  $35,000, fair
value, to settle $29,708 of accounts payable and as payment
for $5,292 of legal services incurred in April 2007.

During the six months ended June 30, 2007,  the Company
granted  1,150,000  warrants  to  consultants valued  at
$751,871, fair value, with expense being recognized monthly
over the terms of the contracts.

During  the  six months ended June 30, 2007  and  2006, the
Company  recognized  consulting  expense of $242,238 and
$644,000  for  warrants  and options issued for consulting
services.

NOTE 5 - STOCK BASED COMPENSATION

On  January  1, 2006, the Company adopted SFAS 123(R) using
the  modified  prospective method as  permitted  under SFAS
123(R).   Under this transition method,  compensation  cost
recognized in  the first  quarter of 2006  includes
compensation cost for all share-based payments granted prior
to  but not yet vested as of December 31, 2005, based on the
grant-date fair  value  estimated in  accordance with the
provisions of  SFAS 123.  In accordance with  the  modified
prospective  method  of adoption, the Company's results of
operations and financial position for prior periods have not
been restated.

The Company uses the Black-Scholes option pricing model to
calculate the grant-date fair value of an award, with the
following assumptions:  no dividend yield, expected
volatility of 186%, risk-free interest rate between 3.8% and
5.1% and expected option life of ten years.

During the six months ended June 30, 2007, the Company's net
income was approximately $61,346 lower as a result of stock-
based compensation expense as a result of the  adoption of
SFAS 123(R).  As of June 30, 2007, there was approximately
$117,269 of unrecognized compensation expense related to non-
vested  market-based share awards that is expected to be
recognized through February 2009.


                            F-9
<PAGE>


             THIRD-ORDER NANOTECHNOLOGIES, INC.
                (A Development Stage Company)
                NOTES TO FINANCIAL STATEMENTS
                   JUNE 30, 2007 AND 2006
                         (UNAUDITED)


NOTE 5 - STOCK BASED COMPENSATION (CONTINUED)

The  following tables summarize all stock option and warrant
activity of the Company since December 31, 2006:

<TABLE>
<CAPTION>
                                         Stock Options and Warrants
                                -------------------------------------------
                                                           Weighted Average
                                  Number         Exercise       Exercise
                                of Shares          Price        Price
                                -------------------------------------------
<S>                             <C>            <C>             <C>
Outstanding, December 31, 2006   1,050,000     $0.25 - $2.00   $     0.83
                                -------------------------------------------
Forfeited                          (56,000)    $        1.00   $     1.00
Expired                           (444,000)    $        1.00   $     1.00
Issued                           1,650,000     $        0.25   $     0.25
                                -------------------------------------------

Outstanding, June 30, 2007       2,200,000     $0.25 - $2.00   $     0.36
                                -------------------------------------------

Exercisable, June 30, 2007       1,761,000     $0.25 - $2.00   $     0.40
                                -------------------------------------------
</TABLE>

NOTE 6 - INCOME TAXES

There  is no income tax benefit for the losses for  the  six
months  ended  June 30, 2007 and 2006 since  management  has
determined  that  the realization of the  net  deferred  tax
asset  is  not assured and has created a valuation allowance
for the entire amount of such benefits.


NOTE 7 - SUBSEQUENT EVENTS

Ronald R. Genova Lawsuit
During July 2007, Ronald R. Genova filed a lawsuit in
Philadelphia County, Court of Common Pleas.  Ronald R.
Genova is the Plaintiff. Third-Order Nanotechnologies, Inc.,
PSI-TEC Holdings, Inc. and Universal Capital Management are
each a Defendant.

Ronald R. Genova ("Genova") served as a consultant and then
as the interim chief executive officer of our Company, Third-
Order  Nanotechnologies, Inc. The Company terminated Genova
effective February 28, 2007. On March 26, 2007 the Company
paid Genova  $9,806, which the Company determined was the
full amount the Company owed Genova. Genova sued, claiming
he  was owed  an  additional $84,650.38 plus  interest for
unpaid consulting  fees  in the  amount  of  $32,515.68, a
performance bonus in the amount of $50,000, and  an  expense
reimbursement in the amount of $2,134.70. Pursuant to the
complaint, Genova is alleging breach of contract, fraud and
promissory  estoppel in an amount in excess of $180,000, in
addition to the right to exercise his options, that  expired
on May 30, 2007, until February 13, 2016 or a judgment in an
additional  amount  equal  to the  monetary  value  of  such
options plus punitive damages, interest and costs.



                            F-10
<PAGE>


             THIRD-ORDER NANOTECHNOLOGIES, INC.
                (A Development Stage Company)
                NOTES TO FINANCIAL STATEMENTS
                   JUNE 30, 2007 AND 2006
                         (UNAUDITED)


NOTE 7 - SUBSEQUENT EVENTS (CONTINUED)

Ronald R. Genova Lawsuit (Continued)
The case is in the early stages, and none of the defendants
have answered the complaint and no discovery has commenced.
The Company intends  to  vigorously contest the matter.
Although  the facts ascertained to date indicate a favorable
outcome  is a likely result, it is too early in the process
to  provide  a  detailed evaluation  of the likelihood of
success. It is also too early to provide an estimate of the
amount or range of potential loss.

ThinkBig Marketing Group LLC Lawsuit
During  July 2007, ThinkBig Marketing Group, LLC, a former
vendor of the Company, filed a lawsuit in the Superior Court
of California, Orange County.

The case is in the early stages, and none of the defendants
have answered the complaint and no discovery has commenced.
The Company intends  to  vigorously  contest  the  matter.
Although the facts ascertained to date indicate a favorable
outcome is a likely result, it is too early in the  process
to  provide a detailed evaluation  of  the  likelihood of
success.    The  outstanding balance owed to the  vendor of
$15,203 is reflected in the Company's accounts payable as of
6/30/07.





                                  -11-
<PAGE>


























               THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)

                     FINANCIAL STATEMENTS

                  DECEMBER 31, 2006 AND 2005































<PAGE>


                 THIRD-ORDER NANOTECHNOLOGIES, INC.
                 (FORMERLY PSI-TEC HOLDINGS, INC.)
                   (A Development Stage Company)



                            CONTENTS

                                                                   PAGE
                                                                   ----

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM            F-12

BALANCE SHEETS                                                     F-13

STATEMENTS OF OPERATIONS                                           F-14

STATEMENT OF COMPREHENSIVE LOSS                                    F-15

STATEMENTS OF STOCKHOLDERS' EQUITY                                 F-16

STATEMENTS OF CASH FLOWS                                        F-17 - F-18

NOTES TO FINANCIAL STATEMENTS                                   F-19 - F-32























<PAGE>



      REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


To the Board of Directors

Third-Order Nanotechnologies, Inc.
(Formerly PSI-TEC Holdings, Inc.)
Wilmington, DE

We have audited the accompanying balance sheets of Third-Order
Nanotechnologies, Inc., (formerly PSI-TEC Holdings, Inc.), as of
December 31, 2006 and 2005 and the related statements of operations,
comprehensive loss, stockholders' equity and cash flows for the years
then ended and for the period from January 1, 2004 (inception of
development stage) through December 31, 2006.  These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements
based on our audits.

We conducted our audits in accordance with standards of the Public
Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free from
material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe
that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present
fairly, in all material respects, the financial position of Third-
Order Nanotechnologies, Inc., (formerly PSI-TEC Holdings, Inc.) as of
December 31, 2006 and 2005 and results of their operations and their
cash flows for the years then ended and for the period from January 1,
2004 (inception of development stage) through December 31, 2006 in
conformity with accounting principles generally accepted in the United
States.

As discussed in Note 11 to the financial statements, the Company
changed its method of accounting for share-based payments as of
January 1, 2006.

The accompanying financial statements have been prepared assuming that
the Company will continue as a going concern. The Company is in the
development stage at December 31, 2006. As discussed in Note 2 to the
financial statements, successful completion of the Company's
development program and, ultimately, the attainment of profitable
operations is dependent upon future events, including obtaining
adequate financing to fulfill its development activities and achieving
a level of sales adequate to support the Company's cost structure.
These factors raise substantial doubt about the ability of the Company
to continue as a going concern. The consolidated financial statements
do not include any adjustments that might result from the outcome of
these uncertainties.

As discussed in Note 3 to the financial statements, net loss for the
year ended December 31, 2006 increased by $337,290 in order to
properly reflect incremental costs associated with the February 2006
and November 2006 modification of an option grant.  Accordingly, the
2006 financial statements have been restated to correct this error.

/s/ MORISON COGEN LLP
Bala Cynwyd, Pennsylvania
March 23, 2007,
except for Note 3 for which
 the date is August 20, 2007




<PAGE>


                  THIRD-ORDER NANOTECHNOLOGIES, INC.
                  (FORMERLY PSI-TEC HOLDINGS, INC.)
                    (A Development Stage Company)
                           BALANCE SHEETS

<TABLE>
<CAPTION>

                                    December 31, 2006     December 31, 2005
                                    -----------------     -----------------
                                       (Restated)
<S>                                 <C>                   <C>
              ASSETS

CURRENT ASSETS
 Cash and cash equivalents          $             528     $         150,027
 Deferred charges                             586,171               445,625
 Prepaid expenses                               9,353                     -
 Receivables                                      100                75,100
                                    -----------------     -----------------
                                              596,152               670,752

AVAILABLE FOR SALE SECURITIES
 Related party                                 59,265               200,000
 Other                                          2,535                     -
                                    -----------------     -----------------
                                               61,800               200,000

PROPERTY AND EQUIPMENT - NET                   42,335                54,496

OTHER ASSETS
 Deferred charges                              97,083                     -
 Intangible assets                             42,376                33,862
                                    -----------------     -----------------
 TOTAL ASSETS                       $         839,746     $         959,110
                                    =================     =================


LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
 Loan payable - current portion     $           4,977     $           4,696
 Accounts payable                             100,714                12,290
 Accounts payable - related party              65,339                     -
 Accrued expenses                              83,712                94,536
 Officer loans                                  1,468                 1,468
                                    -----------------     -----------------
                                              256,210               112,990

CONTINGENCY                                         -                     -

LOAN PAYABLE
  - NET OF CURRENT PORTION                      8,764                14,242
                                    -----------------     -----------------

TOTAL LIABILITIES                             264,974               127,232
                                    -----------------     -----------------

STOCKHOLDERS' EQUITY
 Preferred stock, $0.001 par value,
   1,000,000 authorized
   No shares issued or outstanding                  -                     -
 Common stock $0.001 par value,
   50,000,000 authorized
   27,888,750 and 26,253,750 issued
   and outstanding at December 31,
   2006 and 2005                               27,889                26,254
 Additional paid-in-capital                 5,966,430             3,590,407
 Subscription receivable                            -                (6,500)
 Deferred charges                                   -              (318,545)
 Unrealized loss on Available for
   Sale Securities                            (26,000)                    -
 Accumulated deficit                          (15,827)              (15,827)
 Deficit accumulated during
   development stage                       (5,377,720)           (2,443,911)
                                    -----------------     -----------------

TOTAL STOCKHOLDERS' EQUITY                    574,772               831,878
                                    -----------------     -----------------
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY                $         839,746     $         959,110
                                    =================     =================
</TABLE>



 The accompanying notes are an integral part of these financial statements.

                                  F-13

<PAGE>


                   THIRD-ORDER NANOTECHNOLOGIES, INC.
                   (FORMERLY PSI-TEC HOLDINGS, INC.)
                     (A Development Stage Company)
                       STATEMENTS OF OPERATIONS
          FOR THE YEARS ENDING DECEMBER 31, 2006 AND 2005 AND
     FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT STAGE)
                          TO DECEMBER 31, 2006


<TABLE>
<CAPTION>
                                 Cumulative          For the               For the
                                   Since           Year Ending           Year Ending
                                 Inception       December 31, 2006     December 31, 2005
                                 -----------     -----------------     -----------------
                                 (Restated)         (Restated)
<S>                              <C>             <C>                   <C>
NET SALES                        $         -     $               -     $               -

COST AND EXPENSE
  Research and development         2,257,424             1,179,997               813,725
  General and administrative       3,167,768             1,814,752               894,332
                                 -----------     -----------------     -----------------
                                   5,425,192             2,994,749             1,708,057

LOSS FROM OPERATIONS              (5,425,192)           (2,994,749)           (1,708,057)

OTHER INCOME (EXPENSE)
  Interest income                      7,477                   243                 6,994
  Dividend income                      1,527                 1,527                     -
  Realized gain on investment         63,187                63,187                     -
  Interest expense                   (24,719)               (4,017)              (20,702)
                                 -----------     -----------------     -----------------

NET LOSS                         $(5,377,720)    $      (2,933,809)    $      (1,721,765)
                                 ===========     =================     =================

Basic and Diluted Loss per Share                 $           (0.11)    $           (0.07)
                                                 =================     =================

Basic and Diluted Weighted
  Average Number of Shares                              27,190,449            24,098,833
                                                 =================     =================
</TABLE>





















 The accompanying notes are an integral part of these financial statements.

                                 F-14

<PAGE>


                  THIRD-ORDER NANOTECHNOLOGIES, INC.
                  (FORMERLY PSI-TEC HOLDINGS, INC.)
                    (A Development Stage Company)
                   STATEMENTS OF COMPREHENSIVE LOSS
        FOR THE YEARS ENDING DECEMBER 31, 2006 AND 2005 AND FOR
      THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT STAGE)
                        TO DECEMBER 31, 2006


<TABLE>
<CAPTION>
                                 Cumulative          For the               For the
                                   Since           Year Ending           Year Ending
                                 Inception       December 31, 2006     December 31, 2005
                                 -----------     -----------------     -----------------
                                 (Restated)         (Restated)
<S>                              <C>             <C>                   <C>

NET LOSS                         $(5,377,720)    $      (2,933,809)    $     (1,721,765)

OTHER COMPREHENSIVE LOSS
Unrealized loss on Available
  for Sale Securities                (26,000)              (26,000)                   -
                                 -----------     -----------------     -----------------

COMPREHENSIVE LOSS               $(5,403,720)    $      (2,959,809)    $      (1,721,765)
                                 ===========     =================     =================
</TABLE>



































  The accompanying notes are an integral part of these financial statements.


                                 F-15

<PAGE>


                  THIRD-ORDER NANOTECHNOLOGIES, INC.
                  (FORMERLY PSI-TEC HOLDINGS, INC.)
                    (A Development Stage Company)
                   STATEMENT OF STOCKHOLDERS' EQUITY
    FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT STAGE)
                         TO DECEMBER 31, 2006

<TABLE>
<CAPTION>
                                                                                                 Deficit
                                                                                               Accumulated
                                                                                                 During     Unrealized
                         Number of Common      Paid-in    Subscription  Deferred  Accumulated  Development   Loss on
                           Shares  Stock       Capital     Receivable   Charges    Deficit       Stage     Securities     Total
                        ---------- --------  ----------  ------------ ----------  ----------- ------------ ---------- -----------
<S>                     <C>        <C>       <C>         <C>          <C>         <C>         <C>          <C>        <C>

ENDING BALANCE AT
DECEMBER 31, 2003              100 $      1  $        -  $          - $        -  $  (15,827) $          - $        - $   (15,826)

Retroactive
recapitalization upon
reverse acquisition        706,973      706        (706)            -          -            -            -          -           -
                        ---------- --------  ----------  ------------ ----------  ----------- ------------ ---------- -----------
BALANCE AT
JANUARY 1, 2004            707,073      707        (706)            -          -      (15,827)           -          -     (15,826)

Common stock issued
  to founders           13,292,927   13,293     (13,293)            -          -            -            -          -           -
Common stock issued
  for future services
  in July 2004 at
  $0.16/share            1,600,000    1,600     254,400             -          -            -            -          -     256,000
Common stock issued
  at merger              2,000,000    2,000      (2,000)            -          -            -            -          -           -
Common stock issued
  for future services
  in August 2004 at
  $0.12/share              637,500      638      74,362             -          -            -            -          -      75,000
Conversion of note
  payable in December
  2004 at $0.16/share      187,500      187      29,813             -          -            -            -          -      30,000
Net loss for the year
 ended December 31, 2004         -        -           -             -          -            -     (722,146)         -    (722,146)
                        ---------- --------  ----------  ------------ ----------  ----------- ------------ ---------- -----------
BALANCE AT
DECEMBER 31, 2004       18,425,000   18,425     342,576             -          -      (15,827)    (722,146)         -    (376,972)

Common stock issued in
  private placement in
  April 2005 at
  $0.25/share            4,000,000    4,000     996,000             -          -            -            -          -   1,000,000
Conversion of notes
  payable in May 2005
  at $0.16/share         3,118,750    3,119     495,881             -          -            -            -          -     499,000
Subscription receivable          -        -           -        (6,500)         -            -            -          -      (6,500)
Common stock issued for
  future services in
  August 2005, valued
  at $2.79/share           210,000      210     585,290             -          -            -            -          -     585,500
Common stock issued
  for future services
  in August 2005,
  valued at $2.92/share    200,000      200     583,800             -          -            -            -          -     584,000
Warrants issued for
  services in May 2005,
  vested during 2005,
  valued at $1.13/share          -        -      37,000             -          -            -            -          -      37,000
Warrants issued for
  services in September
  2005, vested during
  2005, valued at
  $1.45/share                    -        -      24,200             -          -            -            -          -      24,200
Warrants issued for
  services in October
  2005, vested during
  2005, valued at
  $0.53/share                    -        -      15,900             -          -            -            -          -      15,900
Warrants issued for
  future services in
  December 2005, vested
  during 2005, valued
  at $1.45/share                 -        -     435,060             -          -            -            -          -     435,060
Deferred charges for
  common stock issued
  for future services
  in August 2005, valued
  at $2.92/share                 -        -           -             -   (584,000)           -            -          -    (584,000)
Amortization of
  deferred charges                                                       265,455                                          265,455
Exercise of warrants in
  December 2005 at
  $0.25/share              300,000      300      74,700             -          -            -            -          -      75,000
Net loss for the year
  ended December 31, 2005        -        -           -             -          -            -   (1,721,765)         -  (1,721,765)
                        ---------- --------  ----------  ------------ ----------  ----------- ------------ ---------- -----------
BALANCE AT
DECEMBER 31, 2005       26,253,750   26,254   3,590,407        (6,500)  (318,545)     (15,827)  (2,443,911)         -     831,878

Common stock issued
  in private placement
  during 2006 at
  $0.50/share              850,000      850     424,150             -          -            -            -          -     425,000
Common stock issued
  for future services
  in February 2006,
  valued at $0.90/share    300,000      300     269,700             -          -            -            -          -     270,000
Common stock issued for
  future services in
  May 2006, valued at
  $1.55/share              400,000      400     619,600             -          -            -            -          -     620,000
Common stock issued for
  future services in
  June 2006, valued at
  $1.45/share               25,000       25      36,225             -          -            -            -          -      36,250
Common stock issued
  for future services
  in November 2006,
  valued at $0.49/share     60,000       60      29,340             -          -            -            -          -      29,400
Warrants issued for
  services in September
  2005, vested during
  2006, valued at
  $1.45/share                    -        -      66,500             -          -            -            -          -      66,500
Warrants issued for
  future services in
  June 2006, vested
  during 2006, valued
  at $1.55/share                 -        -     465,996             -          -            -            -          -     465,996
Options issued for
  services in February
  2006, vested during
  2006, valued at
  $1.01/share                    -        -     428,888             -          -            -            -          -     428,888
Contributed capital
  related to accrued
  interest                       -        -      35,624             -          -            -            -          -      35,624
Subscription receivable          -        -           -         6,500          -            -            -          -       6,500
Amortization of
  deferred charges               -        -           -             -    318,545            -            -          -     318,545
Unrealzed loss on
  securities                     -        -           -             -          -            -            -    (26,000)    (26,000)
Net loss for the year
  ending December 31,
  2006                           -        -           -             -          -            -   (2,933,809)         -  (2,933,809)
                        ---------- --------  ----------  ------------ ----------  ----------- ------------ ---------- -----------
BALANCE AT
DECEMBER 31, 2006
(Restated)              27,888,750 $ 27,889  $5,966,430  $          - $        -  $   (15,827)$ (5,377,720)$  (26,000)$   574,772
                        ========== ========  ==========  ============ ==========  =========== ============ ========== ===========
</TABLE>



 The accompanying notes are an integral part of these financial statements.

                                   F-16

<PAGE>


                    THIRD-ORDER NANOTECHNOLOGIES, INC.
                    (FORMERLY PSI-TEC HOLDINGS, INC.)
                      (A Development Stage Company)
                        STATEMENTS OF CASH FLOWS
            FOR THE YEARS ENDING DECEMBER 31, 2006 AND 2005 AND
        FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT STAGE)
                           TO DECEMBER 31, 2006

<TABLE>
<CAPTION>

                                               Cumulative         For the            For the
                                                  Since         Year Ending        Year Ending
                                                Inception    December 31, 2006   December 31, 2005
                                              -------------  -----------------   -----------------
                                               (Restated)        (Restated)
<S>                                           <C>            <C>                 <C>

CASH FLOWS FROM OPERATING ACTIVITIES
  Net loss                                    $  (5,377,720) $      (2,933,809)  $      (1,721,765)
  Adjustment to reconcile net loss to net
  cash used in operating activities
    Amortization of deferred charges              2,342,952          1,502,562             840,390
    Warrants issued for services                    143,600             66,500              77,100
    Stock options issued for services               762,388            428,888                   -
    Depreciation                                     28,776             12,161              10,222
    Realized gain on investments                    (63,187)           (63,187)                  -
    (Increase) decrease in assets
      Receivables                                    69,439             75,000              11,000
      Prepaid expenses                               (9,353)            (9,353)              1,605
    Increase (decrease) in liabilities
      Accounts payable                              158,921             88,424             (26,334)
      Accounts payable - related party               65,339             65,339                   -
      Accrued expenses                               18,198             24,800              32,484
                                              -------------  -----------------   -----------------
Net cash used in operating activities            (1,860,647)          (742,675)           (775,298)
                                              -------------  -----------------   -----------------

CASH FLOWS FROM INVESTING ACTIVITIES
Cost of intangibles                                 (42,376)            (8,514)            (13,862)
   Proceeds from sale of available for
     sale securities                                175,387            175,387                   -
   Purchase of available for sale securities       (200,000)                 -            (200,000)
   Purchase of equipment                            (24,825)                 -             (24,825)
                                              -------------  -----------------   -----------------
Net cash provided by (used) in
investing activities                                (91,814)           166,873            (238,687)
                                              -------------  -----------------   -----------------

CASH FLOWS FROM FINANCING ACTIVITIES
  Issuance of common stock, private placement     1,425,000            425,000           1,000,000
  Repayment of notes payable                        (10,902)            (5,197)             (4,380)
  Proceeds from subscription receivable               6,500              6,500                   -
  Advances to stockholders                           (3,435)                 -                   -
  Proceeds from convertible notes                   529,000                  -                   -
  Advances from officers                              1,468                  -                   -
                                              -------------  -----------------   -----------------
Net cash provided by financing activities         1,947,631            426,303             995,620
                                              -------------  -----------------   -----------------

NET INCREASE IN CASH AND CASH EQUIVALENTS            (4,830)          (149,499)            (18,365)

CASH AND CASH EQUIVALENTS
  - BEGINNING OF PERIOD                               5,358            150,027             168,392
                                              -------------  -----------------   -----------------
CASH AND CASH EQUIVALENTS - END OF PERIOD     $         528  $             528   $         150,027
                                              =============  =================   =================

</TABLE>

The accompanying notes are an integral part of these financial statements.

                                  F-17

<PAGE>


                    THIRD-ORDER NANOTECHNOLOGIES, INC.
                    (FORMERLY PSI-TEC HOLDINGS, INC.)
                      (A Development Stage Company)
                        STATEMENTS OF CASH FLOWS
            FOR THE YEARS ENDING DECEMBER 31, 2006 AND 2005 AND
        FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT STAGE)
                           TO DECEMBER 31, 2006

<TABLE>
<CAPTION>

                                               Cumulative         For the            For the
                                                  Since         Year Ending        Year Ending
                                                Inception    December 31, 2006   December 31, 2005
                                              -------------  -----------------   -----------------
                                               (Restated)        (Restated)
<S>                                           <C>            <C>                 <C>

SUPPLEMENTAL DISCLOSURES OF CASH FLOW
INFORMATION

CASH PAID DURING THE PERIOD FOR:
   Interest                                   $      12,110  $           4,017   $           2,556
                                              =============  =================   =================

SUPPLEMENTAL DISCLOSURE OF NON-CASH
INVESTING AND FINANCING ACTIVITIES

Common stock issued in exchange for
  future services                             $   2,456,150  $         955,650   $       1,169,500

Warrants issued in exchange for
  future services                             $     901,056  $         465,996   $         435,060

Decrease in fair value of investment
  securities                                  $      26,000  $          26,000   $               -

Accrued interest contributed as capital       $      35,624  $          35,624   $               -

Common stock issued in the conversion
  of notes payable                            $     529,000  $               -   $         499,000

Acquisition of automobile through
  loan payable                                $      24,643  $               -   $               -

Common stock issued upon exercise
  of a warrant in exchange for
  receivable                                  $      75,000  $               -   $          75,000

</TABLE>




















  The accompanying notes are an integral part of these financial statements.

                                F-18
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005



NOTE 1- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

History and Nature of Business
------------------------------
Third-Order Nanotechnologies, Inc., formerly PSI-Tec Holdings, Inc.,
formerly Eastern Idaho Internet Service, Inc. (the "Company") was
organized under the laws of the State of Nevada in 1997.  The Company
was engaged in the business of marketing internet services until June
30, 1998, at which time the principal assets of the business were sold
and operations were discontinued.  The Company was inactive until the
acquisition of PSI-TEC Corporation ("PSI-TEC") on July 14, 2004, at
which time the name was changed to PSI-TEC Holdings, Inc.

Development Stage
-----------------
PSI-TEC was incorporated in 1995 under the laws of the State of
Delaware.  PSI-TEC primarily conducted research for the United States
Government under a contract, which expired in 2003.  Beginning January
1, 2004, PSI-TEC was engaged in the development of electro-optic
polymers for application in the electro-optic device markets.  PSI-TEC
is considered a development stage company as defined in Statement on
Financial Accounting Standards (SFAS) No. 7 from the inception of the
development stage on January 1, 2004.

Merger
------
On July 14, 2004, the Company acquired PSI-TEC.  Under the terms of
the merger agreement, the stockholders of PSI-TEC received 15,600,000
shares of common stock in exchange for its 2,206,280 shares.
Following the merger, the Company changed its name to PSI-TEC
Holdings, Inc.  Under accounting principles generally accepted in the
United States, the share exchange is considered to be a capital
transaction in substance rather than a business combination.  That is,
the share exchange is equivalent to the issuance of stock by PSI-TEC
Holdings, Inc. for the net monetary assets of PSI-TEC, accompanied by
a recapitalization, and is accounted for as a change of capital
structure.  Accordingly, the accounting for the share exchange will be
identical to that resulting from a reverse acquisition, except no
goodwill will be recorded.  Under reverse takeover accounting, the
post-reverse acquisition comparative historical financial statements
of the legal acquirer, PSI-TEC Holdings, Inc., are those of the legal
acquiree, PSI-TEC, which is considered to be the accounting acquirer.
On October 20, 2006, PSI-TEC Holdings, Inc. and PSI-TEC merged and
changed its name to Third-Order Nanotechnologies, Inc.

Estimates
---------
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States requires management
to make estimates and assumptions that affect the amounts reported in
the financial statements and accompanying disclosures.  Although these
estimates are based on management's best knowledge of current events
and actions the Company may undertake in the future, actual results
could differ from the estimates.

Cash Equivalents
----------------
For the purposes of the statement of cash flows, the Company considers
all highly liquid instruments with maturities of three months or less
at the time of purchase to be cash equivalents.

Concentration of Credit Risk
----------------------------
Certain financial instruments potentially subject the Company to
concentrations of credit risk.  These financial instruments consist
primarily of cash.  The Company places its temporary cash investments
with high credit quality financial institutions to limit its credit
exposure.

                             F-19
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005


NOTE 1- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Investment
----------
Securities classified as available-for-sale may be sold in response to
changes in interest rates, liquidity needs, and for other purposes.
Available-for-sale securities are carried at fair value.  Unrealized
gains and losses on investment securities available for sale are based
on the difference between book value and fair value of each security.
These gains and losses are credited or charged to other comprehensive
income, whereas realized gains and losses are recognized in the
Company's net income (loss).

Property and Equipment
----------------------
Equipment is stated at cost.  Depreciation is principally provided by
use of straight-line methods for financial and tax reporting purposes
over the estimated useful lives of the assets, generally 5 years.

Fair Value of Financial Instruments
-----------------------------------
The Company's financial instruments consist of cash, accounts payable
and accrued expenses.  The carrying values of cash, accounts payable
and accrued expenses approximate fair value because of their short
maturities.

Income Taxes
------------
The Company follows Statement of Financial Accounting Standards
("SFAS")  No. 109, "Accounting for Income Taxes," which requires an
asset and liability approach to financial accounting and reporting for
income taxes.  Deferred income tax assets and liabilities are computed
annually for temporary differences between the financial statement and
tax bases of assets and liabilities that will result in taxable or
deductible amounts in the future based on enacted tax laws and rates
applicable to the periods in which the differences are expected to
affect taxable income. Valuation allowances are established when
necessary to reduce deferred tax assets to the amount expected to be
realized.  Income tax expense is the tax payable or refundable for the
period plus or minus the change during the period in deferred tax
assets and liabilities.

Loss Per Share
--------------
The Company follows SFAS No. 128, "Earnings Per Share," resulting in
the presentation of basic and diluted earnings per share.  Because the
Company reported a net loss in 2006 and 2005, common stock
equivalents, including stock options and warrants were anti-dilutive;
therefore, the amounts reported for basic and dilutive loss per share
were the same.

Recoverability of Long Lived Assets
-----------------------------------
The Company follows SFAS No. 144 "Accounting for the Impairment or
Disposal of Long-Lived Assets" ("Statement 144").  Long-lived assets
to be held and used are reviewed for impairment whenever events or
changes in circumstances indicate that the related carrying amount may
not be recoverable.  When required, impairment losses on assets to be
held and used are recognized based on the excess of the asset's
carrying amount.

Comprehensive Income
--------------------
The Company follows SFAS No. 130, "Reporting Comprehensive Income."
Comprehensive income is a more inclusive financial reporting
methodology that includes disclosure of certain financial information
that historically has not been recognized in the calculation of net
income.

                             F-20
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005


NOTE 1- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Reclassifications
-----------------
Certain reclassifications were made to the 2006 financial statements
in order to conform to the 2005 financial statement presentation.

Recently Issued Pronouncements
------------------------------
In June 2006, the Financial Accounting Standards Board ("FASB") issued
Interpretation No. 48 ("FIN 48"), Accounting for Uncertainty in Income
Taxes. FIN 48 prescribes detailed guidance for the financial statement
recognition, measurement and disclosure of uncertain tax positions
recognized in an enterprise's financial statements in accordance with
FASB Statement No. 109, Accounting for Income Taxes. Tax positions
must meet a more-likely-than-not recognition threshold at the
effective date to be recognized upon the adoption of FIN 48 and in
subsequent periods. FIN 48 will be effective for fiscal years
beginning after December 15, 2006, and will become effective for us
beginning with the first quarter of 2007, and the provisions of FIN 48
will be applied to all tax positions under Statement No. 109 upon
initial adoption. The cumulative effect of applying the provisions of
this interpretation will be reported as an adjustment to the opening
balance of retained earnings for that fiscal year. The Company is
currently evaluating the potential impact of FIN 48 on its financial
statements.

In September 2006, the SEC issued Staff Accounting Bulletin No. 108
("SAB No. 108"). SAB No. 108 addresses the process and diversity in
practice of quantifying financial statement misstatements resulting in
the potential build up of improper amounts on the balance sheet. The
Company is required to adopt the provisions of SAB No.108 in fiscal
2006. The adoption of SAB No. 108 did not have a material impact on
its financial statements.

In September 2006, the FASB issued SFAS No. 157, Fair Value
Measurements). SFAS No. 157 establishes a framework for measuring fair
value and expands disclosures about fair value measurements. The
changes to current practice resulting from the application of this
Statement relate to the definition of fair value, the methods used to
measure fair value, and the expanded disclosures about fair value
measurements. The Statement is effective for fiscal years beginning
after November 15, 2007 and will become effective beginning with the
first quarter of 2008.  The Company has not yet determined the impact
of the adoption of SFAS No. 157 on its financial statements and
footnote disclosures.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option
for Financial Assets and Financial Liabilities.  This Statement
permits entities to choose to measure many financial instruments and
certain other items at fair value that are not currently required to
be measured at fair value.  The objective is to improve financial
reporting by providing entities with the opportunity to mitigate
volatility in reported earnings caused by measuring related assets and
liabilities differently without having to apply complex hedge
accounting provisions.  This statement also establishes presentation
and disclosure requirements designed to facilitate comparisons between
entities that choose different measurement attributes for similar
types of assets and liabilities.  This Statement is effective for
financial statements issued for fiscal years beginning after November
15, 2007 and will become effective for us beginning with the first
quarter of 2008.  The Company has not yet determined the impact of the
adoption of SFAS No. 159 on its financial statements and footnote
disclosures.


                             F-21
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005

NOTE 2 - GOING CONCERN

The accompanying financial statements have been prepared assuming the
Company will continue as a going concern.  The Company has incurred
significant losses and experienced negative cash flow during the
development stage.  These conditions raise substantial doubt about the
Company's ability to continue as a going concern.  The financial
statements do not include any adjustments that might result from the
outcome of this uncertainty.

The Company is in the development stage at December 31, 2006.
Successful completion of the Company's development program and,
ultimately, the attainment of profitable operations is dependent upon
future events, including obtaining adequate financing to fulfill its
development activities and achieving a level of revenue adequate to
support the Company's cost structure.  The Company is currently in the
process of raising capital through a private placement memorandum of
up to $1,000,000, of which $999,000 has been raised through March 23,
2007.  However, there can be no assurances that the Company will be
able to secure the necessary financing and/or equity investment or
achieve an adequate sales level.

NOTE 3 - RESTATEMENT

The accompanying December 31, 2006 financial statements have been
restated to reflect additional costs associated with the February 2006
cancellation of a warrant to purchase 100,000 shares of the Company's
common stock and issuance of an option to purchase 500,000 shares of
the Company's common stock at an exercise price of $1 per share and
the November 2006 modification of expiration and vesting terms.  In
accordance with SFAS 123(R), the cancellation of the warrant and the
issuance of the option was deemed to be a modification of the original
award.  As such, the $394,030 incremental cost of the modified option
is to be expensed over the modified vesting schedule.  The result of
the modification was an increase in the general and administrative
costs in 2006 in the amount of $337,290.  The effect of the
restatement was to increase general and administrative costs, net loss
and deficit accumulated during development stage, by $337,290, which
increased the previously reported net loss for the year ended December
31, 2006 from $2,596,519 to a net loss of $2,933,809 and increased the
previously reported cumulative since inception net loss from
$5,040,430 to a cumulative since inception net loss of $5,377,720.
The restatement did not affect the net loss per share for the year
ended December 31, 2006.


















                            F-22
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005


NOTE 4 - DEFERRED CHARGES

Deferred charges represent the unamortized fair value of the issuance
of common stock and warrants for future services to non-employees
which was accounted for in accordance with Emerging Issue Task Force
No. 96-18, Accounting for Equity Instruments That Are Issued To Other
Than Employees for Acquiring, or in Conjunction with Selling, Goods or
Services, as follows:

<TABLE>
<CAPTION>
                                      2006           2005
                                  -----------    -----------
<S>                               <C>            <C>
Common stock                      $ 2,125,150    $ 1,169,500
Warrants                              901,056        435,060
                                  -----------    -----------
                                    3,026,206      1,604,560
Less:  Accumulated amortization     2,342,952        840,390
                                  -----------    -----------
                                      683,254        764,170
Less:  Amount reflected as a
contra-equity account for
management consulting services              -        318,545
                                  -----------    -----------
                                  $   683,254    $   445,625
                                  ===========    ===========
</TABLE>


NOTE 5 - INVESTMENTS

Investments consist of available-for-sale equity securities of a
related party reported at fair value of $59,265 and $200,000 and an
equity security reported at fair value at $2,535 and $0 at
December 31, 2006 and 2005.  Unrealized loss on available-for-sale
securities at December 31, 2006 and 2005 was $26,000 and $0.  The
related party is a stockholder of the Company and also provides
services under a management agreement.

During 2006 the Company sold 56,100 shares of the related party for
proceeds of $175,387 resulting in a short-term capital gain of
$63,187.

NOTE 6 - EQUIPMENT

Equipment consists of the following:

<TABLE>
<CAPTION>
                                      2006           2005
                                  -----------    -----------
<S>                               <C>            <C>

Automobile                        $    24,643    $    24,643
Office equipment                       23,752         23,752
Lab equipment                          24,825         24,825
                                  -----------    -----------
                                       73,220         73,220
Less: Accumulated depreciation         30,885         18,724
                                  -----------    -----------
                                  $    42,335    $    54,496
                                  ===========    ===========
</TABLE>

Depreciation expense for the years ended December 31, 2006 and 2005
was $12,161 and $10,222.


                             F-23
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005


NOTE 7 - INTANGIBLE ASSETS

Intangible assets consist of a patent pending amounting to $42,376 and
$33,862 at December 31, 2006 and 2005.  Amortization will begin upon
issuance of the patent.

NOTE 8 - LOAN PAYABLE

During 2004, the Company entered into a loan payable in the amount of
$24,643 to finance an automobile. This loan is payable in monthly
installments of $489, including interest at 7%, due August 2009, and
is secured by the automobile.

The minimum annual repayment requirements on the loan payable as of
December 31, 2006 are as follows:


                YEARS ENDING
                DECEMBER 31,           AMOUNT
                ------------         ----------

                   2007              $    4,977
                   2008                   4,878
                   2009                   3,886
                                     ----------
                   Total                 13,741
            Less: Current portion         4,977
                                     ----------
                                     $    8,764
                                     ==========


NOTE 9 - COMMITMENTS

The Company is obligated under two operating lease for office and lab
space expiring December 31, 2008.

Aggregate minimum future lease payments are as follows:

                YEARS ENDING
                DECEMBER 31,           AMOUNT
                ------------         ----------

                   2006              $   44,343
                   2007                  44,593


Rent expense approximating $20,275 and $10,200 is included in general
and administrative expenses for the years ended December 31, 2006 and
2005.


                             F-24
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005


NOTE 10 - INCOME TAXES

As discussed in Note 1, the Company utilizes the asset and liability
method of accounting for income taxes in accordance with SFAS 109.
The effective tax rates differ from the statutory rate primarily due
to the Company's historical corporate structure.  The reconciliation
of the statutory federal rate to the Company's historical Income tax
benefit is as follows:

<TABLE>
<CAPTION>
                                                  2006                    2005
                                         ---------------------    --------------------
                                            Amount         %         Amount        %
                                         ------------    -----    ------------   ----
<S>                                      <C>             <C>      <C>            <C>
  Income tax benefit at U.S.
    federal income tax rate              $(1,027,000)    (35)     $  (603,000)    (35)
  State tax, nete of federal tax effect     (189,000)     (6)        (111,000)     (6)
  Non-deductible warrants                     28,000        1          32,000       2
  Non-deductible options                      39,000        1          82,000       5
  Non-deductible amortization                285,000       10               -       -
  Change in valuation allowance              864,000       29         600,000      34
                                         -----------     ----     -----------    ----
                                         $         -        -     $         -       -
                                         ===========     ====     ===========    ====
</TABLE>


The components of deferred tax assets as of December 31, 2006 and
December 31, 2005 are as follows:

<TABLE>
<CAPTION>
                                      2006           2005
                                  -----------    -----------
<S>                               <C>            <C>

Deferred tax asset for
  NOL carryforwards               $ 1,780,000    $   916,000
  Valuation allowance              (1,780,000)      (916,000)
                                  -----------    -----------
                                  $         -    $         -
                                  ===========    ===========
</TABLE>

The valuation allowance for deferred tax assets as of December 31,
2006 and 2005 was $1,780,000 and $916,000. The change in the total
valuation for the years ended December 31, 2006 and 2005 was an
increase of $864,000 and $600,000.  In assessing the realization of
deferred tax assets, management considers whether it is more likely
than not that some portion or all of the deferred tax assets will not
be realized.  The ultimate realization of deferred tax assets is
dependant upon the generation of future taxable income during the
periods in which the net operating losses and temporary differences
become deductible.  Management considered projected future taxable
income and tax planning strategies in making this assessment.  The
value of the deferred tax assets was offset by a valuation allowance,
due to the current uncertainty of the future realization of the
deferred tax assets.

As of December 31, 2006, the Company had net operating loss carry
forwards of approximately $4,297,000, expiring through the year ending
December 31, 2026.  This amount can be used to offset future taxable
income of the Company.

The timing and manner in which the Company can utilize operating loss
carryfowards in any year may be limited by provisions of the Internal
Revenue Code regarding changes in ownership of corporations.  Such
limitation may have an impact on the ultimate realization of its
carryforwards and future tax deductions.



                             F-25
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005


NOTE 11 - STOCKHOLDERS' EQUITY

Preferred Stock
---------------
Pursuant to our Company's Articles of Incorporation, our board of
directors is empowered, without stockholder approval, to issue series
of preferred stock with any designations, rights and preferences as
they may from time to time determine.  The rights and preferences of
this preferred stock may be superior to the rights and preferences of
our common stock; consequently, preferred stock, if issued could have
dividend, liquidation, conversion, voting or other rights that could
adversely affect the voting power or other rights of the common stock.
Additionally, preferred stock, if issued, could be utilized, under
special circumstances, as a method of discouraging, delaying or
preventing a change in control of our business or a takeover from a
third party.

Common Stock and Warrants
-------------------------
The stockholders' deficit at January 1, 2004 has been retroactively
restated for the equivalent number of shares received in the reverse
acquisition at July 14, 2004 (Note 1) after giving effect to the
difference in par value with the offset to additional paid-in-capital.

In July 2004, the Company issued 1,600,000 shares of its common stock
for professional services valued at $256,000, fair value

In August 2004, the Company issued 637,500 shares of its common stock
for professional services valued at $75,000, fair value.

In December 2004, the Company converted a note payable of $30,000 into
187,500 shares of common stock at a conversion price of $0.16 per
share.

In April 2005, the Company issued 4,000,000 shares of its common stock
in a private placement for proceeds of $1,000,000.

On May 4, 2005, the Company converted the notes payable of $499,000
into 3,118,750 shares of common stock at a conversion price of $0.16
per share.  An unpaid note payable in the amount of $6,500 has been
reflected as a subscription receivable.

During August 2005, the Company issued 210,000 shares of common stock
for professional services rendered valued at $585,500, fair value.
Consulting expense of $375,500 was recognized during 2005, and at
December 31, 2005, the remaining balance of $210,000 is reflected as a
deferred charge on the balance sheet.  During 2006, consulting expense
of $210,000 was recognized.  This agreement ended in May 2006.

In August 2005, in conjunction with a management services contract,
the Company issued 200,000 shares of common stock valued at $584,000.
Management expense of $265,455 was recognized during 2005, and at
December 31, 2005, the remaining balance of $318,545 is reflected as a
deferred charge in a contra-equity account.  During 2006, management
expense of $318,545 was recognized.  This agreement ended in June
2006.


                             F-26
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005


NOTE 11 - STOCKHOLDERS' EQUITY (CONTINUED)

Common Stock and Warrants (Continued)
-------------------------
During May 2005, the Company issued Stock Purchase Warrants to
purchase 100,000 shares of common stock at an exercise price of $2.10
in exchange for consulting services. The warrants are exercisable
until May 2008 and vest as follows: 50,000 shares during the first
year of the agreement, 25,000 shares during the second year of the
agreement, and 25,000 shares during the third year. In accordance with
the fair value method, the Company used the Black-Scholes model to
calculate the grant-date fair value, with the following assumptions:
no dividend yield, expected volatility of 60%, risk-free interest rate
of 3.8% and expected life of option of three years.  The fair market
value of the warrants was $113,250.  In accordance with the fair value
method as described in accounting requirements of SFAS No. 123, the
Company recognized consulting expense of $37,000 in 2005.  This
warrant was cancelled during 2006.

During September 2005, the Company issued Stock Purchase Warrants to
purchase 100,000 shares of common stock at an exercise price of $2.00
in exchange for consulting services. The warrants expire in September
2008 and vest as follows: 50,000 shares during the first year of the
agreement, 25,000 shares during the second year of the agreement, and
25,000 shares during the third year of the agreement. In accordance
with the fair value method, the Company used the Black-Scholes model
to calculate the grant-date fair value, with the following
assumptions: no dividend yield, expected volatility of 60%, risk-free
interest rate of 3.8% and expected life of option of three years.  The
fair market value of the warrants was $145,100.  The Company
recognized consulting expense of $66,500 and $24,200 for the years
ended December 31, 2006 and 2005 in conjunction with this agreement.

On October 15, 2005, the Company issued Stock Purchase Warrants to
purchase 30,000 shares of common stock at an exercise price of $1.40
in exchange for consulting services. The warrants expire in October
2006 and are exercisable immediately.  In accordance with the fair
value method, the Company used the Black-Scholes model to calculate
the grant-date fair value, with the following assumptions: no dividend
yield, expected volatility of 60%, risk-free interest rate of 4.15%
and expected life of option of one year.  The fair market value of the
warrants was $15,900.   In accordance with the fair value method as
described in accounting requirements of SFAS No. 123, the Company
recognized consulting expense of $15,900 during 2005.  These warrants
expired in October 2006.

In December 2005, in conjunction with a consulting contract, the
Company issued Stock Purchase Warrants to purchase 300,000 shares of
common stock at an exercise price of $0.25 per share.  The warrants
expire in December 2007 and were exercisable immediately. In
accordance with the fair value method, the Company used the Black-
Scholes model to calculate the grant-date fair value, with the
following assumptions: no dividend yield, expected volatility of 60%,
risk-free interest rate of 4.41% and expected life of option of two
years.  In accordance with the fair value method as described in
accounting requirements of SFAS No. 123, the Company recognized
consulting expense of $199,435, and at December 31, 2005, the
remaining balance in deferred charges amounted to $235,625.  The
300,000 warrants were fully exercised on December 31, 2005 for
$75,000.  During 2006 the Company recognized $217,497 in consulting
expense in conjunction with this agreement, and at December 31, 2006,
the remaining balance in deferred charges amounted to $18,128.

During February 2006, the Company issued 300,000 shares of common
stock for professional services rendered valued at $270,000, fair
value.  The Company recognized consulting expense of $118,125 and
legal expense of $118,125 during 2006, and at December 31, 2006, the
remaining balance in deferred charges amounted to $33,750.



                             F-27
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005


NOTE 11 - STOCKHOLDERS' EQUITY (CONTINUED)

Common Stock and Warrants (Continued)
-------------------------
During May 2006, the Company issued 400,000 shares of common stock for
professional services rendered valued at $620,000, fair value.  The
Company recognized consulting expense of $361,667 during 2006, and at
December 31, 2006, the remaining balance in deferred charges amounted
to $258,333.

During June 2006, the Company issued 25,000 shares of common stock for
professional services rendered valued at $36,250, fair value. The
Company recognized legal expense of $19,635 during 2006, and at
December 31, 2006, the remaining balance in deferred charges amounted
to $16,615.

During November 2006, the Company issued 60,000 shares of common stock
for professional services valued at $29,400, fair value. The Company
recognized investor relations expense of $3,920 during 2006, and at
December 31, 2006, the remaining balance in deferred charges amounted
to $25,480

During 2006, the Company cancelled a warrant issued during May 2005 to
purchase 100,000 shares of the Company's common stock at an exercise
price of $2.10, and issued an option to purchase 500,000 shares of the
Company's common stock at an exercise price of $1 per share and the
same option's expiration and vesting terms were modified during
November 2006 (NOTE #3).  The incremental cost of the modified option
was $394,030 and will be expensed over the vesting terms.  The Company
recognized $428,888 as a consulting expense in 2006, which includes
$337,290 of the incremental cost of the modified option.

In June 2006, in conjunction with an addendum to an existing
consulting contract effective December 2005, the Company issued Stock
Purchase Warrants to purchase 300,000 shares of common stock at an
exercise price of $0.25 per share.  The warrants expire in June 2008
and were exercisable immediately. In accordance with the fair value
method, the Company used the Black-Scholes model to calculate the
grant-date fair value, with the following assumptions: no dividend
yield, expected volatility of 186%, risk-free interest rate of 4.41%
and expected life of option of two years.  The fair market value of
the warrants was $465,996.  During 2006, the Company recognized
consulting expense of $135,048 in conjunction with this agreement, and
at December 31, 2006, the remaining balance in deferred charges
amounted to $330,948.

During 2006, the Company recognized contributed capital of $35,624
related to the conversion of accrued interest payable.

During 2006, the Company deemed an outstanding subscription receivable
of $6,500 to be uncollectible.

During 2006, the Company issued 850,000 shares of common stock and
425,000 warrants for proceeds of $425,000 in accordance to a private
placement memorandum amended December 18, 2006.  Pursuant to the terms
of the amended offering, up to 20 units were offered at the offering
price of $50,000 per unit, with each unit comprise of 100,000 shares
and a warrant to purchase 50,000 shares of common stock at $0.50 per
shares.  As of December 31, 2006, the 425,000 warrants are still
outstanding.



                             F-28
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005



NOTE 12 - STOCK BASED COMPENSATION

In December 2004, the Financial Accounting Standards Board ("FASB")
issued SFAS 123 (revised 2004), Share-Based Payment ("SFAS 123R").
SFAS 123(R) supersedes APB Opinion No. 25, Accounting for Stock Issued
to Employees, and amends SFAS No. 95, Statement of Cash Flows.
Generally, the approach in SFAS 123(R) is similar to the approach
described in SFAS 123.  However, SFAS 123(R) requires share-based
payments to employees, including grants of employee stock options, to
be recognized in the income statement based on their fair values at
the date of grant.  Pro forma disclosure is no longer an alternative.

On January 1, 2006, the Company adopted SFAS 123(R) using the modified
prospective method as permitted under SFAS 123(R).  Under this
transition method, compensation cost recognized in the first quarter
of 2006 includes compensation cost for all share-based payments
granted prior to but not yet vested as of December 31, 2005, based on
the grant-date fair value estimated in accordance with the provisions
of SFAS 123.  In accordance with the modified prospective method of
adoption, the Company's results of operations and financial position
for prior periods have not been restated.

The Company uses the Black-Scholes option pricing model to calculate
the grant-date fair value of an award, with the following assumptions:
no dividend yield, expected volatility of 186%, risk-free interest
rate between 3.8% and 5.1% and expected option life of two and ten
years.

During the year ending December 31, 2006, the Company's net income was
approximately $428,889 lower as a result of stock-based compensation
expense as a result of the adoption of SFAS 123(R).  As of December
31, 2006, there was approximately $225,006 of unrecognized
compensation expense related to non-vested market-based share awards
that is expected to be recognized through February 2016.

Prior to December 31, 2005, the Company followed the provisions of
SFAS No. 123, "Accounting for Stock-Based Compensation".  The
provisions of SFAS No. 123 allowed companies to either expense the
estimated fair value of stock options or to continue to follow the
intrinsic value method set forth in Accounting Principles Board
Opinion No. 25, "Accounting for Stock Issued to Employees" ("APB 25"),
but disclose the pro forma effects on net income had the fair value of
the options been expensed.  The Company elected to apply APB 25 in
accounting for its stock option incentive plans.

In accordance with APB 25 and related interpretations, compensation
expense for stock options was recognized in income based on the
excess, if any, of the quoted market price of the stock at the grant
date of the award or other measurement date over the amount an
employee must pay to acquire the stock.  Generally, the exercise price
for stock options granted to employees was equal to the fair market
value of the Company's common stock at the date of grant, thereby
resulting in no recognition of compensation expense by the Company
prior to December 31, 2005.



                             F-29
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005


NOTE 12 - STOCK BASED COMPENSATION (CONTINUED)

Had compensation cost for the Company's stock option plans been
determined based on the fair value method set forth in SFAS No. 123
during the prior year, the Company's net income (loss) and basic and
diluted net income (loss) per common share would have been changed to
the pro forma amounts indicated below:


                                            Year Ending
                                         December 31, 2005
                                         -----------------
     Net loss:
     As reported                         $       1,721,765
     Less: Total stock-based employee
     compensation expense determined
     under fair value based method
     method for all awards                          24,247
                                         -----------------
     Pro forma net loss                  $       1,746,012
                                         =================

     Net loss per common share
       - basic and diluted:
       As reported                       $            0.07
       Pro forma                         $            0.07


Stock Options
-------------
During 2005, the Board of Directors ("Board") of the Company adopted a
Stock Option Plan (the "Plan") and reserved 1,000,000 shares of common
stock for issuance under the Plan.  The Plan is intended to permit
stock options granted to employees under the Plan to qualify as
incentive stock options under Section 422 of the Internal Revenue Code
of 1986, as amended ("Incentive Stock Options").  All options granted
under the Plan, which are not intended to qualify as Incentive Stock
Options, are deemed to be non-qualified options ("Non-Statutory Stock
Options").  During 2006, 700,000 options were issued under this plan.









                             F-30
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005


NOTE 12 - STOCK BASED COMPENSATION (CONTINUED)

Stock Options (Continued)
-------------
The following tables summarize all stock option activity of the
Company since December 31, 2006:

<TABLE>
<CAPTION>
                                          Non-Qualified Stock Options Outstanding
                                      ------------------------------------------------
                                                                      Weighted Average
                                        Number of       Exercise           Exercise
                                         Shares           Price              Price
                                      ------------     -------------  ----------------
<S>                                   <C>              <C>            <C>
Outstanding, December 31, 2004                   -     $           -      $          -

Granted                                    680,000     $0.25 - $2.10      $       0.99
Cancelled                                 (300,000)    $        0.25      $      (0.25)
                                      ------------     -------------      ------------

Outstanding, December 31, 2005             380,000     $1.40 - $2.10      $       0.68

Granted                                  1,000,000     $0.25 - $1.00      $       0.70
Cancelled                                 (260,000)    $1.40 - $2.10      $      (0.48)
Expired                                    (70,000)    $1.40 - $2.00      $      (0.12)
                                      ------------     -------------      ------------

Outstanding, December 31, 2006           1,050,000     $0.25 - $2.00      $       0.83

Exercisable, December 31, 2006             853,000     $0.25 - $2.00      $       0.77
</TABLE>


<TABLE>
<CAPTION>
                     Non-Qualified Stock Options Outstanding
--------------------------------------------------------------------------------------
                    Number Outstanding    Weighted Average        Weighted Average
Rance of          Currently Exercisable      Remaining       Exercise Price of Options
Exercise Prices   at December 31, 2006    Contractual Life      Currently Exercisable
---------------   ---------------------   ----------------   -------------------------
<S>               <C>                     <C>                <C>
 $0.25 - $2.00            853,000             6.22 years              $      0.77
</TABLE>








                             F-31
<PAGE>


              THIRD-ORDER NANOTECHNOLOGIES, INC.
               (FORMERLY PSI-TEC HOLDINGS, INC.)
                 (A Development Stage Company)
                 NOTES TO FINANCIAL STATEMENTS
                  DECEMBER 31, 2006 AND 2005



NOTE 13 - CONTINGENCY

During 2005, the Company raised $1,000,000 through the sale of
4,000,000 shares of common stock in a limited offering to persons
believed to be accredited investors.  The Company received a legal
opinion from third party outside counsel as to the availability of an
exemption from registration with the SEC with respect to the limited
offering.  In December 2005, the Company was informed by the SEC that
it is investigating the circumstances surrounding the $1,000,000
offering including the subsequent public resale of certain shares
originally sold in the offering, along with related matters.  The
Company has further been informed that the original issuance of the
stock and subsequent resale may have been done, in the opinion of the
SEC, in violation of the registration provisions of the Securities Act
of 1933, as amended.  These matters could lead to enforcement action
by the SEC.  The Company's management is committed to cooperate fully
with the SEC.


NOTE 14 - RELATED PARTY

The Company has available-for-sale securities of a related party
(Footnote 4).  The information is summarized below and is recorded on
the balance sheet as "Available-for-sale securities".  The unrealized
loss on this investment is included on the Statement of Other
Comprehensive Income.

<TABLE>
<CAPTION>
                 Number                   Market    Unrealized
               of Shares     Cost         Value        Loss
               ---------   ---------    ---------   ----------
<S>            <C>         <C>          <C>         <C>
Related party    43,900    $  87,800    $  59,265   $ (28,535)

</TABLE>
Under the management agreement dated August 1, 2005, the related party
was issued 200,000 shares of common stock with a fair value of
$584,000 which is being amortized over the term of the agreement (one
year).  The expense for the years ending December 31, 2006 and 2005
was $318,545 and $265,455.

At December 31, 2006 and 2005, the Company has accounts payable to a
related party of $65,339 and $-0-.

At December 31, 2006 and 2005, the Company has an officer loan payable
of $1,468 and $1,468.


NOTE 15 - SUBSEQUENT EVENTS

Through March 23, 2007, the Company issued 1,148,000 shares of its
common stock and 574,000 warrants for proceeds of $574,000.  In
accordance with Emerging Issue Task Force ("EITF") 00-19, the warrants
will be reflected as equity since the warrant contract requires
physical settlement or net share settlement and does not permit net
cash settlement of the contract.

In February 2007, the Company issued 1,151,785 shares of its common
stock for consulting services valued at $686,250, fair value.  In
accordance with EITF 96-18, the fair value of the common stock issued
for services was determined based on the common stock price on the
performance commitment date since the common stock issued for this
consulting services were fully vested and non-forfeitable at the date
of the agreement.


                             F-32
<PAGE>




                             PART III

Item 1.   Index to Exhibits.

Exhibit No.     Description of Exhibit

(2)             Charter and Bylaws.
       2.1     	Restated Articles of Incorporation*
       2.2     	Bylaws*

(3)             Instruments defining the rights of security holders.
       3.1     	Restated Articles of Incorporation*
       3.2     	Bylaws*

(10)            Material Contracts.
       10.1     Facility Lease*
       10.2     Genova Letter Agreement*
       10.3     Photon X, LLC Memorandum of Understanding*
       10.4     Triple Play Communications Corporation Agreement*
       10.5     Universal Capital Management, Inc. Agreement
       10.6     2005 Stock Option Plan*
       10.7     Consulting Agreement - Harold R. Bennett**
       10.8     Consulting Agreement - David F. Eaton**

(99)

       99.1    Consulting Agreement - Christopher Harrison
       99.2    Consulting Agreement - Janet Shore
       99.3    Consulting Agreement - Draco Financial, LLC
       99.4    Consulting Agreement - Insight Capital Consultants
       99.5    Consulting Agreement - Wall St. Resources
       99.6    Retainer Agreement - David M. Bovi, P.A.
       99.7    Invoice - EQUITIES Global Communications, Inc.
       99.8    Invoice - Mergent

 * Incorporated by reference to Registrant's Form 10-SB filed
   April 13, 2007.

** Incorporated by reference to Registrant's Form 10-SB/A#1 filed
   July 19, 2007.



                               60
<PAGE>

                           SIGNATURES

    Pursuant to the requirements of Section 12 of the Securities
Exchange Act of 1934, the registrant has duly caused this registration
statement to be signed on its behalf by the undersigned, hereunto duly
authorized.

THIRD-ORDER NANOTECHNOLOGIES, INC.

Date: September 7, 2007


By: /s/Frederick J. Goetz, Jr.
   --------------------------------
     Frederick J. Goetz, Jr.,
     President




















                               61
<PAGE>



</TEXT>
</DOCUMENT>
